<SEC-DOCUMENT>0001213900-26-037438.txt : 20260331
<SEC-HEADER>0001213900-26-037438.hdr.sgml : 20260331
<ACCEPTANCE-DATETIME>20260331160842
ACCESSION NUMBER:		0001213900-26-037438
CONFORMED SUBMISSION TYPE:	424B7
PUBLIC DOCUMENT COUNT:		14
FILED AS OF DATE:		20260331
DATE AS OF CHANGE:		20260331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OS Therapies Inc
		CENTRAL INDEX KEY:			0001795091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				825118368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B7
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289443
		FILM NUMBER:		26821762

	BUSINESS ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		410-297-7793

	MAIL ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OS THERAPIES Inc
		DATE OF NAME CHANGE:	20191125
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B7
<SEQUENCE>1
<FILENAME>ea0283925-424b7_ostherap.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Prospectus Supplement</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed Pursuant to Rule 424(b)(7)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To Prospectus dated August 25, 2025)</B></FONT></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration No. 333-289443</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,529,417 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ea028392501_img1.jpg" ALT="A blue text on a white background&#10;&#10;Description automatically generated" STYLE="height: 64px; width: 401px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS THERAPIES INCORPORATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement covers up to 10,529,417 shares of common
stock of OS Therapies Incorporated that may be offered for resale or otherwise disposed of by the selling stockholders set forth under
the caption &ldquo;Selling Stockholders&rdquo; beginning on page&nbsp;S-15 of this prospectus supplement, including their respective pledges,
assignees and successors-in-interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock being offered for resale under this prospectus
supplement consist of (i) 2,622,774 shares of common stock issuable upon exercise of warrants (the &ldquo;2026 Warrants&rdquo;) issued
in our January 2026 warrant exercise inducement and exchange transaction and privately negotiated warrant exercise inducement and exchange
agreements, (ii) 1,666,667 shares of common stock issuable upon exercise of warrants (the &ldquo;Bridge Warrants&rdquo;) issued in our
March 2026 bridge financing and (iii) 6,239,976 shares of common stock issuable upon conversion of our 10.0% original issue discount unsecured
convertible promissory notes (the &ldquo;Bridge Notes&rdquo;) issued in our March 2026 bridge financing. See &ldquo;Description of the
Transactions&rdquo; beginning on page S-9 of this prospectus supplement for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any proceeds
from the sale of shares by the selling stockholders. We will, however, receive proceeds from any cash exercise of the 2026 Warrants and
Bridge Warrants. We will bear all costs, expenses and fees in connection with the registration of shares for resale by the selling stockholders.
The selling stockholders will each bear their respective discounts, commissions, fees of underwriters, selling brokers or dealer managers
and similar expenses, if any, attributable to the sale or disposition of the shares, or interests therein, held by such selling stockholder.
See &ldquo;Use of Proceeds&rdquo; beginning on page&nbsp;S-8 of this prospectus supplement for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
offer all or part of the shares registered hereby for resale from time to time through public or private transactions, at either prevailing
market prices or at privately negotiated prices. Our registration of the shares covered by this prospectus supplement does not mean that
the selling stockholders will offer or sell any of the shares. With regard only to the shares the selling stockholders sell for their
own behalf, such selling stockholder may be deemed an &ldquo;underwriter&rdquo; within the meaning of the Securities Act&nbsp;of&nbsp;1933,
as amended (the &ldquo;Securities Act&rdquo;). See &ldquo;Plan of Distribution&rdquo; beginning on page&nbsp;S-18 of this prospectus supplement
for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded
on the NYSE American under the symbol &ldquo;OSTX.&rdquo; On March 30, 2026, the closing price of our common stock on the NYSE American
was $1.33 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this prospectus,
together with additional information described under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Information by Reference,&rdquo; carefully before you invest in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our common
stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-7 of this prospectus supplement and page 3 of
the accompanying base prospectus, as well as the information under the heading &ldquo;Risk Factors&rdquo; in our Annual Report on Form
10-K for the year ended December 31, 2025, and in the other documents incorporated by reference into this prospectus supplement and the
accompanying base prospectus for a discussion of the factors you should carefully consider before investing in our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
supplement or the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prospectus Supplement dated March 31,
2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 90%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About this Prospectus Supplement</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-ii</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-iii</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Supplement Summary</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of the Offering</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-6</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of the Transactions</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-15</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Experts</A></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-21</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_001">About This Prospectus</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_002">ABOUT THE COMPANY</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_003">Risk Factors</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_004">CAUTIONARY STATEMENT Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_005">USE Of proceeds</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_006">dESCRIPTION OF OUR cAPITAL sTOCK</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_007">dESCRIPTION OF oUR dEBT sECURITIES</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_008">DESCRIPTION OF OUR WARRANTS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_009">DESCRIPTION OF OUR RIGHTS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_010">Description of OUR UNITS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_011">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_012">SELLING STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_013">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_014">EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_015">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_016">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
and the accompanying prospectus are part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration process and consists of two parts. The first part is this prospectus
supplement, which describes the specific terms of this offering and also supplements and updates information contained in the accompanying
prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part
is the accompanying prospectus, which provides more general information, some of which may not apply to this offering. If the information
contained in this prospectus supplement differs or varies from the information contained in the accompanying prospectus, you should rely
on the information set forth in this prospectus supplement. However, if any statement in this prospectus supplement or the accompanying
prospectus is inconsistent with a statement in another document having a later date&mdash;for example, a document incorporated by reference
into this prospectus supplement&mdash;the statement in the document having the later date modifies or supersedes the earlier statement
as our business, financial condition, results of operations and prospects may have changed since the earlier dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before buying any shares of
our common stock offered hereby, we urge you to carefully read this prospectus supplement and the accompanying base prospectus, together
with the information incorporated herein and therein by reference as described under the headings &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Incorporation of Certain Information by Reference.&rdquo; These documents contain important information that you should consider
when making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information contained or incorporated herein by reference in this prospectus supplement and contained or incorporated therein by reference
in the accompanying base prospectus. We have not, and the selling stockholders have not, authorized any other person to provide you with
any information that is different. If anyone provides you with different, additional or inconsistent information, you should not rely
on it. We and the selling stockholders take no responsibility for, and can provide no assurance as to the reliability of, any other information
that others may give you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders are
offering to sell our securities only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement
and the accompanying base prospectus and the offering of the securities in certain jurisdictions may be restricted by law. This prospectus
supplement and the accompanying base prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation
of an offer to buy, any securities offered by this prospectus supplement and the accompanying base prospectus by any person in any jurisdiction
in which it is unlawful for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in
the prospectus supplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement, including,
in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The industry and market
data and certain other statistical information used throughout this prospectus supplement, the accompanying base prospectus and the
documents incorporated by reference into the prospectus and this prospectus supplement are from our own research, surveys or studies
conducted by third parties and industry or general publications. Industry publications and third-party research, surveys, and
studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not
guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this
prospectus supplement, the accompanying base prospectus and the documents incorporated by reference into the prospectus and this
prospectus supplement, and we believe that these sources are reliable; however, we have not independently verified the information
contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this
prospectus supplement, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to
risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled
&ldquo;Risk Factors&rdquo; and elsewhere in this prospectus supplement, the accompanying base prospectus and the documents
incorporated by reference into the prospectus and this prospectus supplement. Some data are also based on our good faith
estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SiLinkers&trade;,
CAPs&trade; and other common law trade names, trademarks or service marks of our company appearing in this prospectus supplement, the
accompanying base prospectus and the documents incorporated by reference into the prospectus and this prospectus supplement are the property
of OS Therapies Incorporated. This prospectus supplement, the accompanying base prospectus and the documents incorporated by reference
into the prospectus and this prospectus supplement contains additional trade names, trademarks and service marks of other companies that
owned by their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus supplement, the accompanying
base prospectus and the documents incorporated by reference into the prospectus and this prospectus supplement appear without the &trade;
or &reg; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law,
our rights, or that the applicable owners will not assert their rights, to these trademarks and trade names. We do not intend our use
or display of other companies&rsquo; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship
by us of, these other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this prospectus
supplement and the accompanying base prospectus to &ldquo;OS Therapies,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our&rdquo; or similar references refer to OS Therapies Incorporated, except where the context otherwise requires or as otherwise
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus supplement, the accompanying base prospectus and the documents incorporated by reference in these documents contain forward-looking
statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), which may include information concerning our beliefs, plans, objectives, goals, expectations, strategies,
anticipations, assumptions, estimates, intentions, future events, future revenues or performance, capital expenditures and other information
that is not historical information. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which
may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future
results, performance or achievements expressed or implied by such forward-looking statements. When used in this prospectus supplement,
the accompanying base prospectus and the documents incorporated by reference in these documents, the words &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;continue,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe&rdquo; and variations of such words or similar expressions are intended to
identify forward-looking statements. All forward-looking statements are based upon our current expectations and various assumptions. We
believe there is a reasonable basis for our expectations and beliefs, but there can be no assurance that we will realize our expectations
or that our beliefs will prove to be correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
are a number of risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements contained
in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference in these documents. Examples
of risks and uncertainties that could cause actual results to differ materially from historical performance and any forward-looking statements
include, but are not limited to, the risks described under the section below titled &ldquo;Risk Factors&rdquo; of this prospectus supplement,
as well as any of our subsequent filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
may be other factors of which we are currently unaware or which we currently deem immaterial that may cause our actual results to differ
materially from the forward-looking statements. All forward-looking statements attributable to us or persons acting on our behalf apply
only as of the date they are made and are expressly qualified in their entirety by the cautionary statements included in this prospectus
supplement, the accompanying base prospectus and the documents incorporated by reference in these documents. Except as may be required
by law, we undertake no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances occurring
after the date they were made or to reflect the occurrence of unanticipated events, or otherwise.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>PROSPECTUS SUPPLEMENT SUMMARY</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
selected information about us and this offering and does not contain all of the information that you should consider in making your investment
decision. You should carefully read this entire prospectus supplement and the accompanying prospectus, including the risks and uncertainties
discussed under the heading &ldquo;Risk Factors&rdquo; beginning on page S-7 of this prospectus supplement, and the information incorporated
by reference in this prospectus supplement and the accompanying prospectus, including our consolidated financial statements, before making
an investment decision. If you invest in our securities, you are assuming a high degree of risk.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OS Therapies is a clinical
stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and
other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing
genotypes and high metastases rates. We are currently seeking to answer the call for new treatments that will prevent metastasis and the
recurrence of metastases with our lead core product candidate OST-HER2 (also known as OST31-164), a cancer immunotherapy product candidate
that produces a cellular immune response against the cancer antigen HER2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, we opened a clinical
study to produce data for the U.S. Food and Drug Administration (FDA) to evaluate the safety and efficacy of OST-HER2 in patients after
resection of recurrent Osteosarcoma, which achieved full enrollment of 41 patients in October 2023. In the first quarter of 2025, we announced
that our Phase IIb clinical trial achieved its primary endpoint with statistical significance. In October 2025, we announced final two-year
overall survival data from the Phase IIb trial, in which 75% (27 of 36 evaluable patients) of OST-HER2-treated patients achieved two-year
overall survival from the most recent pulmonary resection, compared with 40% in historical control patients (p &lt; 0.0001). OST-HER2
was observed to be well-tolerated in the study. In January 2026, we announced positive immune biomarker data from the Phase IIb trial
indicating that activation of immune blood biomarkers in the interferon gamma pathway correlated with, and was predictive of, overall
survival, distinguishing long-term survivors (&#8805; two years) from short-term survivors (&lt; one year). These biomarker findings are
based on exploratory analyses and have not been validated as surrogate endpoints for clinical benefit. Based on the totality of the data
generated to date, including the observed survival outcomes, safety profile and the significant unmet medical need in this patient population,
we intend to engage with the FDA regarding potential regulatory pathways for OST-HER2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged in ongoing regulatory interactions with the FDA, the
United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), and the European Medicines Agency (EMA) regarding the clinical
and biomarker data for OST-HER2 in recurrent, fully resected pulmonary metastatic Osteosarcoma. Following submission of the Non-Clinical
and Chemistry, Manufacturing &amp; Controls (CMC) modules of our Biologics License Application (BLA) to the FDA at the end of January
2026, we anticipate submitting the clinical BLA module following an expected Type B meeting with the FDA in the second quarter of 2026
and completing conditional Marketing Authorization Application (MAA) submissions to both the MHRA and the EMA in the second quarter of
2026. We also anticipate releasing additional biomarker data in the second quarter of 2026 to further characterize immune pathway activation
and its relationship to clinical outcomes. We expect to initiate confirmatory clinical studies in the third quarter of 2026 in support
of conditional approval pathways. If OST-HER2 receives approval under the FDA&rsquo;s Accelerated Approval Program prior to September
30, 2029, we would become eligible to receive a Priority Review Voucher under the Rare Pediatric Disease Designation Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon success in gaining regulatory
approval from the FDA with OST-HER2 in Osteosarcoma, we intend to evaluate OST-HER2&rsquo;s potential use, both alone and in combination
with HER2 targeting antibodies such as Herceptin&reg;, in other solid tumors including breast, esophageal and lung cancers. OST-HER2 has
potential uses in both the prevention of metastases in solid tumors, and therapeutically against HER2-expressing solid tumors treated
with HER targeting antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own rights to an OST-Tunable
Drug Conjugate (OST-tADC) platform, a next generation antibody-drug conjugate (ADC) silicone dioxide linker technology. &ldquo;Tunable&rdquo;
is a term used in drug development that refers to the properties that can be influenced by chemical modifications, and &ldquo;antibody-drug
conjugate&rdquo; or ADC is a term used to describe a drug made up of a monoclonal antibody attached to a cytotoxic payload, or a highly
active and toxic pharmaceutical molecule, through chemical linkers. The ADC links an antibody that can home in on a targeted tumor to
deploy the cytotoxic payload or toxic agent against the tumor. Furthering our founding mission, we intend to investigate clinical indications
for OST-tADC in Osteosarcoma and other solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have built a pipeline of
product candidates targeting multiple indications for solid cancers. Our pipeline includes two drug technologies: (i)&nbsp;OST-HER2, an
off-the-shelf immunotherapy, which is a type of cancer treatment that helps one&rsquo;s immune system fight cancer, comprised of a genetically
weakened and modified strain of <I>Listeria monocytogenes</I>, a species of bacteria that causes the infection listeriosis, that expresses
HER2 peptides, and (ii)&nbsp;OST-tADC,&nbsp;a next generation tunable ADC with a plug-and-play platform that features tunable pH sensitive
silicone linkers (SiLinkers&trade;). The payloads may include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments
directly into and in the vicinity of solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B><I>&nbsp;</I></B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>OST-HER2
(OST31-164). </I></B>Our most advanced product candidate, OST-HER2, is a genetically engineered strain of <I>Listeria
monocytogenes</I>, attenuated for reduced virulence, increased antibiotic susceptibility and the expression of three HER2 protein
epitopes fused to immune-enhancing peptides on the membrane of the bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OST-HER2 has received an orphan
drug designation in the United&nbsp;States. The FDA may designate a biologic product as an orphan product if it is intended to treat a
rare disease or condition, which generally is defined as having a patient population of fewer than 200,000 individuals in the United&nbsp;States.
Osteosarcoma has an incidence rate of approximately 1,000 individuals affected per year in the United&nbsp;States. Orphan product designation,
subject to limited exceptions, can provide a period of market exclusivity for a product that is the first to receive marketing approval
for the designated indication. Other potential indications may include breast, esophageal, lung and other solid tumors. In August&nbsp;2021,
OST-HER2 was awarded rare pediatric disease designation and previously received fast track designation by the FDA.&nbsp;Such designations
by the FDA do not convey any advantages in, or shorten the duration of, the regulatory review or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>OST-tADC. </I></B>Our
tunable drug conjugate (tADC) platform is currently in preclinical development. Each tADC contains four main components: ligand, payload
cassette adaptor, linker and payload. In addition, tADCs contain units to optimize physicochemical properties. The ligands are selected
to bind to receptors overexpressed on cancer cells. Upon binding, the tADC construct gets internalized into the cancer cell, where the
payload is released, to cause cell death. The payload cassette adaptors enable the stoichiometrical attachments of linkers and payloads.
The SiLinkers represent a novel and pH-sensitive linker system. The SiLinker release profile can be tuned with proximal functional groups,
resulting in payload release in the endosome, lysosome or the slightly acidic tumor microenvironment. The SiLinker system is compatible
with a variety of payloads and not limited to the employment of cytotoxic drug delivery. The first set of internal programs focus on the
use of SiLinker and conditionally active payloads (CAPs&trade;) drug products. CAPs are cytotoxic drugs which on their own, due to their
functional groups, cannot readily permeate cells at physiological pH; however, at the slightly acidic pH of the tumor-microenvironment,
after some linker cleavage, these payloads readily permeate into cancer cells, resulting in an enhanced bystander effect. Our lead program
targets folate receptor alpha, a protein expressed on the surface of cells that participates in cell signaling, as well as cellular replication
and division, and is overexpressed in multiple cancers such as ovarian and endometrial cancers. The lead compound employs folic acid,
a small molecule, as the targeting ligands and contains six exatecan-silanols, which is a type of silanol-based cytotoxic payload. This
discovery work is being carried out at Syngene International Limited, an integrated contract research organization (CRO) based in Bangalore,
India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
evaluate collaboration opportunities for our product candidates. We expect to work opportunistically with pharmaceutical and biotechnology
companies, as we have done with BlinkBio, Inc. by in-licensing the OST-tADC technology, seeking to utilize our technology and know-how
for developing additional oncologic drug products. The following table summarizes information regarding our product candidates and development
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="ea028392501_img2.jpg" ALT="" STYLE="height: 318px; width: 630px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="ea028392501_img3.jpg" ALT="" STYLE="height: 190px; width: 630px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our development
of OST-HER2 for multiple indications of solid cancers in humans, OST-HER2 is a product candidate for veterinary use in canines. As part
of our growth strategies, we intend to consider potentially out-licensing OST-HER2 to animal health companies for such use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2026 Warrant Exercise Inducement
and Exchange Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 14, 2026, we closed
on a warrant exercise inducement and exchange offer (the &ldquo;2026 Inducement Offering&rdquo;). The 2026 Inducement Offering was made
to less than 10 accredited investors that held certain of our existing warrants to purchase up to an aggregate of 5,382,148 shares of
our common stock having a then current exercise price of $3.00 or $2.10 per share during the period beginning January 10, 2026 and ending
at 11:59 p.m., Eastern time, on March 2, 2026 (the &ldquo;2026 Inducement Period&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the 2026 Inducement Period, we entered into inducement offer
letter agreements (the &ldquo;2026 Inducement Letters&rdquo;) with such holders, pursuant to which such holders exercised for cash their
existing warrants to purchase an aggregate of 2,499,558 shares of our common stock at a reduced exercise price of $1.40 per share and
in exchange we issued to such holders new warrants (the &ldquo;2026 Warrants&rdquo;) to purchase up to an aggregate of 2,499,558 shares
of our common stock (the &ldquo;2026 Warrant Shares&rdquo;) at an exercise price of $1.40 per share, subject to adjustment as provided
therein. The 2026 Warrants are exercisable for a period of five years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engaged a SEC-registered broker dealer and FINRA member (the &ldquo;Solicitation
Agent&rdquo;) to act as our exclusive warrant solicitation agent in connection with the 2026 Inducement Offering and paid the Solicitation
Agent a cash fee equal to 8.0% of the total gross cash proceeds received from the exercise by the holders of their respective warrants
during the 2026 Inducement Period and in connection with the 2026 Inducement Offering. We also paid the Solicitation Agent $25,000 for
its legal and other expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The gross proceeds to us from
the 2026 Inducement Offering, before deducting transaction fees and other 2026 Inducement Offering expenses, were approximately $3.5 million.
We are using the net proceeds from the 2026 Inducement Offering to support U.S. and international regulatory and pre-commercial efforts
aimed at securing marketing authorizations for OST-HER2 in the prevention or delay of recurrent, fully resected, lung metastatic Osteosarcoma,
provide funding for our wholly owned subsidiary OS Animal Health&rsquo;s proposed spinoff transaction preparations, and for general corporate
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common
stock issued upon exercise of the existing warrants in connection with the 2026 Inducement Offering were previously registered for
resale under the Securities Act. We agreed to file a registration statement on Form S-3 (or other appropriate form, including on
Form S-1, if we are not then eligible to register securities on Form S-3) providing for the resale of the shares of common stock
issued or issuable upon exercise of the 2026 Warrants within 30 calendar days of March 2, 2026, and to use commercially reasonable
efforts to have such registration statement declared effective by the SEC within 60 calendar days (or within 90 calendar days in
case of &ldquo;full review&rdquo; by the SEC) following its initial filing and to keep such registration statement effective at all
times until the earlier of (i) the time no holder owns any 2026 Warrants or shares of common stock issuable upon exercise thereof
and (ii) the Delegend Date (as defined in the 2026 Inducement Offer Letters).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Privately Negotiated Warrant
Exercise Inducement and Exchange Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From January 10, 2026 through February 2026, we entered into privately
negotiated inducement offer letters, pursuant to which certain other holders of our existing warrants having a then current exercise price
of $3.00 or $2.10 per share exercised for cash their existing warrants to purchase an aggregate of 123,216 shares of our common stock
at a reduced exercise price of $1.40 per share and in exchange we issued 2026 Warrants to purchase up to an aggregate of 123,216 shares
of our common stock at an exercise price of $1.40 per share, subject to adjustment as provided therein (such transactions, the &ldquo;Private
Inducement Transactions&rdquo;). The 2026 Warrants are exercisable for a period of five years from the date of issuance. We received gross
proceeds of approximately $172,502 from the Private Inducement Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
issued upon exercise of the existing warrants in connection with the Private Inducement Transactions were previously registered for resale
under the Securities Act. We agreed to file a registration statement on Form S-3 (or other appropriate form, including on Form S-1, if
we are not then eligible to register securities on Form S-3) providing for the resale of the shares of common stock issued or issuable
upon exercise of the 2026 Warrants on or before March 30, 2026, and to use commercially reasonable efforts to have such registration statement
declared effective by the SEC within 60 calendar days (or within 90 calendar days in case of &ldquo;full review&rdquo; by the SEC) following
its initial filing and to keep such registration statement effective at all times until the earlier of (i) the time no holder of these
warrants owns any such warrants or shares of common stock issuable upon exercise thereof and (ii) the Delegend Date (as defined in the
privately negotiated inducement offer letters).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2026 Bridge Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2026, pursuant
to a securities purchase agreement (the &ldquo;Bridge SPA&rdquo;), we issued to certain accredited investors in a private placement transaction
(i) 10.0% original issue discount unsecured convertible promissory notes in an aggregate principal amount of $2,200,000 (the &ldquo;Bridge
Notes&rdquo;) and (ii) warrants to purchase up to an aggregate of 1,666,667 shares of our common stock (the &ldquo;Bridge Warrants&rdquo;
and such private placement transaction, the &ldquo;Bridge Financing&rdquo;), for aggregate gross proceeds of $2,000,000, before deducting
placement agent fees and other Bridge Financing expenses. The Bridge Notes mature on March 4, 2027 and accrue interest at a rate of 4.0%
per annum. The Bridge Warrants are exercisable for a period of five years from the date of issuance and have an exercise price of $1.40
per share, subject to adjustment as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes were sold
at a 10% original issue discount, such that for each $100,000 invested by a purchaser, such purchaser received a Bridge Note in the principal
amount of $110,000. The Bridge Notes are convertible into shares of our common stock under certain circumstances. If we complete a &ldquo;Qualified
Offering,&rdquo; defined as a registered public offering or registered direct offering resulting in at least $2.5 million in gross proceeds
from new money investments, the outstanding principal, together with all accrued and unpaid interest, will automatically convert into
the securities sold in such offering at the offering price. Additionally, prior to any such Qualified Offering or repayment of the Bridge
Notes, holders may elect to convert the Bridge Notes, in whole or in part, into shares of our common stock at a conversion price equal
to 90% of the average daily volume-weighted average price of our common stock during the 10 trading days immediately preceding the holder&rsquo;s
conversion notice, subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are using the net proceeds
of the Bridge Financing to fund clinical development activities, including ongoing and planned clinical trials, and advance our research
and development programs, as well as for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engaged a SEC-registered
broker dealer and FINRA member to act as the exclusive placement agent for the Bridge Financing. In connection with the Bridge Financing,
we paid the placement agent (a) a cash fee equal to 7.0% of the aggregate gross cash proceeds received by us in connection with the Bridge
Financing and (b) a one-time expense reimbursement of $25,000 for its legal and other expenses incurred in connection with the Bridge
Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to file a registration
statement on Form S-3 (or Form S-1 if we are not then eligible to register securities for Form S-3) by April 3, 2026 to register for resale
the shares of our common stock issuable upon conversion of the Bridge Notes and exercise of the Bridge Warrants, and to use commercially
reasonable efforts to cause such registration statement to become effective within 60 calendar days (or 90 calendar days in the case of
a &ldquo;full review&rdquo; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time that no investor owns any Bridge Notes, Bridge Warrants or shares underlying such Bridge Notes and Bridge
Warrants or (ii) the Legend Removal Date (as defined in the Bridge SPA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering for resale
the shares of our common stock issued or issuable upon the exercise or conversion, as applicable, of the 2026 Warrants, the Bridge Warrants
and the Bridge Notes pursuant to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed as a Delaware
limited liability company on April&nbsp;12, 2018 under the name OS Therapies, LLC.&nbsp;On June&nbsp;24, 2019, we converted from a limited
liability company to a Delaware corporation and changed our name to OS Therapies Incorporated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We presently conduct all of
our operations remotely. Our registered corporate address is 115 Pullman Crossing Road, Suite #103, Grasonville, Maryland 21638, and our
telephone number is (410)&nbsp;297-7793. Our website address is <I>www.ostherapies.com</I>. We make our periodic and current reports that
are filed with the SEC available, free of charge, on our website as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. Information contained on, or accessible through, our website is not a part of, and is not incorporated
by reference into, this prospectus supplement or the accompanying base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>SUMMARY OF THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities being offered by the selling stockholders</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 69%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 10,529,417 shares of our common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any proceeds from any sale
    of the shares being offered for sale by the selling stockholders, except upon the exercise of the 2026 Warrants and Bridge Warrants currently
    outstanding that are not exercised on a cashless basis.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information on the use of proceeds, see
    &ldquo;Use of Proceeds&rdquo; on page&nbsp;S-8.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should read the &ldquo;Risk Factors&rdquo; section of this prospectus supplement, the accompanying base prospectus and in the documents incorporated by reference in this prospectus supplement and the accompanying base prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NYSE American symbol</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OSTX</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>An investment in our common
stock involves a high degree of risk. You should carefully consider the risks described under &ldquo;Risk Factors&rdquo; in our most recent
Annual Report on Form 10-K, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC, and all
of the other information contained in this prospectus supplement and the accompanying base prospectus, and incorporated by reference into
this prospectus supplement and the accompanying base prospectus, including our consolidated financial statements and related notes, before
investing in our common stock. If any of the possible adverse events described below or in those sections actually occur, our business,
business prospects, cash flow, results of operations or financial condition could be harmed, the trading price of our common stock could
decline, and you might lose all or part of your investment in our common stock. Additional risks and uncertainties not presently known
to us or that we currently deem immaterial may also impair our operations and results.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The issuance of shares
in connection with the 2026 Inducement Offering, the Private Inducement Transactions and the Bridge Financing, and the resale of a substantial
number of shares of our common stock by the selling stockholders, could cause dilution and adversely affect the market price of our common
stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the 2026 Inducement Offering and the Private Inducement
Transactions, we issued 2026 Warrants to the selling stockholders exercisable for up to an aggregate of 2,622,774 shares of our common
stock in exchange for the cash exercise of their existing warrants for an equal number of shares, pursuant to the 2026 Inducement Letters
or privately negotiated inducement offer letters, as applicable. In addition, in connection with the Bridge Financing, we issued Bridge
Notes in an aggregate principal amount of $2,200,000, which are convertible into a maximum of 6,239,976 shares of our common stock, and
Bridge Warrants to purchase up to an aggregate of 1,666,667 shares of our common stock. The issuance of shares upon the exercise or conversion
of these securities, as well as any future issuances of common stock or securities convertible into or exercisable for common stock, may
result in substantial dilution to our existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, sales by the
selling stockholders of a significant number of shares of common stock, or the perception that such sales could occur, could materially
adversely affect the trading price of our common stock. Even if the selling stockholders do not sell their shares immediately, the registration
of these shares for resale could increase market uncertainty and put downward pressure on our stock price. We cannot predict the effect,
if any, that future sales or the availability of shares for sale will have on the trading price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All shares of our common stock
offered by this prospectus supplement are being registered for resale by the selling stockholders identified herein. We will not receive
any of the proceeds from the sale of the shares of our common stock being offered for sale by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4,289,441 shares of common stock covered by this registration statement
of which this prospectus is a part are issuable upon exercise of the 2026 Warrants and Bridge Warrants at their initial stated exercise
price of $1.40 per share. If all such warrants for the purchase of shares of our common stock covered by this registration statement are
exercised in cash, then we will receive gross proceeds of approximately $6,005,217. Proceeds to us from the exercise of the 2026 Warrants
and Bridge Warrants will be used for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will bear all costs, expenses
and fees in connection with the registration of shares of our common stock for resale by the selling stockholders. The selling stockholders
will each bear their respective discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses,
if any, attributable to the sale or disposition of the shares of our common stock, or interests therein, held by such selling stockholder.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>DESCRIPTION OF THE TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2026 Inducement Offering and Private Inducement
Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of the 10,529,417 shares offered for resale under this prospectus supplement,
2,622,774 shares are issuable upon exercise of the 2026 Warrants, which the selling stockholders acquired from us in either the 2026 Inducement
Offering or the Private Inducement Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>2026 Inducement Offering</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2026 Inducement Offering was made to less than 10 accredited investors
that held certain of our existing warrants to purchase up to an aggregate of 5,382,148 shares of our common stock having a then current
exercise price of $3.00 or $2.10 per share during the 2026 Inducement Period. During the 2026 Inducement Period, we entered into the 2026
Inducement Letters with such holders, pursuant to which such holders exercised for cash their existing warrants to purchase an aggregate
of 2,499,558 shares of our common stock at a reduced exercise price of $1.40 per share and in exchange we issued to such holders 2026
Warrants to purchase up to an aggregate of 2,499,558 2026 Warrant Shares at an exercise price of $1.40 per share, subject to adjustment
as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engaged the Solicitation
Agent to act as our exclusive warrant solicitation agent in connection with the 2026 Inducement Offering and paid the Solicitation Agent
a cash fee equal to 8.0% of the total gross cash proceeds received from the exercise by the holders of their respective warrants during
the 2026 Inducement Period and in connection with the 2026 Inducement Offering. We also paid the Solicitation Agent $25,000 for its legal
and other expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The gross proceeds to us from
the 2026 Inducement Offering, before deducting transaction fees and other 2026 Inducement Offering expenses, were approximately $3.5 million.
We are using the net proceeds from the 2026 Inducement Offering to support U.S. and international regulatory and pre-commercial efforts
aimed at securing marketing authorizations for OST-HER2 in the prevention or delay of recurrent, fully resected, lung metastatic Osteosarcoma,
provide funding for our wholly owned subsidiary OS Animal Health&rsquo;s proposed spinoff transaction preparations, and for general corporate
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to file a registration
statement on Form S-3 (or other appropriate form, including on Form S-1, if we are not then eligible to register securities on Form S-3)
providing for the resale of the shares of common stock issued or issuable upon exercise of the 2026 Warrants within 30 calendar days of
March 2, 2026, and to use commercially reasonable efforts to have such registration statement declared effective by the SEC within 60
calendar days (or within 90 calendar days in case of &ldquo;full review&rdquo; by the SEC) following its initial filing and to keep such
registration statement effective at all times until the earlier of (i) the time no holder owns any 2026 Warrants or shares of common stock
issuable upon exercise thereof and (ii) the Delegend Date (as defined in the 2026 Inducement Offer Letters).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2026 Inducement Letters
contain customary representations, warranties and covenants by us which were made only for the purposes of such agreements and as of specific
dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Private Inducement Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From January 10, 2026 through February 2026, we entered into privately
negotiated inducement offer letters, pursuant to which certain other holders of our existing warrants having a then current exercise price
of $3.00 or $2.10 per share exercised for cash their existing warrants to purchase an aggregate of 123,216 shares of our common stock
at a reduced exercise price of $1.40 per share and in exchange we issued 2026 Warrants to purchase up to an aggregate of 123,216 shares
of our common stock at an exercise price of $1.40 per share, subject to adjustment as provided therein. We received gross proceeds of
approximately $172,502 from the Private Inducement Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to file a registration
statement on Form S-3 (or other appropriate form, including on Form S-1, if we are not then eligible to register securities on Form S-3)
providing for the resale of the shares of common stock issued or issuable upon exercise of the 2026 Warrants on or before March 30, 2026,
and to use commercially reasonable efforts to have such registration statement declared effective by the SEC within 60 calendar days (or
within 90 calendar days in case of &ldquo;full review&rdquo; by the SEC) following its initial filing and to keep such registration statement
effective at all times until the earlier of (i) the time no holder of these warrants owns any such warrants or shares of common stock
issuable upon exercise thereof and (ii) the Delegend Date (as defined in the privately negotiated inducement offer letters).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2026 Bridge Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of the 10,529,417 shares offered for resale under this prospectus supplement,
1,666,667 shares are issuable upon exercise of the Bridge Warrants and 6,239,976 shares are issuable upon conversion of the Bridge Notes,
which the selling stockholders acquired from us in the Bridge Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2026, pursuant
to the Bridge SPA, we issued to certain accredited investors in a private placement transaction (i) Bridge Notes in an aggregate principal
amount of $2,200,000 and (ii) Bridge Warrants to purchase up to an aggregate of 1,666,667 shares of our common stock, for aggregate gross
proceeds of $2,000,000, before deducting placement agent fees and other Bridge Financing expenses. The Bridge Notes were sold at a 10%
original issue discount, such that for each $100,000 invested by a purchaser, such purchaser received a Bridge Note in the principal amount
of $110,000. We are using the net proceeds of the Bridge Financing to fund clinical development activities, including ongoing and planned
clinical trials, and advance our research and development programs, as well as for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engaged a SEC-registered
broker dealer and FINRA member to act as the exclusive placement agent for the Bridge Financing. In connection with the Bridge Financing,
we paid the placement agent (a) a cash fee equal to 7.0% of the aggregate gross cash proceeds received by us in connection with the Bridge
Financing and (b) a one-time expense reimbursement of $25,000 for its legal and other expenses incurred in connection with the Bridge
Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Bridge SPA,
we agreed that, from March 4, 2026 until the later of (i) the date on which no Bridge Notes issued thereunder remain outstanding and (ii)
six months following the effectiveness of the resale registration statement covering the shares of our common stock issuable upon conversion
of the Bridge Notes and exercise of the Bridge Warrants (the &ldquo;Bridge Shares&rdquo;), we will not effect or agree to effect any issuance
of common stock or common stock equivalents in a transaction involving a variable rate or price-based conversion, exercise or exchange
feature that provides for a downward adjustment or reset of the applicable price based on fluctuations in the market price of our common
stock following the issuance of such securities, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to file a registration
statement on Form S-3 (or Form S-1 if we are not then eligible to register securities for Form S-3) by April 3, 2026 to register for resale
the Bridge Shares, and to use commercially reasonable efforts to cause such registration statement to become effective within 60 calendar
days (or 90 calendar days in the case of a &ldquo;full review&rdquo; by the SEC) following its initial filing and to keep such registration
statement effective at all times until the earlier of (i) the time that no investor owns any Bridge Notes, Bridge Warrants or Bridge Shares
or (ii) the Legend Removal Date (as defined in the Bridge SPA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge SPA contains customary
representations, warranties and covenants by us which were made only for the purposes of the Bridge SPA and as of specific dates, were
solely for the benefit of the parties to the Bridge SPA and may be subject to limitations agreed upon by the contracting parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Terms of the 2026 Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of certain terms and provisions of the 2026 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Duration and Exercise
Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each 2026 Warrant has an exercise
price of $1.40 per share. The 2026 Warrants are exercisable for a period of five years from the date of issuance. The exercise price and
number of 2026 Warrant Shares issuable upon exercise of the 2026 Warrants are subject to appropriate adjustment in the event of stock
dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations or similar events affecting our common stock
and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2026 Warrants are exercisable,
at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full
for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).
A holder (together with its affiliates) may not exercise any portion of such holder&rsquo;s 2026 Warrants to the extent that the holder
would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise, except
that upon prior notice from the holder to us, the holder may increase or decrease the amount of ownership of outstanding stock after exercising
the holder&rsquo;s 2026 Warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to
the exercise, as such percentage ownership is determined in accordance with the terms of the 2026 Warrants, provided that any increase
will not be effective until 61 days following notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Forced Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2026 Warrants provide
that, at any time any 2026 Warrants are outstanding, if the closing price of our common stock on the applicable trading market equals
or exceeds 300% of the exercise price then in effect for any 20 consecutive trading days, we may, subject to the satisfaction of certain
equity conditions, require the holder to exercise all or a portion of the 2026 Warrants for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Cashless Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at the time a holder exercises
its 2026 Warrants, a registration statement registering the resale of the 2026 Warrant Shares under the Securities Act is not then effective
or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate
exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part), the net number of shares of common
stock determined according to a formula set forth in the 2026 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Rights as a Stockholder</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in the 2026 Warrants or by virtue of the holder&rsquo;s ownership of shares of our common stock, such holder of 2026 Warrants does not
have the rights or privileges of a holder of our common stock, including any voting rights, until such holder exercises such holder&rsquo;s
2026 Warrants. The 2026 Warrants provide that the holders of the 2026 Warrants have the right to participate in distributions or dividends
paid on shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Fundamental Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the 2026
Warrants are outstanding, we, either directly or indirectly, in one or more related transactions effect a Fundamental Transaction
(as defined in the 2026 Warrants), a holder of 2026 Warrants will be entitled to receive, the number of shares of common stock of
the successor or acquiring corporation or of our company, if our company is the surviving corporation, and any additional
consideration receivable as a result of the Fundamental Transaction by such holder of the number of shares of common stock for which
the 2026 Warrants are exercisable immediately prior to the Fundamental Transaction. As an alternative, and at the holder&rsquo;s
option in the event of a Fundamental Transaction, exercisable at any time concurrently with, or within 30 days after, the
consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable fundamental
transaction), we shall purchase the unexercised portion of the 2026 Warrants from the holder by paying to the holder an amount of
cash equal to the Black Scholes Value (as defined in the 2026 Warrants) of the remaining unexercised portion of the 2026 Warrants on
the date of the consummation of such Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Waivers and Amendments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2026 Warrants may be modified
or amended or the provisions of the 2026 Warrants waived with our and the holder&rsquo;s written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2026 Warrants and 2026
Warrant Shares were offered and sold by us in reliance upon an exemption from the registration requirements of the Securities Act afforded
by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Terms of the Bridge Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of certain terms and provisions of the Bridge Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Duration and Exercise
Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Warrants are exercisable
for a period of five years from the date of issuance. Each Bridge Warrant has an exercise price of $1.40 per share, subject to adjustment
as provided therein. The exercise price of the Bridge Warrants is subject to adjustment upon the occurrence of certain events, including
stock dividends, stock splits, combinations, reclassifications and certain dilutive issuances. If, during the period beginning on March
4, 2026 and ending upon the consummation of a Qualified Offering (as defined below), we issue common stock or common stock equivalents
(other than excluded securities) at an effective price per share that is lower than the then-current exercise price, the exercise price
will be reduced to such lower price. Upon consummation of a Qualified Offering, the exercise price will be adjusted to equal the offering
price per share (or per unit, as applicable) in the Qualified Offering, but only if such price is lower than the then-current exercise
price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Warrants are exercisable,
at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full
for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).
A holder (together with its affiliates) may not exercise any portion of such holder&rsquo;s Bridge Warrants to the extent that the holder
would own more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding common stock immediately after exercise, except
that upon prior notice from the holder to us, the holder may increase or decrease the amount of ownership of outstanding stock after exercising
the holder&rsquo;s Bridge Warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect
to the exercise, as such percentage ownership is determined in accordance with the terms of the Bridge Warrants, provided that any increase
will not be effective until 61 days following notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not issue shares of
common stock upon exercise of the Bridge Warrants, together with shares issued upon conversion of the Bridge Notes and upon exercise of
the other warrants issued pursuant to the Bridge SPA, in excess of 19.99% of our outstanding common stock immediately prior to March 4,
2026, unless stockholder approval is obtained. Each holder of Bridge Warrants is entitled to a pro rata portion of such issuance limit
based on its subscription amount under the Bridge SPA and may allocate such portion among the Bridge Warrants it holds in its discretion.
If stockholder approval is obtained, the Bridge Warrants may be exercised without regard to such limitation; if stockholder approval is
not obtained, any portion of a Bridge Warrant that cannot be exercised due to such limitation will remain outstanding and exercisable
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Forced Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Warrants provide
that, at any time any Bridge Warrants are outstanding, if the closing price of our common stock on the applicable trading market equals
or exceeds 300% of the exercise price then in effect for any 20 consecutive trading days, we may, subject to the satisfaction of certain
equity conditions, require the holder to exercise all or a portion of the Bridge Warrants for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Cashless Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at the time a holder exercises
its Bridge Warrants, a registration statement registering the resale of the shares issuable upon exercise of the Bridge Warrants under
the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us
upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole
or in part), the net number of shares of common stock determined according to a formula set forth in the Bridge Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Rights as a Stockholder</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in the Bridge Warrants or by virtue of the holder&rsquo;s ownership of shares of our common stock, such holder of Bridge Warrants does
not have the rights or privileges of a holder of our common stock, including any voting rights, until such holder exercises such holder&rsquo;s
Bridge Warrants. The Bridge Warrants provide that the holders of the Bridge Warrants have the right to participate in distributions or
dividends paid on shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Fundamental Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the Bridge
Warrants are outstanding, we, either directly or indirectly, in one or more related transactions effect a Fundamental Transaction (as
defined in the Bridge Warrants), a holder of Bridge Warrants will be entitled to receive, the number of shares of common stock of the
successor or acquiring corporation or of our company, if our company is the surviving corporation, and any additional consideration receivable
as a result of the Fundamental Transaction by such holder of the number of shares of common stock for which the Bridge Warrants are exercisable
immediately prior to the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Waivers and Amendments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Warrants may be
modified or amended or the provisions of the Bridge Warrants waived with our and the holder&rsquo;s written consent, and the written consent
of the holder is not required for any amendment that does not adversely affect the rights of the holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Terms of the Bridge Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of certain terms and provisions of the Bridge Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Interest and Maturity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes bear interest
at a rate of 4% per annum and mature on March 4, 2027 (the &ldquo;Maturity Date&rdquo;). Interest on the Bridge Notes accrues from the
funding date until the earlier of the Maturity Date or conversion of the Bridge Notes, and all accrued and unpaid interest under the Bridge
Notes will convert together with principal upon any conversion of the Bridge Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Conversion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes are convertible
into shares of our common stock or other securities of our company under the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Mandatory Conversion</I></B>.
If we consummate a &ldquo;Qualified Offering&rdquo; on or before the Maturity Date, the outstanding principal amount of each Bridge Note,
together with all accrued and unpaid interest, will automatically convert into our securities sold in such Qualified Offering at a conversion
price per share equal to the offering price per share (or per unit, as applicable) in the Qualified Offering, without any discount. A
&ldquo;Qualified Offering&rdquo; means a registered public offering or registered direct offering of our securities from which we receive
gross cash proceeds of not less than $2,500,000 from new money investments (excluding any proceeds attributable to the conversion of the
Bridge Notes or any other of our outstanding convertible securities).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Voluntary Conversion</I></B>.
At any time prior to repayment and prior to a mandatory conversion, the Bridge Notes are convertible, in whole or in part, at the option
of the holder, into shares of common stock at a conversion price equal to 90% of the average daily volume weighted average price of our
common stock for the 10 trading days immediately preceding the date the holder delivers a notice of conversion, subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Conversion Price Adjustments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Bridge Notes are
outstanding, the conversion price of the Bridge Notes is subject to adjustment upon the occurrence of certain events, including stock
dividends, stock splits, combinations, reclassifications and certain dilutive issuances. If we issue common stock or common stock equivalents
at an effective price per share that is lower than the then-current conversion price (other than exempt issuances), the conversion price
will be reduced to such lower price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Conversion Limitations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder (together with its
affiliates) may not convert any portion of such holder&rsquo;s Bridge Notes to the extent that the holder would own more than 4.99% (or,
at the election of the holder, 9.99%) of our outstanding common stock immediately after conversion, except that upon prior notice from
the holder to us, the holder may increase or decrease the amount of ownership of outstanding stock after converting the holder&rsquo;s
Bridge Notes up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, as
such percentage ownership is determined in accordance with the terms of the Bridge Notes, provided that any increase will not be effective
until 61 days following notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total number of shares
of common stock issued upon conversion of the Bridge Notes, together with shares issued upon exercise of the Bridge Warrants, or upon
any anti-dilution adjustment, will not exceed 19.99% of our outstanding common stock immediately prior to March 4, 2026, unless stockholder
approval is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Prepayment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have the option to prepay
the Bridge Notes at any time, provided that (i) we offer such prepayment on the same terms to all holders of Bridge Notes on a pro-rata
basis and (ii) each holder electing to accept such prepayment provides its individual written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Events of Default</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes contain customary
events of default, including, among others: (i) failure to pay principal or interest when due; (ii) failure to observe or perform any
material covenant; (iii) material breaches of representations or warranties; (iv) bankruptcy events; (v) certain defaults under other
indebtedness; (vi) delisting of our common stock; (vii) participation in a change of control transaction or fundamental transaction; (viii)
failure to comply with current public information requirements under Rule 144; and (ix) failure to deliver conversion shares within five
trading days after a conversion date. Upon an event of default, the outstanding principal amount, plus accrued and unpaid interest and
any other amounts owed, will become immediately due and payable in cash at a mandatory default amount of 1.5% per month (18% per annum).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Negative Covenants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As long as any portion
of the Bridge Notes remains outstanding, unless the holders of at least 51% of the principal amount of the then outstanding Bridge
Notes consent in writing, we agreed to not, among other things: (i) incur additional indebtedness other than permitted indebtedness;
(ii) create liens other than permitted liens; (iii) amend its charter documents in a manner that materially and adversely affects
the rights of the holders; (iv) repurchase more than a de minimis number of shares of common stock (subject to certain exceptions);
(v) repay, repurchase or otherwise acquire any indebtedness other than the Bridge Notes (if on a pro-rata basis) and regularly
scheduled principal and interest payments of permitted indebtedness; (vi) pay cash dividends or distributions; or (vii) enter into
affiliate transactions that are not on arm&rsquo;s-length terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes, Bridge Warrants
and Bridge Shares were offered and sold by us in reliance upon an exemption from the registration requirements of the Securities Act afforded
by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_008"></A>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement relates to the possible resale from time
to time by the selling stockholders of any or all of the shares of common stock that have been issued by us or may be issued by us to
the selling stockholders upon the exercise of the 2026 Warrants and Bridge Warrants, as well as the conversion of the Bridge Notes. For
additional information regarding the shares covered by this prospectus supplement that are issuable upon exercise of the 2026 Warrants
and Bridge Warrants and the conversion of the Bridge Notes, see the section titled &ldquo;Description of the Transactions&rdquo; above.
We are registering these shares pursuant to the provisions of the 2026 Inducement Letters, privately negotiated inducement offer letters,
and the Bridge SPA in order to permit the selling stockholders to offer the shares for resale from time to time. Except for their participation
in our warrant exercise inducement and exchange transactions in 2025 and 2026, the Bridge Financing, our PIPE financing in December 2024
and January 2025, and/or our initial public offering in August&nbsp;2024, the selling stockholders have not had any material relationship
with us within the past three&nbsp;years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below lists the
selling stockholders and other information regarding the beneficial ownership (as determined under Section&nbsp;13(d)&nbsp;of the Exchange&nbsp;Act
and the rules and regulations thereunder) of the shares held by each of the selling stockholders. This table is prepared based on information
supplied to us by the selling stockholders and reflects holdings as of March 26, 2026. The number of shares in the column &ldquo;Maximum
No. of Common Shares offered hereby&rdquo; represents all of the shares that the selling stockholders may offer under this prospectus
supplement. The number of shares in the column &ldquo;Common Shares Beneficially Owned After Offering&rdquo; assumes that the selling
stockholders will sell all of the shares offered for sale hereby. The selling stockholders, however, are under no obligation to sell any
shares pursuant to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
below, to our knowledge, each selling stockholder named in the table has sole voting and investment power with respect to the shares of
common stock beneficially owned by it, except to the extent authority is shared by spouses under applicable law. Unless otherwise indicated
below, the address of each beneficial owner listed below is c/o OS Therapies Incorporated, 115 Pullman Crossing Road, Suite 103, Grasonville,
Maryland 21638. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for any selling stockholder
named below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common <BR>
Shares <BR>
Beneficially <BR>
Owned Before<BR>
Offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No. of <BR>
Common <BR>
Shares<BR>
issuable&nbsp;upon<BR>
conversion of <BR>
Bridge</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No. of <BR>
Common Shares <BR>
issuable<BR>
upon<BR>
exercise&nbsp;of</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum<BR>
No. of <BR>
Common <BR>
Shares<BR>
offered</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common<BR>
Shares <BR>
Beneficially <BR>
Owned After <BR>
Offering</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Stockholder</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.<SUP>(2)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%<B><SUP>(2)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>hereby<SUP>(1)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.<SUP>(2)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%<B><SUP>(2)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.&nbsp;Family L.P.<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">928,572</FONT></TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD>
    <TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,091,995</FONT></TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">610,864</FONT></TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,702,859</FONT></TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">928,572</FONT></TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ahmed Gheith<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,960</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83,333</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">395,333</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,960</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clayton A.&nbsp;Struve<SUP>(5)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,108</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,667</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">197,667</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,108</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Dent<SUP>(6)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,108</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,108</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David S.&nbsp;Nagelberg 2003 Revocable Trust dated 7/2/2003<SUP>(7)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,215</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,091,995</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">291,667</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,383,662</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,215</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyke Rogers<SUP>(8)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,108</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,108</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ernest W.&nbsp;Moody Revocable Trust<SUP>(9)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">294,643</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">294,643</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Sabey<SUP>(10)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,108</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,108</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kassandra Hendricks Gift Trust<SUP>(11)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">279,762</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">591,762</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kathleen M.&nbsp;Hendricks Trust<SUP>(12)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,215</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,215</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin J.&nbsp;Hendricks<SUP>(13)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,247,995</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">652,530</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,525</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Larry Tubbs<SUP>(14)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">328,869</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">640,869</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lars Bader<SUP>(15)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,995</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,065,031</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,313,026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas A.&nbsp;Satterfield 2021 Revocable&nbsp;Trust<SUP>(16)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">467,996</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">223,215</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">691,211</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tomsat Investment&nbsp;&amp; Trading Co., Inc.<SUP>(17)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">571,429</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">196,429</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">196,429</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">571,429</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
less than 1% of outstanding shares of common stock.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the shares issuable pursuant to the (i) exercise of the 2026 Warrants and Bridge Warrants, which are reflected in the &ldquo;No. of Common Shares issuable upon exercise of Warrants&rdquo; column, and (ii) conversion of the Bridge Notes, which are reflected in the &ldquo;No. of Common Shares issuable upon conversion of Bridge Notes&rdquo; column.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes that (i) the 2026 Warrants and Bridge Warrants held by the selling stockholders will be exercised for the maximum number of shares of our common stock reflected in the &ldquo;No. of Common Shares issuable upon exercise of Warrants&rdquo; column, (ii) the Bridge Notes held by the selling stockholders will be converted for the maximum number of shares of our common stock reflected in the &ldquo;No. of Common Shares issuable upon conversion of Bridge Notes&rdquo; column and (iii)&nbsp;the selling stockholders will sell all of the common stock offered hereby. Percentages are based on 39,533,227 shares of common stock issued and outstanding as of March 26, 2026.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of (i) 319,197 shares issuable upon exercise of 2026 Warrants and (ii) 291,667 shares issuable upon exercise of Bridge Warrants. A.G.&nbsp;Family L.P. is a partnership managed by a general partner controlled by Thomas A.&nbsp;Satterfield, Jr., who has sole voting and investment power with respect to the shares of common stock issuable upon exercise of the 2026 Warrants and Bridge Warrants and conversion of the Bridge Notes held by such partnership.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of 83,333 shares issuable upon exercise of Bridge Warrants. Ahmed Gheith is affiliated with a broker-dealer regulated by FINRA.&nbsp;Mr. Gheith acquired his securities in the ordinary course of his business and, at the time of the acquisition of the shares to be resold pursuant to this prospectus supplement, Mr. Gheith had no agreements or understandings, directly or indirectly, with any person to distribute them.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of 41,667 shares issuable upon exercise of Bridge Warrants.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of 25,000 shares issuable upon exercise of 2026 Warrants.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of 291,667 shares issuable upon exercise of Bridge Warrants. The trustee of David S.&nbsp;Nagelberg 2003 Revocable Trust dated 7/2/2003 is David Nagelberg, who has sole voting and investment power with respect to the shares of common stock issuable upon exercise of the Bridge Warrants and conversion of the Bridge Notes held by such trust.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(8)</TD>
    <TD STYLE="text-align: justify">The shares issuable upon exercise of warrants consist of 49,108 shares
issuable upon exercise of 2026 Warrants.</TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of 294,643 shares issuable upon exercise of 2026 Warrants. The trustee of Ernest W. Moody Revocable Trust is Ernest Moody, who has sole voting and investment power with respect to the shares of common stock issuable upon exercise of the 2026 Warrants held by such trust.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of 49,108 shares issuable upon exercise of 2026 Warrants.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of (i) 196,429 shares issuable upon exercise of 2026 Warrants and (ii) 83,333 shares issuable upon exercise of Bridge Warrants. The trustee of Kassandra Hendricks Gift Trust is Kassandra Hendricks Hoff, who has sole voting and investment power with respect to the shares of common stock issuable upon exercise of the 2026 Warrants and Bridge Warrants and conversion of the Bridge Notes held by such trust.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of 98,215 shares issuable upon exercise of 2026 Warrants. The trustee of Kathleen M. Hendricks Trust is Kathleen Hendricks, who has sole voting and investment power with respect to the shares of common stock issuable upon exercise of the 2026 Warrants held by such trust.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of (i) 319,197 shares issuable upon exercise of 2026 Warrants and (ii) 333,333 shares issuable upon exercise of Bridge Warrants.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of (i) 245,536 shares issuable upon exercise of 2026 Warrants and (ii) 83,333 shares issuable upon exercise of Bridge Warrants.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of (i) 731,697 shares issuable upon exercise of 2026 Warrants and (ii) 333,334 shares issuable upon exercise of Bridge Warrants.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of (i) 98,215 shares issuable upon exercise of 2026 Warrants and (ii) 125,000 shares issuable upon exercise of Bridge Warrants. The trustee of Thomas A.&nbsp;Satterfield 2021 Revocable Trust is Thomas A.&nbsp;Satterfield, Jr., who has sole voting and investment power with respect to the shares of common stock issuable upon exercise of the 2026 Warrants and Bridge Warrants and conversion of the Bridge Notes held by such trust.</FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable upon exercise of warrants consist of 196,429 shares issuable upon exercise of 2026 Warrants. The President of Tomsat Investment&nbsp;&amp; Trading Co., Inc. is Thomas A.&nbsp;Satterfield, Jr., who has sole voting and investment power with respect to the shares of common stock issuable upon exercise of the 2026 Warrants held by such company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_009"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering the shares
of our common stock that have been issued by us or are issuable by us upon exercise of the 2026 Warrants and Bridge Warrants and conversion
of the Bridge Notes to permit the resale of these shares by the selling stockholders from time to time after the date of this prospectus
supplement. We will not receive any of the proceeds from the sale by the selling stockholders of the shares, although we will receive
the exercise price of any 2026 Warrants and Bridge Warrants not exercised by the selling stockholders on a cashless exercise basis. The
selling stockholders will bear all fees, commissions and discounts, if any, attributable to the sales of shares and any transfer taxes.
We will bear all other costs, expenses and fees in connection with the registration of shares of our common stock to be sold by the selling
stockholders pursuant to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
resell or redistribute shares of our common stock from time to time on any stock exchange or automated interdealer quotation system on
which the shares of our common stock are listed, in the over-the-counter market, in privately negotiated transactions, or in any other
legal manner, at fixed prices that may be changed, at market prices prevailing at the time of sale, at prices related to prevailing market
prices or at negotiated prices. Persons who are pledgees, donees, transferees, or other successors in interest of any of the named selling
stockholders (including but not limited to persons who receive shares of our common stock from a named selling stockholder as a gift,
partnership distribution or other non-sale-related transfer after the date of this prospectus supplement) may also use this prospectus
supplement and are included when we refer to &ldquo;selling stockholders&rdquo; in this prospectus supplement. The selling stockholders
may sell the shares of our common stock by one or more of the following methods, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
trades (which may include cross trades) in which the broker or dealer so engaged will attempt to sell the shares of our common stock
as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
by a broker or dealer as principal and resale by the broker or dealer for its own account;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
exchange distribution or secondary distribution in accordance with the rules of any stock exchange on which the shares of our common
stock may be listed;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
brokerage transactions and transactions in which the broker solicits purchases;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
offering at other than a fixed price on or through the facilities of any stock exchange on which the shares of our common stock are listed
or to or through a market maker other than on that stock exchange;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
negotiated transactions, directly or through agents;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
the writing of options on the shares of our common stock, whether or the options are listed on an options exchange;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
the distribution of the shares of our common stock by any selling stockholders to its partners, members or stockholders;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one
or more underwritten offerings;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreements
between a broker or dealer and any selling stockholder to sell a specified number of the shares of our common stock at a stipulated price
per share; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
combination of any of these methods of sale or distribution, or any other method permitted by applicable law.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
also transfer the shares of our common stock by gift.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any securities
that qualify for sale pursuant to Rule 144 or another exemption from registration under the Securities Act or other such exemption may
be sold under Rule 144 rather than pursuant to this prospectus supplement or the accompanying prospectus. Further, the selling stockholders
may enter into derivative transactions with broker-dealers, other financial institutions or third parties or sell securities not covered
by this prospectus supplement or the accompanying prospectus to third parties in privately negotiated or registered transactions. These
transactions may involve the sale of shares of common stock by the selling stockholders by forward sale or by an offering (directly or
by entering into derivative transactions with broker-dealers, other financial institutions or third parties) of options, swaps, rights,
warrants or other securities that are offered with, convertible into or exchangeable for shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
elect to make an&nbsp;in-kind&nbsp;distribution of the shares of common stock to its members, partners or shareholders. In such event,
we may file a prospectus supplement to the extent required by law in order to permit the distributees to use the prospectus to resell
the shares of common stock acquired in the distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent required, this
prospectus supplement may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with
distributions of the securities or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers or other
financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales
of the securities in the course of hedging the positions they assume with a selling the stockholder. The selling stockholders may also
sell the securities short and redeliver the securities to close out such short positions. The selling stockholders may also enter into
option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other
financial institution of securities offered by this prospectus supplement, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus supplement (as supplemented or amended to reflect such transaction). The selling stockholders may
also pledge securities to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution,
may effect sales of the pledged securities pursuant to this prospectus supplement (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In effecting sales, broker-dealers
or agents engaged by the selling stockholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive
commissions, discounts or concessions from the selling stockholders in amounts to be negotiated immediately prior to the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In offering the securities
covered by this prospectus supplement, the selling stockholders and any broker-dealers who execute sales for the selling stockholders
may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act in connection with such sales. Any profits realized
by the selling stockholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at the time of any offering
made under this prospectus supplement a member of FINRA participating in the offering has a &ldquo;conflict of interest&rdquo; as defined
in FINRA Rule 5121, or Rule 5121, that offering will be conducted in accordance with the relevant provisions of Rule 5121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply with the
securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through registered or licensed
brokers or dealers. In addition, in certain states the securities may not be sold unless they have been registered or qualified for sale
in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
and any other persons participating in the distribution will be subject to the applicable provisions of the Exchange Act and the rules
and regulations under the Exchange Act, including, without limitation, Regulation M, which may limit the timing of purchases and sales
by the selling stockholders and any other relevant persons of any of the securities. Furthermore, Regulation M may restrict the ability
of any person engaged in the distribution of securities to engage in market-making activities with respect to the securities being distributed.
All of the above may affect the marketability of the securities and the ability of any person or entity to engage in market-making activities
with respect to the securities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we will make
copies of this prospectus supplement and the accompanying prospectus available to the selling stockholders for the purpose of satisfying
the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates
in transactions involving the sale of the securities against certain liabilities, including liabilities arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the time a particular offer
of securities is made, if required, an additional prospectus supplement may be distributed that will set forth the number of securities
being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter,
any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid
to any dealer, and the proposed selling price to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify
the selling stockholders against certain liabilities, including liabilities under the Securities Act and state securities laws, relating
to the registration of the shares of common stock offered by this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Olshan Frome Wolosky LLP,
New York, New York, will pass upon the validity of the issuance of the common stock offered by this prospectus supplement as our counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements of OS Therapies Incorporated
incorporated in this prospectus supplement by reference to the Annual Report on Form 10-K for the year ended December 31, 2025 have been
so incorporated in reliance on the report, which contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as
a going concern, of MaloneBailey, LLP, an independent registered public accounting firm, given on the authority of said firm as experts
in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form S-3, of which this prospectus supplement and the accompanying base prospectus are a part, under the Securities
Act, to register the shares of common stock offered by this prospectus supplement. However, this prospectus supplement and the accompanying
base prospectus do not contain all of the information contained in the registration statement and the exhibits and schedules to the registration
statement. We encourage you to carefully read the registration statement and the exhibits and schedules to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the reporting
requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC.
The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers
that file electronically with the SEC, including us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded
on the NYSE American under the symbol &ldquo;OSTX.&rdquo; General information about our company, including our Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as any amendments and exhibits to those reports, are available
free of charge through our website at www.ostherapies.com as soon as reasonably practicable after we file them with, or furnish them to,
the SEC. Information on, or that can be accessed through, our website is not incorporated into this prospectus supplement or other securities
filings and is not a part of these filings.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_013"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We &ldquo;incorporate by reference&rdquo;
into this prospectus supplement the information we file with the SEC, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is an important part of this prospectus supplement and information
that we file subsequently with the SEC will automatically update this prospectus supplement. We incorporate by reference the documents
listed below and any filings we make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after initial filing of
the registration statement that contains the prospectus and prior to the time that we sell all the securities offered by this prospectus
supplement (in each case, except for the information furnished under Item 2.02 or Item 7.01 in any current report on Form 8-K and Form
8-K/A):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026036629/ea0283146-10k_ostherap.htm">Form 10-K</A> for the year ended December 31, 2025, filed with the SEC on March
                                            31, 2026;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Reports on Form 8-K (only to the extent &ldquo;filed&rdquo; and not &ldquo;furnished&rdquo;) filed with the SEC on</FONT> <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026003166/ea0272516-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
12, 2026</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026016408/ea0276846-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
13, 2026</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026024726/ea0280014-8k_ostherapies.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
6, 2026</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            description of our registered securities contained in <A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390026036629/ea028314601ex4-9.htm">Exhibit 4.9</A> to our Annual Report on
                                            <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026036629/ea0283146-10k_ostherap.htm">Form 10-K</A> for the year ended December 31, 2025, filed with the SEC on March 31, 2026,
                                            including any amendment or reports filed for the purpose of updating this description.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may request a copy of
these filings (other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing) at no
cost, by writing to or telephoning us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OS Therapies Incorporated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">115 Pullman Crossing Road, Suite 103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Grasonville, Maryland 21638</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(410) 297-7793</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea028392501_img1.jpg" ALT="A blue text on a white background&#10;&#10;Description automatically generated" STYLE="height: 64px; width: 401px"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$100,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SENIOR DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBORDINATED DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
offer and sell any combination of the securities described in this prospectus in one or more offerings. The securities we may offer may
be convertible into or exercisable or exchangeable for other securities. We may offer the securities separately or together, in separate
classes or series and in amounts, at prices and on terms that will be determined at the time the securities are offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, certain selling
stockholders may from time to time offer and sell shares of our common stock. We will not receive any of the proceeds from the sale of
shares of our common stock by selling stockholders, if any, pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus describes
some of the general terms that may apply to these securities. Each time securities are sold, the specific terms and amounts of the securities
being offered, and any other information relating to the specific offering will be set forth in a supplement to this prospectus. We may
also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. In any prospectus supplement
relating to any sales by the selling stockholders, we will, among other things, identify the number of shares of our common stock that
the selling stockholders will be selling. The prospectus supplement and any related free writing prospectus may also add, update or change
information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related
free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.
This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares of common stock
trade on the NYSE American under the symbol &ldquo;OSTX.&rdquo; On August 25, 2025, the closing price of our common stock was $2.19. The
applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, of the securities covered
by the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, or any selling stockholders
as it only relates to shares of common stock, may offer and sell our securities to or through one or more underwriters, dealers and agents,
or directly to purchasers, on an immediate, continuous or delayed basis. The names of any underwriters, dealers or agents and the terms
of the arrangements with such entities will be stated in the accompanying prospectus supplement. See the sections of this prospectus entitled
&ldquo;About this Prospectus&rdquo; and &ldquo;Plan of Distribution&rdquo; for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading &ldquo;Risk Factors&rdquo;
on page 3 of this prospectus as well as those contained in the applicable prospectus supplement and any related free writing prospectus,
and in the other documents that are incorporated by reference into this prospectus or the applicable prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is August 25, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_001">About This Prospectus</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_002">ABOUT THE COMPANY</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_003">Risk Factors</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_004">CAUTIONARY STATEMENT Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_005">USE Of proceeds</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_006">dESCRIPTION OF OUR cAPITAL sTOCK</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_007">dESCRIPTION OF oUR dEBT sECURITIES</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_008">DESCRIPTION OF OUR WARRANTS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_009">DESCRIPTION OF OUR RIGHTS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_010">Description of OUR UNITS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_011">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_012">SELLING STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_013">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_014">EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_015">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#b_016">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_001"></A>About
This Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement that we filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;), using a &ldquo;shelf&rdquo; registration process. Under the shelf registration
process, we may from time to time, offer and sell to the public any or all of the securities described in this prospectus in one or more
offerings for an aggregate offering amount of up to $100,000,000. In addition, under this shelf registration process, selling stockholders
may from time to time sell shares of our common stock in one or more offerings. Before purchasing any securities, you should read this
prospectus and any applicable prospectus supplement together with the additional information described under the headings &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus only provides
you with a general description of the securities we and/or the selling stockholders may offer. Each time we sell a type or series of securities
under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of the offering,
including the specific amounts, prices and terms of the securities offered. We may also authorize one or more free writing prospectuses
to be provided to you that may contain material information relating to these offerings. This prospectus may not be used to sell our securities
unless accompanied by a prospectus supplement. Each such prospectus supplement and any free writing prospectus that we may authorize to
be provided to you may also add, update or change information contained in this prospectus or in documents incorporated by reference into
this prospectus. If this prospectus is inconsistent with the prospectus supplement or free writing prospectus, you should rely upon the
prospectus supplement or free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains summaries
of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to
herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus
is a part, and you may obtain copies of those documents as described below under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus incorporates
by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry
statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe
these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified
this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus,
any prospectus supplement or any applicable free writing prospectus may involve estimates, assumptions and other risks and uncertainties
and are subject to change based on various factors, including those discussed under the heading &ldquo;Risk Factors&rdquo; contained in
this prospectus, the applicable prospectus supplement and any applicable free writing prospectus, and under similar headings in other
documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, except
as otherwise indicated, the words &ldquo;OS Therapies&rdquo; or the &ldquo;Registrant&rdquo; refer to OS Therapies Incorporated and the
words &ldquo;company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to OS Therapies, together with its consolidated
subsidiaries. In this prospectus, references to &ldquo;securities&rdquo; collectively means our common stock, preferred stock, warrants,
debt securities, or any combination of the foregoing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on information
contained or incorporated by reference in this prospectus. Neither we, any selling stockholders, nor any underwriters have authorized
any person to provide you with information that differs from what is contained or incorporated by reference in this prospectus. If any
person does provide you with information that differs from what is contained or incorporated by reference in this prospectus, you should
not rely on it. This prospectus is not an offer to sell or the solicitation of an offer to buy any securities other than the securities
to which it relates, or an offer or solicitation in any jurisdiction where offers or sales are not permitted. The information contained
in this prospectus is accurate only as of the date of this prospectus, even though this prospectus may be delivered or shares may be sold
under this prospectus on a later date. Our business, financial condition, results of operation and prospects may have changed since those
dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_002"></A><FONT STYLE="text-transform: uppercase"><B>about
the company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OS Therapies Incorporated
is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma
(OS) and other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and
young adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to its
location, changing genotypes and high metastases rates. We are currently seeking to answer the call for new treatments that will prevent
metastasis and the recurrence of metastases with our lead core product candidate OST-HER2 (also known as OST31-164), a cancer immunotherapy
product candidate that produces a cellular immune response against the cancer antigen HER2. In 2021, we opened a clinical study to produce
data for the U.S.&nbsp;Food and Drug Administration (FDA) to evaluate the safety and efficacy of OST-HER2 in patients after resection
of recurrent Osteosarcoma, which achieved full enrollment of 41 patients in October&nbsp;2023. In the first quarter of 2025, we announced
that our Phase&nbsp;IIb clinical trial achieved its primary endpoint with statistical significance. We believe the efficacy results, combined
with the favorable safety profile and the unmet clinical need, support the potential for regulatory approval. In June 2025, we participated
in a Type D meeting with the FDA and subsequently received positive written feedback regarding the design and endpoints of our Phase IIb
trial of OST-HER2 to support a potential Biologics License Application (BLA). Based on this feedback, we have submitted a Breakthrough
Therapy Designation request and, subject to continued positive regulatory guidance, plan to submit a BLA for OST-HER2 following our End
of Phase 2 meeting with the FDA, anticipated in the third quarter of 2025. Upon success in gaining regulatory approval from the FDA with
OST-HER2 in Osteosarcoma, we intend to evaluate OST-HER2&rsquo;s potential use, both alone and in combination with HER2 targeting antibodies
such as Herceptin&reg;, in other solid tumors including breast, esophageal and lung cancers. OST-HER2 has potential uses in both the prevention
of metastases in solid tumors, and therapeutically against HER2-expressing solid tumors treated with HER targeting antibodies. In addition
to our development of OST-HER2 for multiple indications of solid cancers in humans, OST-HER2 is a product candidate for veterinary use
in canines. As part of our growth strategies, we intend to consider potentially out-licensing OST-HER2 to animal health companies for
such use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own rights to OST-Tunable
Drug Conjugate (OST-tADC) platform, a next generation antibody-drug conjugate (ADC) silicone dioxide linker technology. &ldquo;Tunable&rdquo;
is a term used in drug development that refers to the properties that can be influenced by chemical modifications, and &ldquo;antibody-drug
conjugate&rdquo; or ADC is a term used to describe a drug made up of a monoclonal antibody attached to a cytotoxic payload, or a highly
active and toxic pharmaceutical molecule, through chemical linkers. The ADC links an antibody that can home in on a targeted tumor to
deploy the cytotoxic payload or toxic agent against the tumor. Furthering our founding mission, we intend to investigate clinical indications
for OST-tADC in Osteosarcoma and other solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being an Emerging Growth Company and Smaller Reporting
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as an &ldquo;emerging
growth company&rdquo; as defined in the Jumpstart Our Business Startups Act&nbsp;of&nbsp;2012 (the &ldquo;JOBS Act&rdquo;). For as long
as we remain an emerging growth company, we may take advantage of specified reduced reporting requirements and other burdens that are
otherwise applicable generally to other public companies. These provisions include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced obligations with respect to financial data, including presenting only two&nbsp;years of audited financial statements and selected financial data, and only two&nbsp;years of related Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in our initial registration statement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act&nbsp;of&nbsp;2002, as amended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions from the requirements to seek non-binding advisory votes on executive compensation or stockholder approval of any golden parachute arrangements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may take advantage of some
or all of these provisions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest
of (i)&nbsp;the last&nbsp;day the fiscal year following the fifth anniversary of the completion of our initial public offering, (ii)&nbsp;the
last&nbsp;day of the first fiscal year in which our annual gross revenues exceed $1.235&nbsp;billion, (iii)&nbsp;the date on which we
have, during the immediately preceding three-year period, issued more than $1.0&nbsp;billion in non-convertible debt securities and (iv)&nbsp;the
date on which we are deemed to be a large accelerated filer under the rules of the SEC.&nbsp;We may choose to take advantage of some but
not all of these reduced burdens. For example, we have taken advantage of the reduced reporting requirements with respect to disclosure
regarding our executive compensation arrangements, have presented only two&nbsp;years of audited financial statements and only two&nbsp;years
of related &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; disclosure incorporated
by reference in this prospectus, and have taken advantage of the exemption from auditor attestation on the effectiveness of our internal
control over financial reporting. To the extent that we take advantage of these reduced burdens, the information that we provide stockholders
may be different than you might obtain from other public companies in which you hold shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the JOBS Act
permits emerging growth companies to take advantage of an extended transition period to comply with new or revised accounting standards
applicable to public companies. We have elected to use this extended transition period. As a result of this election, our timeline to
comply with new or revised accounting standards will in many cases be delayed as compared to other public companies that are not eligible
to take advantage of this election or have not made this election. Therefore, our financial statements may not be comparable to those
of companies that comply with the public company effective dates for these accounting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also a &ldquo;smaller
reporting company&rdquo; as defined in the Securities Exchange&nbsp;Act&nbsp;of&nbsp;1934, as amended (the &ldquo;Exchange&nbsp;Act&rdquo;),
and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies. To the extent that we
continue to qualify as a &ldquo;smaller reporting company&rdquo; as such term is defined in Rule&nbsp;12b-2 under the Exchange&nbsp;Act,
after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an &ldquo;emerging growth company&rdquo;
may continue to be available to us, including exemption from compliance with the auditor attestation requirements pursuant to the Sarbanes-Oxley
Act and reduced disclosure about our executive compensation arrangements. We will continue to be a &ldquo;smaller reporting company&rdquo;
until we have $250&nbsp;million or more in public float (based on our common stock) measured as of the last business&nbsp;day of our most
recently completed second fiscal quarter or, in the event we have no public float (based on our common stock) or a public float (based
on our common stock) that is less than $700&nbsp;million, annual revenues of $100&nbsp;million or more during the most recently completed
fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed as a Delaware
limited liability company on April&nbsp;12, 2018 under the name OS Therapies, LLC.&nbsp;On June&nbsp;24, 2019, we converted from a limited
liability company to a Delaware corporation and changed our name to OS Therapies Incorporated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We presently conduct all of
our operations remotely. Our registered corporate address is 115 Pullman Crossing Road, Suite #103, Grasonville, Maryland 21638, and our
telephone number is (410)&nbsp;297-7793. Our website address is <I>www.ostherapies.com</I>. We make our periodic and current reports that
are filed with the SEC available, free of charge, on our website as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. Information contained on, or accessible through, our website is not a part of, and is not incorporated
by reference into, this prospectus or any accompanying prospectus supplement.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_003"></A><FONT STYLE="text-transform: uppercase"><B>Risk
Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our securities
involves a high degree of risk. Before making a decision to invest in our securities, you should carefully consider the risks described
under the heading &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement and any related free writing prospectus, and under
similar headings in our most recent annual report on Form 10-K, and in subsequent quarterly reports on Form 10-Q filed subsequent to such
Form 10-K, as well as any amendments thereto, which are incorporated by reference into this prospectus and the applicable prospectus supplement
in their entirety, together with other information in this prospectus and the applicable prospectus supplement, the documents incorporated
by reference herein and therein, and any free writing prospectus that we may authorize for use in connection with a specific offering.
See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_004"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, any prospectus
supplement and any related free writing prospectus, including the information incorporated by reference herein and therein, contain forward-looking
statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Any statements about our expectations,
beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements
are often, but are not always, made through the use of words or phrases such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo;
&ldquo;will,&rdquo; &ldquo;would,&rdquo; or the negative of these words or other comparable terminology. Accordingly, these statements
involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given these uncertainties,
you should not place undue reliance on these forward-looking statements as actual events or results may differ materially from those projected
in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &ldquo;Risk
Factors&rdquo; in any applicable prospectus supplement, the documents incorporated by reference therein or any free writing prospectus
that we authorized. Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements
contained in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement by these cautionary statements.
These forward-looking statements speak only as of the date on which the statements were made and are not guarantees of future performance.
Although we undertake no obligation to revise or update any forward-looking statements (except as required by U.S. federal securities
laws), whether as a result of new information, future events or otherwise, you are advised to review any additional disclosures we make
in the documents we subsequently file with the SEC that are incorporated by reference in this prospectus and any prospectus supplement.
See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="b_005"></A><B>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in a prospectus supplement, we intend to use the net proceeds from the sale of securities offered by this prospectus and any applicable
prospectus supplement for working capital and other general corporate purposes, which may include funding our ongoing and planned clinical
trials, advancing our research and development programs, and acquiring or investing in technologies, product candidates or businesses
that are complementary to our strategic objectives. Until we apply the proceeds from a sale of securities to their intended purposes,
we may invest those proceeds in short-term, interest-bearing, investment-grade, securities or hold as cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any of
the proceeds from the sale of shares of our common stock by selling stockholders, if any, pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_006"></A>DESCRIPTION OF OUR CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary of
the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities, and is
qualified by reference to our third amended and restated certificate of incorporation, as amended (&ldquo;certificate of incorporation&rdquo;),
our certificate of designation, preferences, rights and limitations of Series A senior convertible preferred stock (the &ldquo;certificate
of designation&rdquo;), our amended and restated bylaws, as amended (&ldquo;bylaws&rdquo;), and the warrant-related documents described
herein, which are exhibits to the registration statement of which this prospectus is a part. We urge you to read each of our certificate
of incorporation, our bylaws and the warrant-related documents described herein in their entirety for a complete description of the rights
and preferences of our securities.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized capital stock
currently consists of 50,000,000&nbsp;shares of common stock, par value $0.001 per share, and 5,000,000&nbsp;shares of preferred stock,
par value $0.001 per share, of which 2,500,000 shares of which are designated as Series A senior convertible preferred stock, par value
$0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock
do not have any cumulative voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject
to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or
other subscription rights or redemption or sinking fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all
debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares of common stock to be issued
by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares of common stock
are traded on the NYSE American under the symbol &ldquo;OSTX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is VStock Transfer, LLC, Woodmere, New&nbsp;York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
the authority, without further action by our stockholders, to issue up to 5,000,000&nbsp;shares of preferred stock in one or more series
and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend
rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting,
or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred
stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments
and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing
a change in control of our company or other corporate action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Series A Senior Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of designation
sets forth the rights, preferences and limitations of our Series A senior convertible preferred stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right of the holder to convert such shares of Series A senior convertible preferred stock into shares of our common stock, with mandatory conversion upon (i) a qualified firm commitment underwritten public offering of common stock raising gross proceeds in excess of $10.0 million, with a per share price not less than $12.00, (ii) a qualified PIPE financing raising gross proceeds in excess of $20.0 million, with a per share price not less than $12.00, (iii) a closing of a third-party acquisition where all outstanding shares of common stock (including the shares of common stock issued pursuant to the mandatory conversion of the Series A senior convertible preferred stock) are purchased or exchanged by an unaffiliated third party and in which the consideration paid to all holders of outstanding shares of common stock for such purchase or exchange consists solely of cash at a purchase price per share of common stock not less than $12.00, or (iv) such time as the daily VWAP for the common stock is greater than 300% of the then applicable conversion price for a period of 20 consecutive trading days with minimum average daily trading volume of $2.0 million;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a liquidation preference of 150% of the original issue price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right to one vote per share and vote together with the common stock on an as-converted&nbsp;basis (subject to a voting price floor equal to $3.78), except that holders of Series A senior convertible preferred stock shall vote as a separate class with respect to certain specified matters; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such other terms and provisions as are set forth in the certificate of designation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of Series A senior
convertible preferred stock is convertible into a number of shares of common stock at a conversion ratio equal to (A) the original issue
price of the Series A senior convertible preferred stock divided by (B) the conversion price of the Series A senior convertible preferred
stock. The original issue price and the conversion price of the Series A senior convertible preferred stock will initially be $4.00 (resulting
in an initial conversion ratio of 1:1) and are subject to adjustment as set forth in the certificate of designation. The Series A Preferred
Stock will not be traded on any securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The conversion price of the
Series A senior convertible preferred stock was automatically reset to $1.12 per share on April 23, 2025 and is subject to further adjustment
upon the occurrence of certain events, including the sale of equity securities by us at an effective price per share less than the then
conversion price during the two-year&nbsp;period beginning from the initial issuance date, subject to certain exceptions (the &ldquo;Series
A Dilutive Issuances&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Ayala Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the acquisition
of the&nbsp;<I>Lm</I>-based immune-oncology programs and related intellectual property assets from Ayala Pharmaceuticals, Inc. (&ldquo;Ayala&rdquo;),
we issued to Ayala a warrant to purchase 2,166,381&nbsp;shares of common stock. The warrant is exercisable upon issuance at an exercise
price per share of $0.001 (as adjusted from time to time in accordance with the terms thereof) and will expire three years from the date
of issuance. This warrant may not be exercised to the extent that the holder, together with its affiliates, would beneficially own more
than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. The holder may increase
or decrease this percentage, but not in excess of 19.99%, unless and until we obtain stockholder approval as required by NYSE American
LLC Company Guide Section 713.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>IPO Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We issued warrants to Brookline
Capital Markets, a division of Arcadia Securities, LLC, the representative of the underwriters in our initial public offering, to purchase
an aggregate of 112,000 shares of common stock at an exercise price of $4.40 per share. These warrants are currently exercisable and have
a cashless exercise provision and will terminate on the fifth anniversary of July 31, 2024. These warrants also provide for customary
anti-dilution&nbsp;provisions, a single demand registration right, and immediate &ldquo;piggyback&rdquo; registration rights with respect
to the registration of the shares of common stock underlying the warrants, with a term of such demand and &ldquo;piggyback&rdquo; registration
rights not exceeding five&nbsp;years from July 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Series A Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&nbsp;31, 2024
and January&nbsp;14, 2025, we issued warrants exercisable into 7,211,303&nbsp;shares of common stock at an exercise price of $1.12 per
share, subject to adjustment as set forth therein. The exercise price of these warrants is subject to the Series A Dilutive Issuances.
These warrants are exercisable by the holder for a period of five years from April&nbsp;9, 2025. As of August 8, 2025, warrants to purchase
3,446,308 shares of common stock remain outstanding and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>New Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From June 23 to July 11, 2025,
we issued warrants to purchase an aggregate of 3,764,995 shares of common stock at an exercise price of $3.00 per share, subject to adjustment
as set forth therein. These warrants are immediately exercisable from the date of issuance and have a term of exercise of five years from
such date. The exercise price and number of shares issuable upon exercise of these warrants are subject to appropriate adjustment in the
event of stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations or similar events affecting
our common stock and the exercise price. The exercise price of these warrants is also subject to adjustment upon the occurrence of subsequent
sales of equity securities by us during such time any of these warrants are outstanding at an effective price per share less than the
exercise price of these warrants then in effect (such lower price, the &ldquo;Dilutive Issuance Price&rdquo; and such issuances, collectively,
&ldquo;Dilutive Issuances&rdquo;), subject to certain exceptions. In the event of a Dilutive Issuance, the exercise price will be reduced
to the greater of (x) such lower Dilutive Issuance Price and (y) $1.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These warrants also provide
that, at any time any of these warrants are outstanding, if the closing price of our common stock on the applicable trading market equals
or exceeds 300% of the exercise price then in effect for any 20 consecutive trading days, we may, subject to the satisfaction of certain
equity conditions, require the holder to exercise all or a portion of the warrants for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws
and Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation
and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control
of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board
of directors rather than pursue non-negotiated&nbsp;takeover attempts. These provisions include the items described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Board composition and
filling vacancies. </I></B>Our certificate of incorporation provides that directors may be removed with or without cause only by the affirmative
vote of the holders of two-thirds&nbsp;or more of the shares then entitled to vote at an election of directors. Further, any vacancy on
our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled
by the affirmative vote of a majority of our directors then in office even if less than a quorum. The limitations on removal of directors
and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>No written consent of
stockholders. </I></B>Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the
stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This
limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of
directors by our stockholders without holding a meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Meetings of stockholders.</I></B>
Our certificate of incorporation and bylaws provide that a special meeting of stockholders may be called only by resolution adopted by
our board of directors, chairman of the board of directors or chief executive officer or upon the written request of stockholders owning
at least 33&amp;frac13;% of the outstanding common stock and only those matters set forth in the notice of the special meeting may be
considered or acted upon at a special meeting of stockholders. Stockholders owning less than 33&amp;frac13;% may not call a special meeting,
which may delay the ability of our stockholders to force consideration of a proposal or for holders controlling a majority of our capital
stock to take any action, including the removal of directors. Our bylaws limit the business that may be conducted at an annual meeting
of stockholders to those matters properly brought before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Advance notice requirements.
</I></B>Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for
election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder
proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally,
to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior
to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content
of all stockholders&rsquo; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual
or special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Amendment to certificate
of incorporation and bylaws. </I></B>Any amendment of our certificate of incorporation must first be approved by a majority of our board
of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding
shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except
that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by
not less than two-thirds&nbsp;of the outstanding shares entitled to vote on the amendment, and not less than two-thirds&nbsp;of the outstanding
shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors
then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the
outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating
to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds&nbsp;of the outstanding
shares entitled to vote on the amendment, and not less than two-thirds&nbsp;of the outstanding shares of each class entitled to vote thereon
as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority
of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Undesignated preferred
stock. </I></B>Our certificate of incorporation provides for 5,000,000 authorized shares of preferred stock. The existence of authorized
but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of
a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors
were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares
of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute
the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of
incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred
stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders
of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and
may have the effect of delaying, deterring or preventing a change in control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations on Liability and Indemnification
of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation
and bylaws provide indemnification for our directors and officers to the fullest extent permitted by the Delaware General Corporation
Law. We have entered into indemnification agreements with each of our directors that may, in some cases, be broader than the specific
indemnification provisions contained under Delaware law. In addition, as permitted by Delaware law, our certificate of incorporation includes
provisions that eliminate the personal liability of our directors and officers for monetary damages resulting from breaches of certain
fiduciary duties as a director or officer, as applicable, except to the extent such an exemption from liability thereof is not permitted
under the Delaware General Corporation Law. The effect of these provisions is to restrict our rights and the rights of our stockholders
in derivative suits to recover monetary damages against a director or officer for breach of fiduciary duties as a director or officer,
subject to certain exceptions in which case the director or officer would be personally liable. An officer may not be exculpated for any
action brought by or in the right of the corporation. A director may not be exculpated for improper distributions to stockholders. Further,
pursuant to Delaware law a director or officer may not be exculpated for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any breach of his or her duty of loyalty to us or our stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction from which the director or officer derived an improper personal benefit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These limitations of liability
do not apply to liabilities arising under the federal or state securities laws and do not affect the availability of equitable remedies
such as injunctive relief or rescission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide that we
will indemnify our directors and officers to the fullest extent permitted by law, and may indemnify employees and other agents. Our bylaws
also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action
or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into separate
indemnification agreements with our directors and officers. These agreements, among other things, require us to indemnify our directors
and officers for any and all expenses (including reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of experts,
witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees) judgments,
fines and amounts paid in settlement actually and reasonably incurred by such directors or officers or on his or her behalf in connection
with any action or proceeding arising out of their services as one of our directors or officers, or any of our subsidiaries or any other
company or enterprise to which the person provides services at our request provided that such person follows the procedures for determining
entitlement to indemnification and advancement of expenses set forth in the indemnification agreement. We believe that these bylaw provisions
and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The limitation of liability
and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against
directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers,
even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition
may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed
that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At present, there is no pending
litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not
aware of any threatened litigation or proceeding that may result in a claim for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section&nbsp;203 of the Delaware General Corporation Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the provisions
of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation
from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a three-year&nbsp;period following
the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner.
Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one
of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds&nbsp;of the outstanding voting stock which is not owned by the interested stockholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;203 defines a
business combination to include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section&nbsp;203
defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation
and any entity or person affiliated with or controlling or controlled by the entity or person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_007"></A><B>DESCRIPTION OF OUR DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary, together with
the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the debt
securities that we may offer under this prospectus. While the terms we have summarized below will generally apply to any future debt securities
we may offer, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus
supplement. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The debt securities may be
either secured or unsecured and will either be senior debt securities or subordinated debt securities. We will issue the senior notes
under the senior indenture which we will enter into with one or more trustees. We will issue the subordinated notes under the subordinated
indenture which we will enter into with one or more trustees. We have filed forms of these documents as exhibits to the registration statement
of which this prospectus forms a part. We use the term &ldquo;indentures&rdquo; to refer to both the senior indenture and the subordinated
indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures will be qualified
under the Trust Indenture Act of 1939, as amended, (the &ldquo;Trust Indenture Act&rdquo;). We use the term &ldquo;debenture trustee&rdquo;
to refer to either the senior trustee or the subordinated trustee, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summaries of
the material provisions of the senior notes, the subordinated notes and the indentures are subject to, and qualified in their entirety
by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the
applicable prospectus supplements related to the debt securities that we sell under this prospectus, as well as the complete indenture,
that contain the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated
indenture are identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in the applicable
prospectus supplement the terms relating to a series of debt securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the principal amount being offered and, if a series, the total amount authorized and the total amount outstanding;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any limit on the amount that may be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not we will issue the series of debt securities in global form and, if so, the terms and who the depositary will be;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the maturity date;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the principal amount due at maturity and whether the debt securities will be issued with any original issue discount;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a U.S. person for U.S. federal income tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the annual interest rate, which may be fixed or variable, or the method for determining the rate, the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not the debt securities will be senior or subordinated, and the terms of the subordination of any series of subordinated debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the place where payments will be payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on transfer, sale or other assignment, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date, if any, after which, the conditions upon which, and the price at which we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions, and any other applicable terms of those redemption provisions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions for a sinking fund, purchase or other analogous fund, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the indenture will restrict our ability and/or the ability of our subsidiaries to:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional indebtedness;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue additional securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create liens;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay dividends and make distributions in respect of our capital stock and the capital stock of our subsidiaries;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redeem capital stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">place restrictions on our subsidiaries&rsquo; ability to pay dividends, make distributions or transfer assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make investments or other restricted payments;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell or otherwise dispose of assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into sale-leaseback transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage in transactions with stockholders and affiliates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue or sell stock of our subsidiaries; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effect a consolidation or merger;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material or special U.S. federal income tax considerations applicable to the debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information describing any book-entry features;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the procedures for any auction and remarketing, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if other than U.S. dollars, the currency in which the series of debt securities will be denominated; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any events of default that are in addition to those described in this prospectus or any covenants provided with respect to the debt securities that are in addition to those described above, and any terms which may be required by us or advisable under applicable laws or regulations or advisable in connection with the marketing of the debt securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will set forth in the applicable
prospectus supplements the terms on which a series of debt securities may be convertible into or exchangeable for common stock or other
securities of ours or a third party, including the conversion or exchange rate, as applicable, or how it will be calculated, and the applicable
conversion or exchange period. We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder
or at our option. We may include provisions pursuant to which the number of our securities or the securities of a third party that the
holders of the series of debt securities receive upon conversion or exchange would, under the circumstances described in those provisions,
be subject to adjustment, or pursuant to which those holders would, under those circumstances, receive other property upon conversion
or exchange, for example in the event of our merger or consolidation with another entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures in the form
initially filed as exhibits to the registration statement of which this prospectus forms a part may contain covenants that restrict our
ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any
successor of ours or acquirer of such assets must assume all of our obligations under the indentures and the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the debt securities are
convertible into our other securities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions
for the conversion of the debt securities into securities which the holders of the debt securities would have received if they had converted
the debt securities before the consolidation, merger or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Events of Default Under the Indentures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in the applicable prospectus supplement, the following are events of default under the indentures with respect to any series of debt securities
that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been validly extended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to pay the principal, or premium, if any, or to make payment required by any sinking fund or analogous fund when due and payable and the time for payment has not been validly extended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 30 days after we receive notice from the debenture trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if specified events of bankruptcy, insolvency or reorganization occur.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an event of default with
respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above,
the debenture trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series may,
by notice to us in writing (and to the debenture trustee if notice is given by such holders), declare the unpaid principal, premium, if
any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs
with respect to us, the principal amount of and accrued interest, if any, of each series of debt securities then outstanding shall be
due and payable without any notice or other action on the part of the debenture trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of a majority
in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to
the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless
we have cured the default or event of default in accordance with the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the
indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be under no obligation
to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series
of debt securities, unless such holders have offered the debenture trustee reasonable indemnity. The holders of a majority in principal
amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding
for any remedy available to the debenture trustee, or exercising any trust or power conferred on the debenture trustee, with respect to
the debt securities of that series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of the debt securities
of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek
other remedies, if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the holder has given written notice to the debenture trustee of a continuing event of default with respect to that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the debenture trustee, to institute the proceeding as trustee; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the debenture trustee does not institute the proceeding and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions, within 60 days after the notice, request and offer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These limitations do not apply
to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on the
debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will periodically file
statements with the debenture trustee regarding our compliance with specified covenants in the indentures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and the debenture trustee
may modify an indenture without the consent of any holders with respect to specific matters, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fix any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to comply with the provisions described above under &ldquo;Consolidation, Merger or Sale&rdquo;;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to evidence and provide for the acceptance of appointment under the indenture by a successor trustee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to provide for uncertificated debt securities in addition to or in place of certificated securities and to make all appropriate changes for such purpose; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to change anything that does not adversely affect the rights of any holder of debt securities of any series in any material respect.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the indentures,
the rights of holders of debt securities of any series may be changed by us and the debenture trustee with the written consent of the
holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However,
we and the debenture trustee may only make the following changes with the consent of each holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extending the fixed maturity of the debt securities of any series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest or reducing any premium payable upon the redemption of any debt securities; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing the percentage of debt securities the holders of which are required to consent to any supplemental indenture.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures provide that
we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for certain obligations,
including obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">register the transfer or exchange of debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">replace mutilated, destroyed, lost or stolen debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain paying agencies; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensate and indemnify the debenture trustee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to exercise our rights
to be discharged, we must deposit with the debenture trustee money or government obligations, or a combination of both, sufficient to
pay all of the principal, premium, if any, and interest on the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Concerning the Debenture Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The debenture trustee, other
than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically
set forth in the applicable indenture. Upon an event of default under an indenture, the debenture trustee must use the same degree of
care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the debenture trustee
is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless
it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we otherwise indicate
in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the
person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular
record date for the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay principal of,
and any premium and interest on, the debt securities of a particular series at the office of the paying agents designated by us, except
that, unless we otherwise indicate in the applicable prospectus supplement, we may make certain payments by check which we will mail to
the holder or by wire transfer to certain holders. Unless we otherwise indicate in a prospectus supplement, we will designate an office
or agency of the debenture trustee in the city of New York as our sole paying agent for payments with respect to debt securities of each
series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities
of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All money we pay to a paying
agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities which remains unclaimed
at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the
debt security thereafter may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures and the debt
securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Subordination of Subordinated Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The subordinated debt securities
will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement.
The indentures in the form initially filed as exhibits to the registration statement of which this prospectus forms a part do not limit
the amount of indebtedness which we may incur, including senior indebtedness or subordinated indebtedness, and do not limit us from issuing
any other debt, including secured debt or unsecured debt. Additional or different subordination provisions may be described in a prospectus
supplement relating to a particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_008"></A><B>DESCRIPTION OF OUR WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary, together with
the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the warrants
that we may offer under this prospectus, which consist of warrants to purchase our common stock, preferred stock and/or debt securities
in one or more series. Warrants may be offered independently or together with our common stock, preferred stock, debt securities and/or
rights offered by any prospectus supplement and may be attached to or separate from those securities. While the terms we have summarized
below will generally apply to any future warrants we may offer under this prospectus, we will describe the particular terms of any warrants
that we may offer in more detail in the applicable prospectus supplement. The terms of any warrants we offer under a prospectus supplement
may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will issue the warrants
directly or under a warrant agreement which we will enter into with a warrant agent to be selected by us. Each series of warrants will
be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent, all as set forth
in the prospectus supplement relating to the particular issue of offered warrants. We use the term &ldquo;warrant agreement&rdquo; to
refer to any of these warrant agreements. We use the term &ldquo;warrant agent&rdquo; to refer to the warrant agent under any of these
warrant agreements. The warrant agent will act solely as an agent of ours in connection with the warrants and will not act as an agent
for the holders or beneficial owners of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary of material
provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all of the provisions
of the warrant agreement applicable to a particular series of warrants. We urge you to read the applicable prospectus supplements related
to the warrants that we sell pursuant to this prospectus, as well as the complete warrant agreements that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in the applicable
prospectus supplements the terms relating to a series of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If warrants for the purchase
of our common stock or preferred stock are offered, the prospectus supplements will describe the following terms, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the offering price and the aggregate number of warrants offered;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares that can be purchased if a holder of the warrants exercises them and, in the case of warrants for preferred stock, the designation, total number and terms of the series of preferred stock that can be purchased upon exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of any series of preferred stock with which the warrants are being offered and the number of warrants being offered with each share of common stock or preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on and after which the holder of the warrants can transfer them separately from the related common stock or series of preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of common stock or preferred stock that can be purchased if a holder exercises the warrant and the price at which such common stock or preferred stock may be purchased upon exercise, including, if applicable, any provisions for changes to or adjustments in the exercise price and in the securities or other property receivable upon exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any rights to redeem or call, or accelerate the expiration of, the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the right to exercise the warrants begins and the date on which that right expires;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of warrants outstanding, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material U.S. federal income tax considerations applicable to the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms, if any, on which we may accelerate the date by which the warrants must be exercised;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the warrants are issued pursuant to a warrant agreement with a warrant agent or issued directly by us; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants for the purchase
of common stock or preferred stock will be in registered form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If warrants for the purchase
of debt securities are offered, the prospectus supplement will describe the following terms, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the offering price and the aggregate number of warrants offered;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the currencies in which the warrants are being offered;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation, aggregate principal amount, currencies, denominations and terms of the series of debt securities that can be purchased if a holder exercises a warrant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of any series of debt securities with which the warrants are being offered and the number of warrants offered with each such debt security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on and after which the holder of the warrants can transfer them separately from the related series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the principal amount of the series of debt securities that can be purchased if a holder exercises a warrant and the price at which and currencies in which such principal amount may be purchased upon exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any rights to redeem or call the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the right to exercise the warrants begins and the date on which such right expires;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of warrants outstanding, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material U.S. federal income tax considerations applicable to the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms, if any, on which we may accelerate the date by which the warrants must be exercised;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the warrants are issued pursuant to a warrant agreement with a warrant agent or issued directly by us; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants for the purchase
of debt securities will be in registered form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of warrant certificates
may exchange them for new certificates of different denominations, present them for registration of transfer and exercise them at the
corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants
to purchase common stock or preferred stock are exercised, holders of the warrants will not have any rights of holders of the underlying
common stock or preferred stock, including any rights to receive dividends or to exercise any voting rights, except to the extent set
forth under &ldquo;Warrant Adjustments&rdquo; below. Until any warrants to purchase debt securities are exercised, the holder of the warrants
will not have any of the rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive
payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of a warrant is
entitled to purchase the number of shares of common stock or preferred stock or principal amount of debt securities, as the case may be,
at the exercise price described in the applicable prospectus supplements. After the close of business on the day when the right to exercise
terminates (or a later date if we extend the time for exercise), unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of warrants may exercise
them by following the general procedure outlined below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivering to us or to the warrant agent the payment required by the applicable prospectus supplements to purchase the underlying security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">properly completing and signing the reverse side of the warrant certificate representing the warrants; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivering the warrant certificate representing the warrants to us or to the warrant agent within five business days of receipt of payment of the exercise price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the holder complies with
the procedures described above, the warrants will be considered to have been exercised when we receive or the warrant agent receives,
as applicable, payment of the exercise price, subject to the transfer books for the securities issuable upon exercise of the warrant not
being closed on such date. After the holder has completed those procedures and subject to the foregoing, we will, as soon as practicable,
issue and deliver to such holder the common stock, preferred stock or debt securities that such holder purchased upon exercise. If the
holder exercises fewer than all of the warrants represented by a warrant certificate, a new warrant certificate will be issued to such
holder for the unexercised amount of warrants. Holders of warrants will be required to pay any tax or governmental charge that may be
imposed in connection with transferring the underlying securities in connection with the exercise of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amendments and Supplements to the Warrant Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may amend or supplement
a warrant agreement without the consent of the holders of the applicable warrants to cure ambiguities in the warrant agreement, to cure,
correct or supplement a defective provision in the warrant agreement, or to provide for other matters under the warrant agreement that
we and the warrant agent deem necessary or desirable, so long as, in each case, such amendments or supplements do not materially adversely
affect the interests of the holders of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrant Adjustments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the applicable prospectus
supplements state otherwise, the exercise price of, and the number of securities covered by, a common stock warrant or preferred stock
warrant will be adjusted proportionately if we subdivide or combine our common stock or preferred stock, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, unless the prospectus
supplements state otherwise, if we, without payment therefor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue capital stock or other securities convertible into or exchangeable for common stock or preferred stock, or any rights to subscribe for, purchase or otherwise acquire any of the foregoing, as a dividend or distribution to holders of our common stock or preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay any cash to holders of our common stock or preferred stock other than a cash dividend paid out of our current or retained earnings or other than in accordance with the terms of the preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue any evidence of our indebtedness or rights to subscribe for or purchase our indebtedness to holders of our common stock or preferred stock; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue common stock or preferred stock or additional stock or other securities or property to holders of our common stock or preferred stock by way of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then the holders of common stock warrants and
preferred stock warrants, as applicable, will be entitled to receive upon exercise of the warrants, in addition to the securities otherwise
receivable upon exercise of the warrants and without paying any additional consideration, the amount of stock and other securities and
property such holders would have been entitled to receive had they held the common stock or preferred stock, as applicable, issuable under
the warrants on the dates on which holders of those securities received or became entitled to receive such additional stock and other
securities and property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as stated above, the
exercise price and number of securities covered by a common stock warrant or preferred stock warrant, and the amounts of other securities
or property to be received, if any, upon exercise of those warrants, will not be adjusted or provided for if we issue those securities
or any securities convertible into or exchangeable for those securities, or securities carrying the right to purchase those securities
or securities convertible into or exchangeable for those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of common stock warrants
and preferred stock warrants may have additional rights under the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain reclassifications, capital reorganizations or changes of the common stock or preferred stock, as applicable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain share exchanges, mergers, or similar transactions involving us and which result in changes of our common stock or preferred stock, as applicable; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain sales or dispositions to another entity of all or substantially all of our property and assets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If one of the above transactions
occurs and holders of our common stock or preferred stock are entitled to receive stock, securities or other property with respect to
or in exchange for their securities, the holders of the common stock warrants and preferred stock warrants then outstanding, as applicable,
will be entitled to receive upon exercise of their warrants the kind and amount of shares of stock and other securities or property that
they would have received upon the applicable transaction if they had exercised their warrants immediately before the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_009"></A><B>DESCRIPTION OF OUR RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary, together with
the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the rights
that we may offer under this prospectus, which consist of rights to purchase our common stock, preferred stock and/or debt securities
in one or more series. Rights may be offered independently or together with our common stock, preferred stock, debt securities and/or
warrants offered by any prospectus supplement and may be attached to or separate from those securities. While the terms we have summarized
below will generally apply to any future rights we may offer pursuant to this prospectus, we will describe the particular terms of any
rights that we may offer in more detail in the applicable prospectus supplements. The terms of any rights we offer under a prospectus
supplement may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicable prospectus
supplements relating to any rights that we offer will include specific terms of any offering of rights for which this prospectus is being
delivered, including the following, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date for determining the persons entitled to participate in the rights distribution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price, if any, per right;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise price payable for each share of common stock, share of preferred stock or debt security upon the exercise of the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of rights issued or to be issued to each holder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and terms of the shares of common stock, shares of preferred stock or debt securities that may be purchased per each right;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which the rights are transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other terms of the rights, including the terms, procedures and limitations relating to the exchange and exercise of the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the respective dates on which the holder&rsquo;s ability to exercise the rights will commence and will expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of rights outstanding, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material U.S. federal income tax considerations applicable to the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which the rights may include an over-subscription privilege with respect to unsubscribed securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering of such rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description in the applicable
prospectus supplements of any rights that we may offer will not necessarily be complete and will be qualified in its entirety by reference
to the applicable rights agreement and/or rights certificate, which will be filed with the SEC in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_010"></A>DESCRIPTION OF OUR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary, together with
the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the units
that we may offer under this prospectus, which may consist of one or more shares of our common stock, shares of our preferred stock, debt
securities, warrants, rights or any combination of such securities. While the terms we have summarized below will generally apply to any
future units we may offer pursuant to this prospectus, we will describe the particular terms of any units that we may offer in more detail
in the applicable prospectus supplements. The terms of any units we offer under a prospectus supplement may differ from the terms we describe
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicable prospectus
supplements relating to any units that we offer will include specific terms of any offering of units for which this prospectus is being
delivered, including the following, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether we will apply to have the units traded on a securities exchange or securities quotation system;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material U.S. federal income tax considerations applicable to the units; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how, for U.S. federal income tax purposes, the purchase price paid for the units is to be allocated among the component securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description in the applicable
prospectus supplements of any units that we may offer will not necessarily be complete and will be qualified in its entirety by reference
to the applicable unit agreement, which will be filed with the SEC in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_011"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales by Us</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
being offered hereby in one or more of the following ways from time to time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to or through underwriters;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions other than on these exchanges or systems or in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in &ldquo;at the market offerings,&rdquo; within the meaning of Rule 415(a)(4) of the Securities Act, to or through market makers or into an existing market for the securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an accelerated securities repurchase program;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any of these methods of sale; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will identify the specific
plan of distribution, including any underwriters, dealers, agents or other purchasers, persons or entities, and any applicable compensation,
in a prospectus supplement, in an amendment to the registration statement of which this prospectus is a part, or in other filings we make
with the SEC under the Exchange Act, which are incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sale through Underwriters or Brokers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If underwriters are used in
the sale, the underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions,
at a fixed public offering price or at varying prices determined at the time of sale. Underwriters may offer securities to the public
either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
Unless we inform you otherwise in the applicable prospectus supplement, the obligations of the underwriters to purchase the securities
will be subject to certain conditions, and the underwriters will be obligated to purchase all of the offered securities if they purchase
any of them. The underwriters may change from time to time any initial public offering price and any discounts or concessions allowed
or re-allowed or paid to brokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe the name
or names of any underwriters, brokers or agents and the purchase price of the securities in a prospectus supplement relating to the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale
of the securities, underwriters may receive compensation from us or from purchasers of the securities, for whom they may act as agents,
in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through brokers, and these brokers may
receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers
for whom they may act as agents, which is not expected to exceed that customary in the types of transactions involved. Underwriters, brokers
and agents that participate in the distribution of the securities may be deemed to be underwriters, and any discounts or commissions they
receive from us, and any profit on the resale of the securities they realize may be deemed to be underwriting discounts and commissions,
under the Securities Act. The prospectus supplement will identify any underwriter or agent and will describe any compensation they receive
from us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Underwriters could make sales
in privately negotiated transactions and/or any other method permitted by law, including sales deemed to be an &ldquo;at the market&rdquo;
offering, sales made directly on the NYSE American, the existing trading market for our shares of common stock, or sales made to or through
a market maker other than on the NYSE American. The name of any such underwriter or agent involved in the offer and sale of our securities,
the amounts underwritten, and the nature of its obligations to take our securities will be described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in the prospectus supplement, each series of the securities will be a new issue with no established trading market, other than our shares
of common stock, which are currently traded on the NYSE American. It is possible that one or more underwriters may make a market in a
series of the securities, but underwriters will not be obligated to do so and may discontinue any market making at any time without notice.
Therefore, we can give no assurance about the liquidity of the trading market for any of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under agreements we may enter
into, we may indemnify underwriters, brokers, and agents who participate in the distribution of the securities against certain liabilities,
including liabilities under the Securities Act, or contribute with respect to payments that the underwriters, brokers or agents may be
required to make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any compensation we pay underwriters
or brokers will be subject to the guidelines of the Financial Industry Regulatory Authority, Inc. We will disclose the compensation in
any applicable prospectus supplement or pricing supplement, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To facilitate the offering
of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect
the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating
in the offering of more securities than we sold to them. In these circumstances, these persons would cover such over-allotments or short
positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may
stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids,
whereby selling concessions allowed to brokers participating in the offering may be reclaimed if securities sold by them are repurchased
in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the
securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
engage in transactions with these underwriters, brokers, and agents in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Direct Sales and Sales through Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
directly. In this case, no underwriters or agents would be involved. We also may sell the securities through agents designated by us from
time to time. In the applicable prospectus supplement, we will name any agent involved in the offer or sale of the offered securities,
and we will describe any commissions payable to the agent. Unless we inform you otherwise in the applicable prospectus supplement, any
agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect
to any sale of those securities. We will describe the terms of any sales of these securities in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales by Selling Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
resell or redistribute shares of our common stock from time to time on any stock exchange or automated interdealer quotation system on
which the shares of our common stock are listed, in the over-the-counter market, in privately negotiated transactions, or in any other
legal manner, at fixed prices that may be changed, at market prices prevailing at the time of sale, at prices related to prevailing market
prices or at negotiated prices. Persons who are pledgees, donees, transferees, or other successors in interest of any of the named selling
stockholders (including but not limited to persons who receive shares of our common stock from a named selling stockholder as a gift,
partnership distribution or other non-sale-related transfer after the date of this prospectus) may also use this prospectus and are included
when we refer to &ldquo;selling stockholders&rdquo; in this prospectus. The selling stockholders may sell the shares of our common stock
by one or more of the following methods, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades (which may include cross trades) in which the broker or dealer so engaged will attempt to sell the shares of our common stock as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker or dealer as principal and resale by the broker or dealer for its own account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution or secondary distribution in accordance with the rules of any stock exchange on which the shares of our common stock may be listed;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker solicits purchases;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an offering at other than a fixed price on or through the facilities of any stock exchange on which the shares of our common stock are listed or to or through a market maker other than on that stock exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions, directly or through agents;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing of options on the shares of our common stock, whether or the options are listed on an options exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the distribution of the shares of our common stock by any selling stockholders to its partners, members or stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one or more underwritten offerings;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreements between a broker or dealer and any selling stockholder to sell a specified number of the shares of our common stock at a stipulated price per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any combination of any of these methods of sale or distribution, or any other method permitted by applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
also transfer the shares of our common stock by gift.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
engage brokers and dealers, and any brokers or dealers may arrange for other brokers or dealers to participate in effecting sales of shares
of our common stock. These brokers, dealers or underwriters may act as principals, or as an agent of a selling stockholder. Broker-dealers
may agree with a selling stockholder to sell a specified number of shares of our common stock at a stipulated price per share. If the
broker-dealer is unable to sell shares of our common stock acting as agent for a selling stockholder, it may purchase as principal any
unsold shares of our common stock at the stipulated price. Broker-dealers who acquire shares of our common stock as principals may thereafter
resell the shares of our common stock from time to time in transactions in any stock exchange or automated interdealer quotation system
on which shares of our common stock are then listed, at prices and on terms then prevailing at the time of sale, at prices related to
the then-current market price or in negotiated transactions. Broker-dealers may use block transactions and sales to and through broker-dealers,
including transactions of the nature described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, one or
more of the selling stockholders may pledge, hypothecate or grant a security interest in some or all of the shares of our common stock
owned by them. The pledgees, secured parties or persons to whom the shares of our common stock have been hypothecated will, upon foreclosure
in the event of default, be deemed to be selling stockholders. The number of a selling stockholder&rsquo;s shares of our common stock
offered under this prospectus will decrease as and when it takes such actions. The plan of distribution for that selling stockholder&rsquo;s
shares of our common stock will otherwise remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
any underwriters, brokers, dealers or agents that participate in the distribution of the shares of our common stock may be deemed to be
&ldquo;underwriters&rdquo; within the meaning of the Securities Act, and any discounts, concessions, commissions or fees received by them
and any profit on the resale of the shares of our common stock sold by them may be deemed to be underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A selling stockholder may
enter into option or other transactions with broker-dealers that involve the delivery of the shares of our common stock offered hereby
to the broker-dealers, who may then resell or otherwise transfer those shares of common stock. A selling stockholder may also loan or
pledge the shares of our common stock offered hereby to a broker-dealer and the broker-dealer may sell the shares of our common stock
offered hereby so loaned or upon a default may sell or otherwise transfer the pledged shares of our common stock offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
other persons participating in the sale or distribution of the shares of our common stock will be subject to applicable provisions of
the Exchange Act and the related rules and regulations adopted by the SEC, including Regulation M. This regulation may limit the timing
of purchases and sales of any of the shares of our common stock by the selling stockholders and any other person. The anti-manipulation
rules under the Exchange Act may apply to sales of shares of our common stock in the market and to the activities of the selling stockholders
and their affiliates. Furthermore, Regulation M may restrict the ability of any person engaged in the distribution of the shares of our
common stock to engage in market-making activities with respect to the particular shares of our common stock being distributed for a period
of up to five business days before the distribution. These restrictions may affect the marketability of the shares of our common stock
and the ability of any person or entity to engage in market-making activities with respect to the shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may agree to indemnify
the selling stockholders and their respective officers, directors, employees and agents, and any underwriter or other person who participates
in the offering of the shares of our common stock, against specified liabilities, including liabilities under the federal securities laws
or to contribute to payments the underwriters may be required to make in respect of those liabilities. The selling stockholders may agree
to indemnify us, the other selling stockholders and any underwriter or other person who participates in the offering of the shares of
our common stock, against specified liabilities arising from information provided by the selling stockholders for use in this prospectus
or any accompanying prospectus supplement, including liabilities under the federal securities laws. In each case, indemnification may
include each person who is an affiliate of or controls one of these specified indemnified persons within the meaning of the federal securities
laws or is required to contribute to payments the underwriters may be required to make in respect of those liabilities. The selling stockholders
may agree to indemnify any brokers, dealers or agents who participate in transactions involving sales of the shares of our common stock
against specified liabilities arising under the federal securities laws in connection with the offering and sale of the shares of our
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any proceeds
from sales of any shares of our common stock by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
the selling stockholders will sell all or any portion of the shares of common stock offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will supply the selling
stockholders and any stock exchange upon which the shares of our common stock are listed with reasonable quantities of copies of this
prospectus. To the extent required by Rule 424 under the Securities Act in connection with any resale or redistribution by a selling stockholder,
we will file a prospectus supplement setting forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate number of shares of common stock to be sold;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purchase price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The public offering price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If applicable, the names of any underwriter, agent or broker-dealer; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any applicable commissions, discounts, concessions, fees or other items constituting compensation to underwriters, agents or broker-dealers with respect to the particular transaction (which may exceed customary commissions or compensation).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a selling stockholder notifies
us that a material arrangement has been entered into with a broker-dealer for the sale of shares of our common stock through a block trade,
special offering, exchange, distribution or secondary distribution or a purchase by a broker or dealer, the prospectus supplement will
include any other facts that are material to the transaction. If applicable, this may include a statement to the effect that the participating
broker-dealers did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_012"></A>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
the registration statement of which this prospectus forms a part is used by selling stockholders for the resale of any shares of our common
stock registered hereunder, information about such selling stockholders, their beneficial ownership of our securities and their relationship
with us will be set forth in a prospectus supplement, in a post-effective amendment, or in filings we make with the SEC under the Exchange
Act that are incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_013"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in the applicable prospectus supplement, the validity of the securities being offered by this prospectus will be passed upon for us by
Olshan Frome Wolosky LLP, New York, New York. Additional legal matters may be passed upon for us or any underwriters, dealers or agents
by counsel that we will name in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_014"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
OS Therapies Incorporated incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31,
2024 have been so incorporated in reliance on the report, which contains an explanatory paragraph regarding the Company&rsquo;s ability
to continue as a going concern, of MaloneBailey, LLP, an independent registered public accounting firm, given on the authority of said
firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="b_015"></A><B>Where
You Can Find More Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">We
have filed with the SEC a registration statement on Form S-3 under the Securities Act relating to the offering of these securities. The
registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus
does not contain all of the information set forth in the registration statement. We encourage you to carefully read the registration statement
and the exhibits and schedules to the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the reporting
requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC.
The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers
that file electronically with the SEC, including us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
registration statement and the documents referred to below under &ldquo;Incorporation of Certain Information by Reference&rdquo; are also
available on our Internet website www.ostherapies.com. We have not incorporated by reference into this prospectus the information on our
website, and you should not consider it to be a part of this prospectus</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_016"></A>Incorporation
of CERTAIN INFORMATION by Reference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC and applicable law
allows us to &ldquo;incorporate by reference&rdquo; the information from other documents we file with the SEC, which means that we can
disclose important information to you by referring you to those documents instead of having to repeat the information in this prospectus.
The information incorporated by reference is considered to be part of this prospectus, and later information that we file with the SEC
will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings
(including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior
to the effectiveness of such registration statement) we will make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange
Act until the termination of the registration statement of which this prospectus is a part (other than, in each case, documents or information
deemed to have been furnished and not filed in accordance with SEC rules):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025026238/ea0235597-10k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2024, filed with the SEC on March 31, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025044336/ea0242061-10q_ostherap.htm">May 15, 2025</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025077916/ea0252948-10q_ostherap.htm">August 18, 2025</A></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Reports on Form 8-K (only to the extent &ldquo;filed&rdquo; and not &ldquo;furnished&rdquo;) filed with the SEC on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025000844/ea0226635-8k_osthera.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 3, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025003460/ea0227697-8k_osthera.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 14, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025003886/ea0227757-8k_osthera.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 15, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/ea0229055-8k_osthera.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 29, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025027522/ea0236724-8k_ostherapies.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025030375/ea0237768-8k_ostherapies.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025032071/ea0238051-8k_ostherapies.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 15, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025056911/ea0246590-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 24, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025058603/ea0247272-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025063479/ea0248754-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2025</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025077431/ea0253338-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 15, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our registered securities contained in </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025026238/ea023559701ex4-9_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 4.9</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to our Annual Report on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025026238/ea0235597-10k_ostherap.htm">Form 10-K</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2024, filed with the SEC on March 31, 2025.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained in
this prospectus, or in a document all or a portion of which is incorporated by reference, shall be modified or superseded for purposes
of this prospectus to the extent that a statement contained in this prospectus, any applicable prospectus supplement and any related free
writing prospectus or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or
superseded shall not, except as so modified or superseded, constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon request, we will provide,
without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered a copy of the documents
incorporated by reference into this prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated
by reference as an exhibit in this prospectus, at no cost by writing or telephoning us at the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OS Therapies Incorporated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">115 Pullman Crossing Road, Suite 103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Grasonville, Maryland 21638</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(410) 297-7793</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional information about
us is available at our website located at www.ostherapies.com. Information contained on, or accessible through, our website is not a part
of, and is not incorporated by reference into, this prospectus or any accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,529,417 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea028392501_img1.jpg" ALT="A blue text on a white background&#10;&#10;Description automatically generated" STYLE="height: 64px; width: 401px"></p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS Therapies Incorporated </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus Supplement dated March 31, 2026</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>ea028392501ex-fee.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Template (c) 2024-2025 Novaworks, LLC -->
<!-- Field: Set; Name: AliasFileType; Value: Forms View; Template: Fee Exhibit\Fee Exhibit FC.xds -->
<!-- Field: Set; Name: Platform; Value: Novaworks Fee Exhibit Editor; Version: 1.4a -->
<!-- Field: Set; Name: Control; Value: VGVtcGxhdGU6IChkZWZhdWx0KQ0KQmFzZSBGb250OiBUaW1lcyBOZXcgUm9tYW4sIFRpbWVzLCBTZXJpZg0KQ2FwdGlvbiBTaXplOiAxMnB0DQpUYWJsZSBUaXRsZSBTaXplOiAxMXB0DQpUYWJsZSBIZWFkIFNpemU6IDhwdA0KVGFibGUgQm9keSBTaXplOiAxMHB0 -->
<!-- Field: Set; Name: MD5; Value: f6908cd76f642c3e9efc6e589683ecb6 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
  <title>Filing Fee Exhibit</title>
  <meta http-equiv="Content-Type" content="text/html"/>
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">

<div style="display: none">
  <ix:header>
    <ix:hidden>
      <ix:nonNumeric name="ffd:SubmissnTp" contextRef="c_report" id="fee_001">424B7</ix:nonNumeric>
      <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="c_report" id="fee_002">EX-FILING FEES</ix:nonNumeric>
      <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="c_report" id="fee_003">0001795091</ix:nonNumeric>
      <ix:nonNumeric name="ffd:RegnFileNb" contextRef="c_report" id="fee_004">333-289443</ix:nonNumeric>
      <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="c_report" xs:nil="true" id="fee_005"></ix:nonNumeric>
      <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="c_report" id="fee_006">N/A</ix:nonNumeric>
      <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="c_report" id="fee_007">N/A</ix:nonNumeric>
      </ix:hidden>
    <ix:references>
      <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
      </ix:references>
    <ix:resources>
      <xbrli:context id="c_offering_1">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-03-27</xbrli:startDate>
          <xbrli:endDate>2026-03-27</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_report">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-03-27</xbrli:startDate>
          <xbrli:endDate>2026-03-27</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:unit id="USD">
        <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="pure">
        <xbrli:measure>xbrli:pure</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="shares">
        <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unit>
      </ix:resources>
    </ix:header>
  </div>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right">Ex-Filing Fees</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">CALCULATION OF FILING FEE TABLES</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><ix:nonNumeric name="ffd:FormTp" contextRef="c_report" id="fee_008">S-3</ix:nonNumeric></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="c_report" id="fee_009">OS Therapies Incorporated</ix:nonNumeric></p>

<p style="font: bold 11pt Times New Roman, Times, Serif; border-top: Gray 3pt double; padding-top: 6pt; text-align: center; margin-top: 0pt; margin-bottom: 4pt">Table 1: Newly Registered and Carry Forward Securities</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font-size: 2pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="width: 12%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 6.5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="border-bottom: Black 1pt solid">Line Item Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Class Title</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Notes</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Calculation<br/> Rule</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Amount Registered</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Proposed Maximum Offering<br/> Price Per Unit</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Maximum Aggregate Offering Price</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Rate</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Amount of Registration Fee</td></tr>
<tr style="font-size: 2pt; vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="22" style="padding-top: 2pt; font-style: italic; text-align: center; padding-bottom: 2pt">Newly Registered Securities</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_1" format="ixt:booleanfalse" id="fee_010">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_1" id="fee_011">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_1" id="fee_012">Common Stock, par value $0.001 per share</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(1)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_1" format="ixt:booleantrue" id="fee_013">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="shares" decimals="0" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_014">10,529,417</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_015">1.41</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_016">14,846,478.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_017">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="ixv-226">2,051.00</ix:nonFraction></td></tr>
<tr style="font-size: 4pt; vertical-align: top; text-align: left">
  <td style="width: 11%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Offering Amounts:</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-227">14,846,478.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-228">2,051.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fees Previously Paid:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-229">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fee Offsets:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-230">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Net Fee Due:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 3pt double">$</td>
  <td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-231">2,051.00</ix:nonFraction></td></tr>
</table>

<p style="font: bold 8pt Arial, Helvetica, Sans-Serif; color: rgb(50,101,255); margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 8pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt">__________________________________________<br/>
Offering Note(s)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_1" id="ixv-177">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), of OS Therapies Incorporated (the &#8220;Registrant&#8221;) being registered hereunder include such indeterminate number of shares of Common Stock as may be issuable as a result of stock splits, stock dividends, or other distribution, recapitalization or similar events.<br/><br/>The offering price estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The maximum offering price per share and maximum aggregate offering price are based upon the average of the high and low sales prices of the Registrant&#8217;s Common Stock on September 26, 2025, as reported on NYSE American.<br/><br/>The amount registered represents (i) 4,289,441 shares of Common Stock issuable upon the exercise of outstanding warrants and (ii) 6,239,976 shares of Common Stock issuable upon the exercise of outstanding unsecured convertible promissory notes, each of which is to be offered for resale from time to time by certain of the selling stockholders named in the prospectus that forms a part of the registration statement to which this exhibit is attached.<br/></ix:nonNumeric></td></tr>
  </table>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028392501_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028392501_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  9$# 2(  A$! Q$!_\0
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MB@ HHHH **** "BBB@ HI,CU'YBEH ***0D#J: %HI 0>AI: "BBDR/4?F*
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MZ)X'L+KX=ZE\.WU+PO<>%=-U*[O5L=2=Y=26/6;BYMS>QX2-HS;D94U]M_\
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M_9S12R6FI:/K%B69]/UG1M0@N-.U2R8MY-U;OY4DT#132?GE_P %R/"/PO\
M$?\ P39_:'U7XB6.A2:CX2T/2M<^'.J:DMNNIZ5X^7Q!I-OHW_"/7$A6X&I:
M@LL]C):VQ<WEG-<1RQ21QL4^*/\ @V,U'Q'<?L<_&#3M0>Y?PUIGQZU5O#8E
M:1K>.YOO#.@S>((K7=E4 N([*26.(*HEE+%0SDGEQU# 8_)IYOAL%'+Z]#%Q
MPU6E3E)T*L:BNG34]4XMKFMYI]#IP-?'X#.8Y5B,8\?0Q&'E7IU)I*K3E!V:
MFX]'T?71H_I- P>.!Q[YP/S&/UK^:S_@M#_P6"^,7[%OQF^''P'_ &9Y/!DO
MC(>%IO&7Q4N?%&@GQ*+"WUR9+?P;H-G:+=6QM+^:VL]0UFYE F\ZSNK%5,>U
MMW]$_CSQMX>^&_@GQ=\0?%M_#I7A?P1X:UKQ7XAU*X<)#9:-H&G7.J:E<.QP
M"(;6UE;;U8@* 2P!_C!_X)0?#.__ ."FO_!37]H7]M+XPZ&FM_#[PE-XC\0K
MHVK0&YTPZUXWM;_PE\,O"#0RF:,CPIX&AO-6DBC<+:ZI96%RJA;P!L.'\)A6
M\7F.84U5P. I)RIR6E:M5:A3IQV3DDW*U]['1Q'B\3&.%R[ 5)4L;CJC4:D/
MBI4H+FG-VNTG9*]K:G]!7_!'K]OS6_V_/V8KKQE\0WT*+XR_#[Q=J7@[XDV7
MA^T73--G\[&K>%?$%AIGGSO:66LZ%=1Q,-QA_M/3=4AB=A <?K">WN1^G/\
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MNH037HU%/\3-U'1M(U=8EU;2M.U-8"[0KJ%E;7BPF0 2&,7$<@C+A0'*8W
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?O.4I?^E2D_Q%"E2IJU.G""_N0C'7_MV*"BBBI-#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ea028392501_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028392501_img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )]!.\# 2(  A$! Q$!_\0
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MVVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'M?_ &@?"^J>%[E9!(OEW4L<+Q;WPX.0P!)VD#/ICTKI?VCO^2>:?_V%8_\
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MX7U3PO<K()%\NZECA>+>^'!R& ).T@9],>E=U\*O!WA;_A7VCWR:3I]W<W,
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M ^ UK;R_#&W:2")V^U3<L@)^]5/X^WY@\-Z-H:3"UMM1O@L\@P%6-,<'MC+
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MZ*OY5ZG:^%?#FG1@6NA:9;JBXREJBX'N<5Y?\!F1M1\:;"I7^T%(VGC&9,4
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M(IEM%:WF0'E&5CC/U&#^-<Y^T+?))X8TO0;<K)J%]?HT< Y8J PR![LRC\Z
M+OQNN?MGP>^U 8\Z6WDQZ9YJ_P##_P"&7A33/#^FZB=+BO+ZXMHYWN+P"4AF
M4'Y0>% SQ@9]S6?\;+8V?P<%J3DPR6\9/KCBN^\)_P#(G:)_UX0?^BUH \N^
M/<$4L_@VW>-3"]^R,F."I,8Q^5>OV>FV&GV8M+*RM[:V"[?)AB5$QZ8 Q7DG
MQW_X_P#P5_V$3_..O91TH \&\%:!I-M^T-XHTTZ=:RV\%NUS LD080L6B/R@
M]/\ 6$<5Z9\2](L]4^&^NQ7,$;"WLI;B$E1E'C4L"OI]W'TKA?"?_)S?BW_L
M'G^=O7I'CK_DGWB7_L%77_HIJ .>^"EY+>?"C2#,Q9HO-B!/]U9& _(8'X5R
M.KD6?[4^CR*>+FT^<#OF&11G_OD5TWP*_P"24:;_ -=9_P#T8U<O89UW]J6\
MN(SF+2;9AD#TB$9!_P"!2-^5 'N%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116=J^K
MPZ/;"61&D=CA(UZG_P"M6=2I"E%SF[)%1BY.R/"?B+XMO)O$U[:R[A]FD:**
M(]$ /7\>M87A;3&UJ>YO+J1F$3QQ[L_=W;B2/3A"/^!9KTKQ59^'/&A\R\MY
MM,U$#:EXB[P?0.!U'ZBN9\/:9<>#M2NM*UIHDL-51?LVHQG=#YB$[3N[ Y(.
M>1FNFACZ&(I_N9)VZ&<Z4J3O-6.ITJYM]-N;=852&&,X4*,!?>NLT+59HKT6
MDY8QR'Y2><'_  ->:ZDEYIDYANX6C/\ "W\+#U!Z$?2K7AH7VIZ[9PVYD9(Y
M5D?!.U5!R2:X<3@W5JPK1FXN/W-/<UI5E&,H.-[GM=%%<_XFU2ZMC;:?8<7=
MVVT/_<'3/^?2NN,7)V1C.:A'F9OY&<9&:6N73P3:M%NN+VZDNCR90_?VHT.]
MO;#69-"OYC/A=\$IZD>GY?RJN1-/E=S-59)I3C:YTY('4@?6EKSRW2UUK6[U
M-<OI89$<K%$7"*.3P,_A75Z+HG]D22F.^FGMW V1N<A?>G*"BM7J*G6<WHM/
M7]#7) ZD"DWK_>'YUE>(?#EEXFLH[2^:=8XY/,!A?:<X(]/>O+4\$:6WQ,D\
M/F6\^Q+:^</WOS[L#OCWJ8Q3ZFLI-=#VC<N,[ACUS2UY=X\T"T\,?#E[.P><
MQM>I(3*^XY((Z\<<5Z%8WUH+"W!NH<^4O_+0>E#CI=#4M;,O9!. 1FC>H_B'
MYUYWX1E$OQ.\4E7WIA<$'(ZUSVFZ!H^O^,_$ZZS>R0"&[/E8N!'G+-GKUZ"G
MR=R>?L>RAE)P&!_&C>H."P_.N/\ #?@WPYI.JB]TJ^EGN(T(VFY60 'CD 5R
M5EX8L?%/Q$\2PZA)<A() R>3)MY)/L?2A13OJ#DU;0]>!!&117E.KZ._P\U?
M2+W1M1NVMKJY$$]I/)N# XY'3_ZQQ7H'B76DT#P[>:DY&Z*/]V#_ !.>%'YT
MG':W4:EO?H:H(/0CBE) &2<5X[X3_M#PCXETJ;4YG:#7X<N7_@E)RH/OR/\
MOJNQ^*)*^ ;X@D'='R#_ +8IN%I)"4[Q;.P#*3@,#^-*3@<UYKI?PNT6]T.S
MNQ=ZA%<S6Z2;TF&%8J#P,>M4M,U6_N/A]XJTZ^N6N7TW?#'<,<EE^O?I^M'(
MGLPYVMT>K9&,Y&/6DWK_ 'A^=>9SLW_"AU;<=WV=.<\_ZT55T/P-X2OM"L+J
M[U25+B:!'D7[:JX8C)XQQ1R+JPYWT1ZN"",@YHW+NV[AN],UQ.K6@\(_#B__
M .$<FEDVC>DI<.5#, S CT&?I7)^&/"/AKQ-I$%P=?NSK+KNE_?@.C]_E(R1
M[YH4%:]P<W>UCV.BL[0].FTG1[>RN+V6]EB7#3RGYFY_R*T:S9H@HHHH *QO
M$WA71_%^E'3M9M!/#G<C [7C;^\K=C6S10!Y#'\ M.M3LL?%.NVUMG)B65?Y
M@ ?I74>"OACH_@>_N+^RO-0NKNXB\J22[D5OER#P H]!ZUVU% ',Z3X&TS1O
M&.J^)[>>[:]U-=LT<CJ8U&0?E 4$?='4FC5O VF:SXQTKQ/<3W:WNF+MACC=
M1&PR3\P*DG[QZ$5TU% ',^,? VF>-X;&+4I[N);*?SX_LSJI+8QSN4\?E734
M44 <R_@;3)/'T?C(SW?]HQP>0(@Z^5MVE>FW.<'UHU;P-IFL^,=*\3W$]VM[
MIB[88XW41L,D_,"I)^\>A%=-10!G:YH>G>(](GTO5;9;BTF WH21R#D$$<@@
M]Q7F:? +2[:1EL/$VNVEJQ),,<R_S '\J]=HH YGP]X'TO0/"T_ATR7.H6-P
M7,WVYP[/N !' '''_P!>N.B^!.G6DDD6G^*/$%E8.Q8VL%R%&?KCZ=03Q7J]
M% 'EUS\!?!\ME%';/J-K>1OYGVY+G,K-_M9&WWX YKHO$7P]T[Q5X0TWP[JU
M_?O%8F)A<1R*)972,IN8LK9SN)/O77T4 ,BC$,*1*2510HSUXI]%% !7E^I_
M KPY?:G<ZC!J6L65U<2M+(8+A0I8G)."N>OO7J%% 'D\?P#T&:YCEU76];U)
M(R2(I[@;3ST)QG\B*]/L+"TTNP@L;&WCM[6! D448P% JS10!Y_XQ^$NC^+=
M;&MK>WVF:IM"//:.!Y@ P"01UQQD$<>M:'AGX>6/A_1]1TRYU"^UB#4 %G6_
MD#C;@C"CMG)[^E=A10!Y1%\"=.M))(M/\4>(+*P=BQM8+D*,_7'TZ@GBIKGX
M"^#Y;**.V?4;6\C?S/MR7.96;_:R-OOP!S7J-% 'B_QJ\0WG@[P%I'AFUE-P
M]_;M:S7=P [M'$J*Q.?XFW#GZ]\&LGP%X&^*6F^%K=](\26>E6MT/M"VD\2R
MLN[H3E&VY&#@'Z\YKTCXE?#NW^(6CV]NUT;2\M'+V\^S<!D892/0X'Y#Z5H:
M,/%.EZ);VE_8:;>36T2Q"6VO&4RA1C<5:,!2<=-QH \TU3Q;\2?AK?Z=<>+K
MS3=7T>ZG\IY;>,*R#J<81,'&3T(."*])\:> =#\=V,<&K12"6')AN8&VR1YZ
M@$@@@XZ$&N1\7^#_ !7\2-1TVSU:TL=(T&TF\Z4)<F>:8],#"@#C(]LYYZ5Z
MM0!Y+%\"K>/Y3XP\0^4.$1)PNT>G3^E=]X4\+VGA'1SIMG<WES&96E:6\E$D
MA9L9Y 'IZ5N44 %<RG@;3(_'TGC(3W?]HR0>08BZ^5MVA>FW.<#UKIJ* "BB
MB@#F+KP+IEWX_LO&4D]V-1M(3#'$KKY14JZ\C;G.'/?TKSO]H*W6\E\(6SLR
MI->O&S(<$ ^6,CWYKVNN&^(?@2Y\:7.@RV][%;#3+HSN)%)WC*G QT^[0!SK
M_ FT=?L[>+_$+61&# TX((QC'3'Z5W?A+P9HG@K3&L=&MB@D(:::1MTDI'0L
M?Z# '/'-=!10!S'C3P#H?CNQC@U:*02PY,-S VV2//4 D$$''0@UQD7P*MX_
ME/C#Q#Y0X1$G"[1Z=/Z5ZU10!A^%/"]IX1T<Z;9W5Y<QF5I6EO)1)(6.,\@#
MT]*J^$_ VF>#9]4ETZ>[E;4IO/F%PZL%;)^[M48'S'KFNFHH YBV\"Z9:>/[
MWQE'/=G4;N$0R1,Z^2%"HO VYSA!W]:75_ VF:SXPTKQ/<3W:WNF+MACC=1&
MPR3\P*DG[QZ$5TU% !7,Z'X&TSP_XHUCQ!:3W;W>JMNG25U**=V?E 4$<GN3
M7344 <CXV^'&@^.XXFU..:*[@7;%=6[!9%'7!R"",]B/7&,URD/P,MT.)/&/
MB)DXP$N N!^1KUFB@#(\,^';7PKH4.DV<]S/#$68274@>1BQ).2 .Y]*UZ**
M /%_%,?_  AGQ]T3Q$?DL-<3[)<-C@28"<^G_+(_@:]$\:^"M-\>:-#I>J3W
M<,$5PMPK6KJK%@K+@[E88PY[>E;UQ:6UV%%S;Q3!3E1(@;!]1FIJ /'_ /AG
M'P?_ -!+7/\ O_#_ /&JZ'P;\(M \#ZXVK:9>:G+.T+0E;F6-EVD@GA4!SP.
M]=_10!S'A;P+IGA+4]:O[">[DEU>837 G=2JL&<_+A1@?.>N>U<[K_P9T?6]
M?N];BUC6+"]NFWR&VF4+G&.!MS^M>DT4 >567P'T%;Z&ZUC5=5U@PG*Q7,PV
M'V/&<>V17J2Q1I$(EC58PNT(!@ =,8]*?10!Y//\!M&2_FGTK7=8TN"9]SV]
MO*-H]@<9Q]<UW<?A/36\(1^&;\2ZA8K"(7-TVYW Y!)&.<\@CIBMVB@#R-?@
M'IMM(5T[Q-KMG:EMWDQS#CZ$ ?J*ZCPA\-K#PAJDNI1:OJ]_=20&W/VVX#J%
M+!N %&#\H[GOZUVE% ',R>!M,D\?1^,3/=_VC'#Y B#KY6W:5Z;<YP?6NFHH
MH YG0_ VF:!XHUCQ!:3W;W>JMNG25U**=V[Y0%!'/J365XP^%6C>+=7BUD75
MYIFK1@#[79.%9\# +<=0.,@@XX]*[NB@#S*U^!_AUIA-K>HZQKD@' O;L[0?
M4!<']:VO!7PXL/ MY>2:9J-_+:W(P+6XD#)&<YRN /IZUV=% !7,6W@73+7Q
M_>>,DGNSJ-W"(9(F=?)"A47@;<YP@[^M=/10 4444 <QJ/@73-3\<Z=XNFGN
MUU#3X?)BC1U$3+\_W@5)S^\/0CM1XU\!Z-X[T^*VU594D@8M!<P$+)&3U )!
M&#@9!]*Z>B@#RR'X':9-M36/$FOZG O2WFNL1D=@1@G\B*TM(^$.A>'O%D&N
MZ'=7]B$/SV2S;H9!@C!S\W?/)/(KT&B@#D?''P[T?QY#:_;Y+BWNK4DP7-LP
M#KG&0<@@C@?3L:I^#OAI%X1U9M1_X2'5]0E,+0^7=2@QX)!SCU^4=Z[JB@#F
M-/\  NF:;XZU'Q=#/=MJ%_#Y,L;NIB"_)]T!<Y_=CJ3WKIB 001D'J#2T4 >
M8:E\#M!FU.74-&U+5-#FE.YDLI@L8YSP,9'TS@=A5WPQ\'O#_AW6(]8GN+[5
M=2CP8YKZ0,$;^\ !U],YQVKT*B@#"\7>%+#QIH#Z/J,MS%;O(LA:W95?*G(Y
M8$?I6II]E'INFVMA"SM%;0I"A<@L0H &<=^*LT4 <SXM\#Z9XRFTN749[N)M
M-F\^'[.ZJ&;(^]N4Y'RCIBNFHHH YC3_  +IFF^.M1\70SW;:A?P^3+&[J8@
MOR?= 7.?W8ZD]ZV]6TZ'6-'OM,N&=8+RWDMY&C(#!74J2,@C.#Z5<HH YS0M
M$TOX>>#7LX)YVT^P26X:2Y92^.7;)  ]>U<!\"-,GO(M>\97B8FUB[;R\G/R
MABS$'T+,1_P"O7Y(HYHVCE19(V&&5AD$>XHAABMXEBAC2.-?NHB@ ?@* 'T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<WXJAW&VD) 097)]:Z2J>IV":E8O;L<,>4;T
M:N',,,\3AI4EN_TU-\/-0J*3V. FMEQAE'(X(YS44-G%?03:)= /:W8(0-_R
MSEQ\K#T.>/QK1N+*XL+6*.Y7;(7? Z\<#_'\ZRKN_BTN(ZA,VU83N09^^_8#
M\:^$P<:]#'0A3OS76GK:]_D>MB?9RH2<_ALSCM#\6ZGX9D%I*JW^F*V&M)_F
M"C_9)Z?RKV[PYJ>E:QI$=[I"1I _#(J!"K#J"!WKY[AMI;Z<?(S&1N% R6)]
MJ]T\"^'Y?#^@^5.-L\[^:\8_@X  ^N!7ZE64=SX3+,15G)TWJEU['3URWBN*
M>UO;#68HS(EJV)5'4+GK_/\ 2NII" P((!!X(-81ERNY[52'/&QF1>(](FMA
M.+^%5QDJ[88>V.M8>FRG6O%4NL)&RV5M&41R.7.#V_$G\JW'\-Z.\OF-I\.[
M.> 0/R'%:,44<,:QQ(J(HP%48 J^:*3Y3/DJ2:YVK+L<N][X7U]"]YY4,XX/
MFGRW'X]ZK>$I#%K=]9V<[SZ:BY1FZ Y&,?K]<5TEUH>EWLIEN+*)Y#U;&"?K
MCK5FUL[:QB\JU@2).N$&,TW./*TKDJC/G4G;3MNR>O.XO^2Y3_\ 7A_1:]$J
MB-'T\:N=5%JGV\IY9FYSM]/TK.+M<Z)*]CD?B]_R)!_Z^8_Y-1:_"OPK+9PR
M-:S[G16/[]NI%=AJ>E6.LVGV74+9+B#<&V-G&1WXJTB+&BH@PJC 'H*:FU&R
M$X)RNSS+P!IUMI/Q!\26%HI6WA550,V2!GUK&TW3?#&H^-/% \1RP1A+L^3Y
MMP8LY9LXY&>U>M6VCZ?9ZC<W]O:I'=7/^NE&<O\ 6LVZ\#^&KRZEN;C2())I
M6+NY+98GDGK5^T5VR/9NR11\,6'@S2M0<:!=6INITVE$N_,9@.> 2:XVSTS6
M=3^(OB9='UC^S720&1O+W[QDX%>B:?X/\/Z5>I>6.F0P7"9VR*6R,C!ZGT-7
MK71]/LK^YOK:U2.ZN3F:09R_UI<Z5Q\C=CS+3=-N$^)4%CXOU&>]GA02Z<['
M$4C=>G8\=/4?2KGQ#GOO$'B*P\,Z3"EQ);C[7<1NV%)[!CZ8_P#0J[_4-$TW
M59K>:^M$FEMFW0N<@H>#P1]!3K;1M.M-2N-1@M42\N.)9N2S?G1SJ]PY':QY
MCXKL/'>LZ-B_TG3HX[,_:$>WD_>+M!Z?,>W;VJ_XDUM?$/P::_R/-;RDF'HX
M< _X_C7II (((R#VK'3PIH<>FSZ<FG1+9SN))(03M9ACGK["A36EUL#@];/<
MXO2_"GBZ\T2RV^,'AM9;="L:0\HI48 (([5J:CX:L_"_PUU>RM6>1F@=Y97^
M](Q[FNT@@CMK>."% D4:A$4=  , 4V[M(+ZTEM;J,2P2KM=#T84N=MCY%8\V
MG_Y(*O\ U[I_Z-%5-#\/_#J?0;"6_N;07CP(TP:^*D/CG(W<<UZ4VAZ8VC?V
M0;1#I^T+Y'.W .?KUK*_X5]X4_Z L'YM_C5*:U)<&12Z]X=\,>%89+1A<Z7%
M(+?_ $=O."YY.3GT/>N/\26?P[O]'N-2T^^MK2]$9>+[-(58OU \OW/L*]*T
M_0M+TNQDLK.RBBM9&+/%C<K$@ Y!SZ"L[_A!/"_VCS_[$M-^<XVG;_WST_2E
M&23OJ-Q;5M"K\.;R_O\ P59S:BSO+EE223[SH#@$^OUKJZ1$6-%1%"JHP% P
M *6LV[NYHE96"BBBD,RKSQ-H&GW3VM[KFFVUPF-\4UW&CKD9&03D<$'\:A_X
M3/PM_P!#+H__ ('1?_%5Q'B_X-_\)7XIO-:_M[[+]IV?N?L>_;M14^]O&?NY
MZ=ZP_P#AGK_J:/\ RG__ &RM5&%M69MSOHCU/_A,_"W_ $,NC_\ @=%_\51_
MPF?A;_H9='_\#HO_ (JO+/\ AGK_ *FC_P I_P#]LH_X9Z_ZFC_RG_\ VRCE
MI]Q<T^QZG_PF?A;_ *&71_\ P.B_^*H_X3+PM_T,NC_^!T7_ ,57EG_#/7_4
MT?\ E/\ _ME+_P ,]_\ 4T?^2'_VRCEI]PYI]CU+_A,O"_\ T,FC_P#@=%_\
M51_PF7A?_H9-'_\  Z+_ .*KR[_AGS_J9_\ R0_^V4O_  S[_P!3/_Y(?_;*
M?+3[AS5.QZA_PF/A?_H9-'_\#HO_ (JC_A,?"_\ T,FC_P#@=%_\57E__#/W
M_4S_ /DA_P#;*7_AG_\ ZF?_ ,D/_ME'+3[BYJG\IZA_PF/AC_H8](_\#HO_
M (JC_A,/#'_0QZ1_X'1?_%5YA_PH#_J9O_)#_P"V4?\ "@?^IF_\D/\ [91R
MT_YA<U3^4]/_ .$P\,?]#'I'_@='_P#%4?\ "8>&/^ACTC_P.C_^*KS'_A0/
M_4S?^2'_ -LI?^%!?]3-_P"2'_VRGRT_Y@YZO\IZ;_PE_AG_ *&+2/\ P-C_
M /BJ7_A+_#/_ $,6D?\ @;'_ /%5YC_PH/\ ZF7_ ,D/_ME+_P *$_ZF7_R1
M_P#ME'+2_F%SU?Y3TW_A+_#/_0Q:3_X&Q_\ Q5'_  EWAK_H8M)_\#8__BJ\
MS_X4+_U,O_DC_P#;*7_A0W_4R?\ DC_]LHY:7\P<]7^4]+_X2[PU_P!#%I/_
M (&Q_P#Q5'_"7>&O^AATG_P-C_\ BJ\T_P"%#?\ 4R?^2/\ ]LI?^%$?]3)_
MY(__ &RCDI?S"YZW\OXGI7_"6^&O^AATG_P-C_\ BJ7_ (2WPW_T,.D_^!L?
M^->:_P#"B?\ J9/_ "1_^V4O_"B?^IC_ /)'_P"V4^2E_,'/6_E_$])_X2WP
MW_T,.D_^!L?^-'_"6>&_^A@TK_P-C_QKS;_A17_4Q_\ DC_]LI?^%%_]3'_Y
M(_\ VRCDI?S"YZ_\OXGI'_"6>&_^A@TK_P #(_\ &C_A+/#G_0P:5_X&1_XU
MYQ_PHS_J8_\ R2_^V4O_  HW_J8O_)+_ .V4<E+^8/:5_P"3\3T?_A*_#G_0
M?TK_ ,#(_P#&C_A*_#G_ $']*_\  R/_ !KSC_A1W_4Q?^27_P!LI?\ A1__
M %,7_DE_]LHY*/\ -^ O:5_Y/Q/1O^$K\._]!_2__ R/_&C_ (2KP[_T']+_
M / R/_&O.O\ A2'_ %,7_DE_]LH_X4A_U,/_ ))?_;*?)1_F_ /:8C^3\3T7
M_A*O#O\ T'M+_P# R/\ QH_X2KP[_P!![2__  ,C_P :\[_X4C_U,/\ Y)?_
M &RE_P"%)?\ 4P_^27_VRCDH_P WX"]IB/Y%]YZ)_P )3X>_Z#VE_P#@9'_C
M1_PE/A[_ *#VE_\ @9'_ (UYY_PI/_J8/_)+_P"V4H^"N/\ F8/_ "3_ /ME
M')1_F_ /:8C^1?>>A_\ "3Z ?^8YIG_@7'_C2_\ "2Z">FMZ;_X%)_C7GZ_!
MK;_S'_\ R3_^SJ5?@_M_YCO_ )*?_9T<E'^;\ ]IB/Y/Q.\_X2/0S_S&=._\
M"D_QI?\ A(=$/_,8T_\ \"4_QKAE^$F/^8W_ .2G_P!G4@^%./\ F-?^2O\
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M348OY?B<&*D%1BI!74CA8^BBBJ("BBB@ KUGX)_\QS_MW_\ :E>35ZS\$_\
MF.?]N_\ [4K#$_PF=6$_C+^NAT7Q>_Y)=K/_ &P_]'1U\M5]2_%[_DEVL_\
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M]"UK'_@#+_\ $T?\(9XI_P"A:UC_ , 9?_B:NZ(LS$I16U_PAGBG_H6M8_\
M &7_ .)I1X,\4_\ 0M:Q_P" ,O\ \31=!9F0*>*V!X-\4?\ 0MZQ_P" ,O\
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MD'A;Q#C_ ) .J?\ @')_A5IQO>YBXSM:S_$R:*UO^$6\0_\ 0!U3_P  Y/\
M"C_A%O$/_0!U3_P#D_PJN:/<CDEV?W&316M_PBWB'_H ZI_X!R?X4?\ "+>(
M?^@#JG_@')_A1S1[AR2[/[CZ<KY:^+W_ "5'6/\ MA_Z)CKZEKYO^*7AG7]0
M^(^JW5EH>I7-N_D[)8;21T;$* X(&#R"/PKR:+]X^AJ_">9T5M_\(9XI_P"A
M:UC_ , 9?_B:/^$,\4_]"UK'_@#+_P#$UU71S69B5KMXGUB3PW'X>:\SI4;^
M8L'E)PV2<[L;NI/>I/\ A#/%/_0M:Q_X R__ !-*/!GBG_H6M8_\ 9?_ (FB
MZ"S*>E:G>:-J4&H6$WDW4!W1R;0VTXQT((Z&MBQ\:^(;#5KW5+;4-E[?#%Q+
MY,9W_@5P/P JNO@WQ1_T+>L?^ ,O_P 34B^#O$__ $+FK_\ @#+_ /$T_=>Y
M#YEL:>C?$3Q-H6D#3+#4 ELN?+#1*QCR<G:2*G7XD>*/[775!?H+L0+;,_D)
MAT#%L$8QU)Y&*R1X/\3_ /0N:O\ ^ ,G_P 34@\(>)O^A=U;_P  I/\ XFG:
M'D0W4\RYK?C?Q!XAEMY+^^;_ $9Q)"L2B,(X_B&._OVK5D^*7BZ:S^S-J* $
M89Q;IN8>AXQ^0K!7PCXEQ_R+VK?^ 4G_ ,34B^$O$G_0OZK_ . 4G^%5:G;H
M9.53S_$K:9J-UI.H0WUE+Y5S"<H^T-@XQT(([UTS?$SQ?+&R/J^588(^S1=/
M^^*QE\)^(_\ H7]5_P# .3_"I!X4\1?] #5/_ .3_"K?(][&5ZD=(W_$T-&\
M<>(-#TTZ?87H2WR2BM&K>62<G;D53UOQ'J?B*2"34YUFD@38K! I(SGG% \+
M>(?^@#JG_@')_A2_\(MXA_Z .J?^ <G^%4O9IWTN9MU6N5WM\S)HK6_X1;Q#
M_P! '5/_  #D_P */^$6\0_] '5/_ .3_"KYH]S/DEV?W&37T+\,_P#DGVE_
M]M?_ $:]>(?\(MXA_P"@#JG_ (!R?X5[K\/+6XLO VG6]W;RP3IYNZ.5"C+F
M1B,@\]"*Y<4TX*SZG=@8M5'==#SG]H7IX<_[>?\ VE7B%>^?'31M4U<:#_9F
MFWE[Y7VCS/LT#2;,^7C.T'&<'\J\>_X0SQ3_ -"UK'_@#+_\36-)KE1VU$^9
MF)16W_PAGBG_ *%K6/\ P!E_^)H_X0SQ3_T+6L?^ ,O_ ,36ET19D>F^)]8T
MC2K[3+&\\JSOE*W,?E(V\$$=2"1P>Q%9BUL?\(9XI_Z%K6/_  !E_P#B:>O@
MWQ1_T+>L?^ ,O_Q-":$TRQ-XU\0W7B&WUZ;4-VIVR>7%/Y,8VKSQM"[3]X]1
MWJ_I?Q%\3Z5?7MW;Z@#)>OYDX>)2K/TW 8P#],5F#P=XH_Z%O6/_  !E_P#B
M:D'@_P 3_P#0N:O_ . ,G_Q-.T/(AN?F:L_Q(\57;6<D^I!IK24RPR^1'N5B
MI4_PX(P3U'>G:S\0_$OB#3S87U\OV9L;TCB5-^.>2!GM68OA#Q-_T+NK_P#@
M%)_\33U\(^)?^A>U;_P"D_\ B:I*'D9MU/,VK#XF^*[#3TLH=1!CC4)&TD*.
MR@=!DCG\<US=S=37MY-=W+^9//(TDCX W,3DGCW-7AX2\2?]"]JW_@%)_A4B
M^$_$?_0OZK_X!R?X5<>1.ZL8S]I)6=S;'Q/\8_\ 08_\EH?_ (BJFD^,M;TB
M_O;RUN4\V^?S+G?$I$C9)SC''+'IBJ8\*>(_^@!JO_@')_A4B^%?$7_0!U3_
M , Y/\*:5/R_ ARJWOK^)-KOBS6?$FQ=2N_,CC.Y(E0*JGUP.OXUBUK?\(MX
MA_Z .J?^ <G^%'_"+>(?^@#JG_@')_A6B<$K*QE)5).[3_$R:*UO^$6\0_\
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M.5"C#,C$9!YZ5U%>/4^-^I]#1_AQ]#F?$][XMM;F!?#FEVEY"R$RM.P!5L\
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MB7_H)?\ D"/_ .)KAQF8TL/5Y91^[_AS;#X:<Z=U+[_^&.E_M?XH?]"YI?\
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M%O'<7Z@>3%*<*QR,YY';/<5YG_PFGB#_ *"'_D&/_P")I?\ A,_$'_/_ /\
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M6SP!EU[50T74O'T^KV\>KZ)86]@Q/G2Q."RC!QC]Z>^.QKGO^$PU[_G_ /\
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MO?%MK<0+X<TNTO(60F5IV *MG@#+KVK*_P"$AU3_ )^O_(:_X4O_  D&J?\
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M .0U_P */[?U/_GY_P#(:_X4/BG!M6Y']R_S%'*ZR=^>_P#7H:/B>]\6VMQ
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MBLR.@?@$'*<XSU[T:AX<\;ZUINE7=]_8,6LZ/?)<VL<+RF&90I5E?(RI/4$
MX]J -.3XI^&HM&CU.1KU4>[-DT!M6\Z.<+N*,G4'%5;#XQ>%-1>R$)U%8[N9
M;<3R6;K%'*3PC/TS],U6T/P/X@LM4M]9O+FP^WS:U)J-[%"S^6D30M$$3Y?F
M8;LY./KQDUX?A]K,G@,Z*[VL5U_;AU#+R$J8O.W]0#SCM0!TY\>Z7'XDBT2X
MM-4M99YVMH+FXLG2":1<_*CD8;H<$<'UJGXDUS4%^(GA7P[I\[0QW)FN[YE
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M@.!QT K::?+?II^1A&4>>W77\SH:***Q-PHHHH **** "BBB@ HHHH ****
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M(:,",'[##_Z *UB0HR2 /4TH((R.15\WN\IGR>_S^5CSS2/^2X:__P!>"_\
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M7:XM]?FN)=7MY)=1NWCCBNI85=2QVD*" 0?7O6/;V:V>M6$FJ0^(;>,>'+"
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M\.W=[IVEV4,L<=O;(!,SG'. ,X_/\ZEL=1M+GQ+#8VC*T%G:,D39X9\J./7
M'7ZUYO3E)5@P)!'(([5O_:D8U.>$+;7UOI'9+33OZD?5FXV<N_XG<&RN-&\,
M:M<73I)>73;9-K9QDXY]_F)I-4M"/#FBX\O[%'L>=MW=L=/7JU<3DDDDDD]2
M:=O8H$+$J.@SP*QEF$.5P4-.6RU_O<UWIK?J6J#O>_6_X6/3)M,GN?%5O?/(
M@M8(OW2;N6.#T'X]?I7(:[82@#5I9D87LC-&@ZA>WZ8K$+,V S$@# R>E J<
M5CZ=>+CR6NV]^KLNW1*R0Z5"4&G?RV.F\&1*M]<WCXV6\)))[9_^L#4_A.1[
MBXU65"GVV2(M&3QR<D_AG;7)T]&9&#*Q5AT(.*RH8[V7LURZ1;>^]]/E9;%3
MH\W-KO;\#LI-/DT_PPEB\@:>^NE1F0Y )/3/_ :CU^\N&\1VME:R-LA,8$>3
MM+9SR![8KD16GH>III.HBXDB,B%"A /(SW%;+'QJ6I)<D?=5[WLE=_BW<CV#
MC>6[U^]G7ZPSZ<+V\MM/D:::,+)<;P5 QC.,YX^E+;Q2OI6E26EL)_*B5O\
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MR[E !W/;_P"O42IV5[FD*W-)1:M<[:BBBL3<Y3XE?\D_U3Z1_P#HU*T_"?\
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MJ]+UFR^'WAZYCMM4C^SRR)YBKNG?*Y(SE<]P:ATM?ASK.H1V&GCSKF3)5/\
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MM\.]9U".QT\^=<R E4_TA<X!)Y.!T!K5U3P]X1T;3Y+Z_M?)MH\;W\R5L9(
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MV-T<J!U.#D9!XZU-11=[@HI*UC)_X1;P]_T =+_\ X_\*U418T5$4*JC 4#
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MR:;M_7R/;$18T5$4*JC 4#  ]*RW\,:!([.^AZ8S,<EC:1DD_E7GO_"9:_\
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MG@5R!Z D=*9:Z#H]C<+<6FDV%O,N=LD5LB,,C!P0,UP/_"6ZY_S^_P#D)/\
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MGI6M_P )1K/_ #^?^0D_PJI<289I:2_#_,2RVHK[?U\CL/\ A%O#W_0!TO\
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M9;[3;.ZD4;5:>!7('H"1TKD_^$@U3_GZ_P#(:_X4O_"0:I_S]?\ D-?\*/\
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M^TVSNI%&U6G@5R!Z D=*9:Z#HUC<+<6FDV%O,N=LD5LB,,\'! S7-?V]J?\
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M(A#*RVB J1T(.*U**.9KJ#C%ZM#9(TEC:.1%>-P596&0P/4$>E9?_"+>'O\
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M9+:"9G\LCRPNV7 R!D?PYXJG\-?!FM^%;O49-0DM;>RF1$M].M+J:>*(KG+
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M'W_82/\ Z,AKU*O+?BI_R.GP^_["1_\ 1D-73^(B>QZE1114%A1110 4444
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M#^NT^S/):6O6O^$+\/\ _0/_ /(TG_Q5'_"&>'_^?#_R-)_\51_8>([K\?\
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M#R.]'^K6+?VH_>_\@>84NS.8I16C\.+6'7O 6FZEJ:>?>3>;YDF2N<2NHX7
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M4 %%%% !1110 4444 %>6_%3_D=/A]_V$C_Z,AKU*O+?BI_R.GP^_P"PD?\
MT9#5T_B(GL>I4445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<_\ ?YO\:/\ 6:C_ ,^W]Z#^SI_S+\3TJBO-O[3U#_G^N?\ OZW^-+_:=_\
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MOEALD#:6SGCK0!Y;J>BZA<WGQ.\*V=OYM_J1@U&R0NJF9&8;R"Q PI&*M_\
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M_K7#,[.V78L>F2<TY7<(R!V"MU4'@TI9A%MVAHU+KK>77;Y>@UAWW[=.QZ1
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MHHH **** "BBB@ HHHH \MT3_DXOQ'_V#4_]!MZ]2KRW1/\ DXOQ'_V#4_\
M0;>O4JN?3T(AU"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRW
MXJ?\CI\/O^PD?_1D->I5Y;\5/^1T^'W_ &$C_P"C(:NG\1$]CU*BBBH+"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9\7Y%QX:D8_N$U
MF+S<^\<BI_Y$:.NFJM?V%MJ=HUK>1>9"S*Y7<5^96#*00000R@_A0!P^G>(M
M&\/Z-K>EZO?V]KJ*7U](;:5PLUPLDTDD;(G5]RNH&T'GCM52WBTWPYI.E&Z\
M7P:!KT>DVL-W;S3Q,)C''@;HG^8X.X94@GI7I912RL5!9>A(Y%!56QD X.1D
M=#0!R,MY=ZAI?@N]O[?[/>7%W#+/#@C8[6\I88/(P3T-;5TOB ZM$;233!IN
MY?,66.0S8S\V"#MSCIQ6K10!YOJ-_::-=S1Z'XO^TZJVIY_L9)()-QDF_>H4
M"^8,!F.[(VXSP!5*74K)? E_X9-U$OB%[^>(660)WD:Z9UD"#G:00^X< <YX
MKU3:N[=@;L8SCG%&U=^_:-V,9QSB@#S[XD:(M]I$ZW6F:=_9,DT/VNZC_P"/
MP*77)C!7&[.!][."< G K7\+V\-KXE\206:[+.W:TMPH.0'2!<C/LAB'X5J2
M>%]$FOQ?2Z=$]P)1,&?) <'(;:3C.><XZ\U>M+"VL!.+:/9Y\S3R$L26=NIR
M?PXZ   <"@"S1110 4444 %%%% !1110 4444 %8GC/_ )$7Q!_V#;G_ -%-
M6W6)XS_Y$7Q!_P!@VY_]%-36XGL<!X=_Y-ZMO^!?^E9KCZ]/^%-O!=?"?2(;
MB&.:)O.W)(H93B=SR#[UU7_"/Z+_ - BP_\  9/\*\G,,OEB:W.I)=#JPV(5
M.%FCP<4X5[M_PC^B_P#0(L/_  &3_"C^P-&_Z!%A_P" R?X5YW]BU/YU]S.G
MZY'L>%BG"O<O[ T;_H$V'_@,G^%+_8.C?] FP_\  9/\*7]B5/YU]S#Z['L>
M&BG"O</[!T?_ *!-C_X#I_A1_8.C_P#0*L?_  '3_"E_8=3^=?<Q_78]CQ$4
MX5[9_86D?] JQ_\  =/\*7^PM(_Z!5C_ . Z?X4O["J?SK[F'UV/8\4%.%>T
M_P!AZ1_T"K'_ ,!T_P */[#TG_H%V7_@.G^%3_8-3^=?<Q_7H]CQ@4HKV;^Q
M-)_Z!=E_X#I_A1_8FD_] NR_\!T_PI?V#4_G7W,/KT?Y3QL4X5['_8FE?] R
MR_\  =?\*/[%TK_H&67_ 'X7_"E_8%7^=?<Q_7X_RGCPIPKU_P#L72O^@99_
M]^%_PH_L;2_^@;9_]^%_PI?ZOU?YU]S#Z_'^4\A%.%>N_P!C:7_T#;/_ +\+
M_A7F^C11R_'GQ#ITD:/8Q:>CQVS*#$C;8.0O0'YCS[GUH7#M5W_>+[F#S"*^
MRS,%.%>L_P!CZ9_T#K/_ +\+_A1_8^F?] ZT_P"_"_X5/^KM7_GXON8_[0C_
M "L\H%.%>J_V1IG_ $#K3_OPO^%+_9&F_P#0.M/^_*_X4O\ 5VK_ ,_%]S'_
M &A'^5GE0IPKU/\ LG3?^@?:?]^5_P */[)TW_H'VG_?E?\ "I_U<J_\_%]S
M#^T(_P K/+A3A7I_]DZ=_P! ^U_[\K_A2_V5IW_/A:_]^5_PI?ZMU?\ GXON
M8_[1C_*_P/,12UZ;_96G?\^%K_WY7_"C^R]/_P"?"U_[\K_A2_U:J_\ /Q?<
MQ_VC#^5_@>9TM>E_V7I__/A:_P#?E?\ "C^R]/\ ^?&U_P"_*_X4?ZM5?^?B
M^YA_:,/Y7^!YK2UZ3_9>G_\ /C;?]^5_PH_LS3_^?&V_[\K_ (4O]6:W_/Q?
M<P_M&'\K_ \WI:](_LS3_P#GQMO^_2_X4?V98?\ /C;?]^E_PI?ZLUO^?B^Y
MA_:,/Y7^!YQ2BO1O[,L/^?&V_P"_2_X4?V98?\^-M_WZ7_"C_5BM_P _%]S%
M_:,/Y7^!YU2U'\2";'QCX$@LS]GAN=0*3QP_(LJ^9",,!]X8)X/J:](_LVP_
MY\K;_OTO^%#X7K))^T7W,2S*#=N5_@>>"E%>A?V;8_\ /E;?]^E_PH_LVQ_Y
M\K?_ +]+_A4_ZKUO^?B^YC_M&'\K_ \]%.%>@_V=8_\ /E;_ /?I?\*/[.L?
M^?*W_P"_2_X4?ZKUO^?B^YA_:,/Y7^!Y^*!7H']G6/\ SYV__?I?\*/[.L?^
M?.W_ ._2_P"%+_5>M_S\7W,?]HP_E?X' "EKOO[.LO\ GSM_^_2_X4?V?9?\
M^=O_ -^E_P */]5JW_/Q?<Q?VC#^5_@<%3A7=_V?9?\ /G;_ /?I?\*/[/LO
M^?.W_P"_8_PI?ZK5O^?B^YA_:,/Y7^!PE+7=_P!GV7_/I;_]^Q_A1]@LO^?2
M#_OV/\*7^JM;_GXON8?VC#^5_@<+2UW/V"S_ .?2#_OV/\*/L%G_ ,^D'_?L
M4?ZJUO\ GZON8?VC'^5_@<0 20 ,D]JZ?2-(%N!<7"YF/W5/\/\ ]>M%+.UC
M8,EM"K#H0@!%3UZF6</0PM3VM9J36VFB\]>O8Y\1C74CRQ5@K$\9?\B/X@_[
M!MQ_Z*:MNL3QE_R(_B#_ +!MQ_Z*:OJ5N><]C#^$'_)+M'_[;_\ HYZ[>N(^
M$'_)+M'_ .V__HYZ[>G/XF*/PH****DH**** "BBB@ HHHH **** "BBB@ H
MHHH **** "N(^''WO%W_ &,EW_[)7;UQ'PX^]XN_[&2[_P#9*I;,E[H[>BBB
MI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \MT3_DXOQ'_ -@U
M/_0;>O4J\MT3_DXOQ'_V#4_]!MZ]2JY]/0B'4****@L**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O+?BI_R.GP^_P"PD?\ T9#7J5>6_%3_ )'3X??]
MA(_^C(:NG\1$]CU*BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBO._C+-=1^$K".TO+FT>?5;>%I;>0HX5MP/(H ]$HKP_P_P"+
M+RTUG13JEW<.VC:1J$.HQ>:2'DMFQN/]YMH!R>>:WK+XEZ]$+"76='L8(-8T
MRXU#33;SNS?NHO-V29 Y*\Y'J* /4J*\WT;XA:RNKZ=#XFTRQLK'4M-DU"VF
MM9FE9%1 [!QC^Z<\?K4/B7Q/_P )]X0F'@'4+B]>UNX?MZ6N^VF> Y+(CN%P
MQP.F> ?7% 'IU%>1Z%XGATO0[U/#=GK$^LK>VUK<:7K]VX:%I,A<%B0H(!Z=
M<#CI4+?%'QG!I&L:E<>&M,6#0[S[/J %XQ9N0,1C&.-P.2>?2@#V*BO+_$'Q
M1NM%\30VL1T6ZL&NH;=X8KB0W:!\?,P"[%QD\$YKFK^_O!_:^+N<;?'<$(Q(
M>$X^7_=]NE 'NM%>??$>6[N]:\)>'X=0N;&UU2]<74EM*8Y&2--VT,.1G_"J
MOB378OA;8:;I6G7/G3ZI<R,EQK=[(\4"HB[B6P6Q]W"CNQH ]+HKQ[3O&4_B
MWQC\.[X#[.))M5@N(H)2T4C1PC# \;E[C(XS5GP??7;?LUSWK74YNETS4'$Y
MD.\,&FP=W7(P,?2@#UBBO.+?Q7=^'/@MH>N%/MMR;:T5_/<DN7*J23U)YS5C
M7_B#>:3?>*[:&P@E.BV]K+%O<CS3,0"&],9H [^BO,KCXD:YH?\ PD5OK^B6
M@OM,L4OX([.X9DDC9]F&8KP0>IQTSQ4_@GXAZUXAUV+1]5T&WMII;(:@)[:\
M5T6!N$RO)W9XQGWQ0!Z-1110 5B>,_\ D1?$'_8-N?\ T4U;=8GC/_D1?$'_
M &#;G_T4U-;B>QA_"'_DEVC?]M__ $=)7;UY3X5N)[7X 6DUO-)#*N_:\;%6
M&;IAP1[5SG_"0:U_T%[_ /\  E_\:\[&YA'#5>1Q;ZG10P[J0NF>\T5X./$&
MM?\ 07O_ /P)?_&G#7]9_P"@O?\ _@2_^-<7]M4_Y']Z-_J<NY[M17A8U_6?
M^@M?_P#@2_\ C2C7M9_Z"U__ .!+_P"-+^VZ?\C^]!]2EW/<Z*\.&O:Q_P!!
M:^_\"'_QI1KVL?\ 05OO_ A_\:7]N4_Y']Z']2EW/<**\1&NZO\ ]!6^_P#
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M_01N_P#O^W^-.&KZE_T$;O\ [_-_C2_UBI?\^W]Z'_9\OYD>K45Y5_:VI?\
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M>?\ 82/_ *-@KU*O+[H"^GMY[P?:)K9M\$DWSM$V0<J3]TY Y'H*N?VE?_\
M/[<_]_6_QIOBBBTE[-_>A++9IM\R_$]$HKSO^TK[_G]N?^_K?XTO]I7W_/[<
M?]_6_P :G_6BC_S[?WH?]G3_ )E^)Z'17GO]HWW_ #^W'_?UO\:4:C??\_MQ
M_P!_6_QH_P!:*/\ S[?WH/[.G_,OQ/0:*\__ +1OO^?RX_[^M_C1_:-]_P _
MEQ_W];_&E_K11_Y]O[T']G3_ )E^)Z!17 ?VC>_\_EQ_W];_ !I?[0O?^?RX
M_P"_K?XT?ZTT?^?;^]!_9T_YE^)WU%<%_:%[_P _EQ_W];_&E&H7O_/Y<?\
M?P_XTO\ 6FC_ ,^W]Z#^SI_S+\3O**X3^T+W_G[N/^_A_P :/M][_P _<_\
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M8YKM*** "BBB@ HHHH *Q/&?_(B^(/\ L&W/_HIJVZQ/&?\ R(OB#_L&W/\
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M^_YFL<4"@5YN)Q$L14YY)+1*RVLE8Z*=-05D**6D%+7*6+3A3:<*0!2TE+2
M6EI*6D M+24H!)  R3VI * 20 ,D]JN:UI1M? NOSS?ZXZ9<X7^Z/*;]:VM(
MT@6P%Q<+F8_=4_P__7IGC+_D1_$'_8-N/_135][D62>R<<3B%[W1=O-^?Y>N
MWC8S%\R=.&W4P_A!_P DNT?_ +;_ /HYZ[>N(^$'_)+M'_[;_P#HYZ[>OL9_
M$SRX_"@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCX<?>\7?
M]C)=_P#LE=O7$?#C[WB[_L9+O_V2J6S)>Z.WHHHJ2@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /+=$_P"3B_$?_8-3_P!!MZ]2KRW1/^3B_$?_
M &#4_P#0;>O4JN?3T(AU"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KRWXJ?\ (Z?#[_L)'_T9#7J5>6_%3_D=/A]_V$C_ .C(:NG\1$]CU*BB
MBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:\8 QOX
M>NV)$%MK$+2^F'5XES[;Y4KI:CN+>"ZA:&XACFB;&Y)%#*<'(R#[B@#A[/5&
M\.:;JNC76FZI->M=WDMJ+>QEE6Y665Y4(D52@/SX.XC&.>.:JMIFDZ)I&D6E
MZFNPZU9Z9!:FZTBUNF\PI'@*6C4QOR#@/G'L*]&HH Y0PZO<:3X/?4H6?48[
MB&2^\M<A'^SR!R<< ;CCTR:UKK3M4FU:*Y@UR2WM%92]H+:-@X!Y&XC<,^W2
MM6B@#SK5K>SCOI(M B\0IKK:@LJG9=I;C,P,I)8"$QE2^>N<\9.*@E^T_P#"
M(WG@XZ=J)U26[FC1A:R&%XWN"XF,V-F-K9.6SD$8SBO3** . ^($L5[I[VTN
MK6%SI[7$,4^D  37)\Q08PX;(.[!QM[8R,DC7\-Q)_PD_B:2WC$=K'+;VB*H
MPI:.%2<?0.J_\!K?_L^R^U?:OL=O]HSGS?*&_/UQFI8;>&V5E@ACB#NTC!%"
M[F8Y+''<GDF@"2BBB@ HHHH **** "BBB@ HHHH *Q/&?_(B^(/^P;<_^BFK
M;K$\9_\ (B^(/^P;<_\ HIJ:W$]C@/#O_)O5M_P+_P!*S7'UZ?\ "FW@NOA/
MI$-Q#'-$WG;DD4,IQ.YY!]ZZK_A']%_Z!%A_X#)_A7DYAE\L36YU)+H=6&Q"
MIPLT>#BG"O=O^$?T7_H$6'_@,G^%']@:-_T"+#_P&3_"O._L6I_.ON9T_7(]
MCPL4X5[E_8&C?] FP_\  9/\*7^P=&_Z!-A_X#)_A2_L2I_.ON8?78]CPT4X
M5[A_8.C_ /0)L?\ P'3_  H_L'1_^@58_P#@.G^%+^PZG\Z^YC^NQ['B(IPK
MVS^PM(_Z!5C_ . Z?X4O]A:1_P! JQ_\!T_PI?V%4_G7W,/KL>QXH*<*]I_L
M/2/^@58_^ Z?X4?V'I/_ $"[+_P'3_"I_L&I_.ON8_KT>QXP*45[-_8FD_\
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MI?\ "A\+UDD_:+[F)9E!NW*_P//!2BO0O[-L?^?*V_[]+_A1_9MC_P ^5O\
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M4 %%%% !1110 4444 %>6_%3_D=/A]_V$C_Z,AKU*O+?BI_R.GP^_P"PD?\
MT9#5T_B(GL>I4445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:=;:^U75(--CN"@?R?,SE@#P3\N/QKLZY[QEX63Q;HL=G]L>RNK>XCN[2Z1
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M*-[8.L7V5-H#9;]X&[\#'O0!&?C%8PZ%>WEUI,T5]:WT=BUHMS$ZF20%E_?
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M]C'=_P#LE4MF2]T=O1114E!1110 4444 %%%% !1110 4444 %%%% !1110
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M4X5I_:=5M\T4T[W6O5W[][?+0GZM'HW_ $K':1ZY!.VK:AYL<;F(0VR,<,0
M><?4BJ5CJMG9:%:VZONF-TLLZ!3PH;/7&#]T5S0IPJ)9G6;YK*]G^+3;_!+T
M*6&A:WI^"L=GJ>JVSPSRVVM.ID4[(8X@#G'3=C(_&L7P]?0:?JHFN,B,H5W
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M._Y!!!';0K%$NU5J2BBOT:,8PBHQ5DCPVVW=A1115""BBB@ HHHH *Q/&/\
MR(^O_P#8-N/_ $6U;=8OC'_D2-?_ .P;<?\ HMJ:W0GLS"^$7_)+]'_[;?\
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M_P#L(G_T9!7I]-\*62?M=_[O_!)69W;7+MY_\ \YIPKT2BI_U5_Z>_\ DO\
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MHHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%W_(E:]_V#KC_P!%M3CNA2V9B?";_DF>D?\ ;;_T<]=I7%_"?_DFFD_]MO\
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MUNWII?:VM^P/%244[+6_7L<72UK7=V;/7[B2S1&8G:!MSSQG'OG-7=9E8Z/
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M4 %8WB[_ )$O7?\ L'7'_HMJV:QO%W_(F:[_ -@^X_\ 1;4X[HF6S,7X4?\
M)--)_P"VW_HYZ[.N-^%/_)-=)_[;?^CGKLJJ?Q,5/X$%%%%06%%%% !1110
M4444 %%%% !1110 4444 %%%% !7&?#[[WBK_L8;O_V6NSKC?A]][Q5_V,-U
M_P"RU:^%_(B7Q+YG94445!84444 %%%% !1110 4444 %%%% !1110 4444
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MN"%.%>=]<G=NRUM_Y+LO\SJ]C&UO7\3N/$-UX>U)KV]BURZ>XD7*6XC<(2
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M1DD\XZ?PU#XFU*TO6L;>QD\RWMH=H;:5YZ8P0.P%<\*<*57&3G%PMHTE_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Q_%O_(F:Y_V#[C_T6U;%8_BS_D3=<_[!
M\_\ Z+:JCNB9?"SA-(_Y()#_ ,"_]*C7$"O6OA=_R3G2O^VW_HYZ["O,S#+O
MK-9SYK=-O,Z,)B/9TDK'SN*<*^AJ*\[^Q/[_ .'_  3J^N_W3Y[%.%?05%+^
MP_\ IY^'_!#Z[_=/ !3A7OM%+^PO^GGX?\$?U[^[^)X(*<*]YHJ?[!_Z>?A_
MP1_7O[OXGA IXKW2BE_8'_3S\/\ @A]?_N_B>&BG"O<**7^K_P#T\_#_ ((_
MK_\ =_$\1%.%>V44O]7O^GGX?\$/K_\ =_$\6%.%>ST5/^KO_3S\/^"/^T/[
MOXGC0IPKV.O-]&_Y+QXA_P"P>G_H,%5'AKFO^]V\O^"1+,^5KW=WW_X!C"G"
MO7Z*S_U;_P"GOX?\$T_M'^[^)Y&*<*]:HI?ZM?\ 3W\/^"']H_W?Q/)Q2UZO
M12_U9_Z>_A_P1_VE_=_$\II:]5HI?ZL_]/?P_P""']H_W?Q/+!2BO4J*/]6/
M^GOX?\$/[2_N_B>74HKU"BE_JQ_T]_#_ ((?VC_=_$\PI:].HI?ZK_\ 3W\/
M^"']I?W?Q/,A2BO3**7^JW_3W_R7_@A_:/\ =_$\U%+7I-%'^JW_ $]_\E_X
M(?VE_=_$\WI:3XD?\CCX%_["!_\ 1D->D54N%+)/VN_]W_@D1S2\FN7;S_X!
MYS3A7HE%1_JK_P!/?_)?^"7_ &C_ '?Q//!2BO0J*7^JG_3W_P E_P""']H_
MW?Q//JT]*TM[Z3>^5@4\G^]["NNHK?#\+TZ=12JSYDNEK7_$B>82<;15F-CC
M2*-410JJ, #M3J**^M225D>9N%%%%, HHHH **** "BBB@ K'\6?\B;KG_8/
MG_\ 1;5L5D>*_P#D3M<_[!\__HMJJ.Z)E\+,7X6?\DXTK_MM_P"CGKL:X_X6
M_P#).=*_[;?^C7KL*=3XV32^!>@4445!H%%%% !1110 4444 %%%% !1110
M4444 %%%% !7'^ ?O>*/^P_=?^RUV%<?X!^]XH_[#]U_[+5Q^%_(SE\<?G^1
MV%%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >;Z1_R7K7_
M /L'K_Z#!7I%>;Z1_P EXU__ +!Z_P#H,%>D5K5W7HC&CL_5A11161L%%%%
M!1110 4444 %%%% !1110 4444 %%%% !7FWQ*_Y&WP-_P!A#_VI#7I->;_$
MG_D;? __ &$/_:D-:TOB^_\ (QK_  ?=^:/2****R-@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***:TB(5#NJECA<G&30 ZBBB@ HIJ2)(NZ-U9?53D4Z@ K'\6?\
M(G:Y_P!@^?\ ]%M6Q61XK_Y$[6_^P?/_ .BVJH_$B9_"S#^&UQ!:?#/3)KB:
M.&)?-W/(P51F9QR3[UT7_"0:+_T%[#_P)3_&O/\ 2_\ D@\7X_\ I4:X85Y.
M99A+#5W",4^OXG3@\.JE%-L]Y_M_1O\ H+V'_@2G^-']OZ-_T%K#_P "4_QK
MPD4\5YCSNI_(OO9U_4H]SW3^WM'_ .@M8_\ @2G^-']NZ/\ ]!6Q_P# A/\
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M5<DEF!4Y8ECD_I5B\^&NDW>J_;$O=1MHGT[^S;BUAF CGA"% &XSD!O7L/Q
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M **** "BBB@ HHHH *\Z^(W_ "-?@G_K_P#_ &>*O1:\[^(O_(U^"O\ K_\
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MP1GWKLM(T:PT*P6RTZ#R8 2VW<6R3U.2:-2T73]7>U>_M_.-K*)8<NP"L.^
M>>G0YK'VG[SG-W1_=>S1POB+28[[6/"GA/SGAB@A,TCQ'YL*N%QZ'Y3S[U-\
M.D:'7/$=O:7$LVEPSJD)D<OEOFR0?RS^%=)K?@S0O$-P+G4;1I)PH42+*RD
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M_BGQ7<W=K)%#=70>!V'$B[Y#D?F/SKMJJHDI:$TG)QO+?7\PHHHK,U"BBB@
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MQ/C9=WB7PF?2\_\ 9XJ[:MY_#'^NIA3^.?R_(****R-@HHHH **** "BBB@
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M_?Y?\:\JI:/]8ZO_ #[7WL/[/C_,SU3^UM-_Z"%I_P!_E_QH_M;3?^@A:_\
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M2=.2Y5>UWJTGRWT7<4<2K+F6OZVN8!1E +*0#R,CK2"NMU*"VO[Z#3E#B6(
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M-ZBBBOMCR@HHHH **** "BBB@ KF?$R[M8T$^EQ_[,E=-7/^(5W:IHQ])_\
MV9*N'Q&=3X?Z[G04445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<[XNN)5ATBQBE>)M0U."!F0X.Q<RN,^ZQ,/QKHJP_$^GW-[;6%
MQ91>;=6%_#=1QY W '9( 3P#Y;OB@#%M8]3U_3M5UA-;O;.1+JZBLHX-GE1K
M#(T8+*5.[<8R3GUP,5FKK\^H/9:IK5YJVFZ5>:9:W-L]C&WDJ[J6D\QU5BI&
M5QN(7'XUN2^&=:MS?VND:W;6NG7TTLSI+9&6:%I"2_EN)%7EB2-RG!/<<5<E
MTC6K2TMM/T+4M.L]/@MTMXX[C3WFD157:"&$JCH!P5_/I0!CZWITTEQHEQ9>
M)]7$%_<QPDPW$>QH_)8[E^3JQ0'/3DUTD-_INEFWTJXUF)[S"HJW5RGGR$GC
M(XR3["J\/AF&UTO0-/MIV6'1WC*%UW&0)$T8!/&#\V<^W2M22PLY;E;B2T@>
M=2"LK1@L,=,'&: ..T[QA!!!KL-_<WCW$&H74<12TED"H&.T!E0CCZUBC5I;
MS5]/AU+7M:M(F\/V5T!I\;-OE=I0[-MC;D[5]*[S3-$_LZTU*#[1YGVVZGN-
MVS&SS#G'7G'KQFLB#PIJVFW]O=Z5K-E&T>EV^G2+=:>\P;R2Y#C;,F,[SQST
MZT 9.K7]I9^*K33]1\8W6E62:5'-%)-=Q0M/)YC EMZX8X R,"M/1'U+6?#*
M74WB*\LX8)YPE]%# K7-NKD1R/YD;*!M&<@ 'KT-;%OHDO\ ;?\ :M[<PSRO
MIZV<L:0%$8ARQ8 LV =V-IS]36-=>#-2DT'3=&M]:MOL5E(Q:*[LFE6>(']S
M&^V5"0@P#SAMHR.H(!4TO5M0DD\):E>7$CB_FN[!G*[!/&1))!*4' 9D@4\#
MCS#T!Q7>US4NE:M=ZYH#ZA);SQ:>9[F6>"(PQM*4\N-1&7<_=DD.<XX'KBNE
MH **** "BBB@ HHHH **** "JVHC.F78_P"F+_R-6:@O1FPN1ZQ-_(TUN)['
M(ZZ-OPQN!_N_^CA7E->M>(QM^&UR/]W_ -'"O):^6SK_ 'A>GZL]+ _PCM[?
MQ#X?O_#]EI^M078:R'R^2>'QQZ^G_P"NJM_XCTO6]=674[2X_LR&'RH(HB R
MG(^8\C_.*Y.E%<$L94<4G;ITWMM?N=*HQ3N=G=>(=#T[0[O3-"@N2;L8DEGZ
M '@XYZX_G5V]\5>%;\69N-.OY?L:[848*%[=0'YZ"N I:KZ]56EE;M;3O^8O
M81\_O.VM_&\1U.]U2YMY#=&'R;*)0"D0Z_,<CJ<9XI3X\>]T+4+3448W$\92
M(P1@* 1_%ELUQ-+4_7ZZ5N;O\[]Q^PAV-GPOK*:%K27<L;/$5*.%ZX/<?B!6
ME-K&B6'B*SU+28+E@DCO<"4XSNX^7\VZ^U<J*45C#$SA!05M'=::I_TBW3BW
M<[:]\3Z/:VVH/HL%P+W4<F:27@)G.<<]>3T_I4.KZYI<MUH,-N\LMEIZJ9"J
M8+$8X ;']W]:Y"E%:2QU62:TZ=/._P"+W)5&*_KY'=IXRTZZO=62^BN?L-XB
MK'M WJ N"#SWZU6NO$VC/%I%I:6EU#96=P)Y$(4DD<C'S<Y).<XKCA2BAYA6
M:L[?=YWMZ7$J$%_7R.UL?%M@OBG4-0N(YQ#<QB.-@ 6C  XQGOCMWJC_ &[I
MMIH&IZ=I\5RK74N4:0+@)\HP3G.>#V[US(I14/'56K:=>G\VY7L8?E^!W:^*
M]$G^QW]W:W#:A:1[$1<;"<=>M49/$4,WAG4D>8_VC?W&]D"'"IP,9Z8P,?C7
M)BE%.685I+6VSZ=U:_K;0%0@CK[?Q9:6J:'%#!,8K$,9P5 +,4*Y7G_:8\XJ
M>7Q+H=M;ZJFGV]TL]ZK9F8#EFS[Y &:XH4HI+,*R5M/NVTMI\@]A#^O6YO:S
MK5O?:1IFGVJRJEK'B0R*!N; &1@GW_.K&AZSID&@W>E:G%.T<LGF@Q=_N\=>
M/NBN:%**Q6+J*I[32]K;:6M;8OV4>7E^9WUEJ5IX@U[1[>R@DAM[%&D:-P,#
M  7&"<X..M1W7B71[&]O;ZQAGDU*;,>Z3&Q<<9Z].!^7:N.L;^ZTZ9IK28Q2
M,I0L .GIS]!4 KJ>93Y-$N:][VVT25NUD9?5XWUV_IZGH6HR:18:1I>GZPL[
MLD8F*Q="W?/U)/ZUGQ^,8#JUW?R02@^1Y-JBX.T9SEN>,G'2N6O;^ZU&837<
MQED"A0Q &!Z<?6H!4U<RGSWI*R5K::Z*ROZ:CCAXV][5F]X<U>TTY+VVOHY&
MM[Q C-'U7&1_[,:LWOB"R!TZST^&5-/LYEE;=]]R#GU^OY]JYD4HKECC*L::
MIJUEY:VO>U^US5T8N7,_ZZ'4^(O$]KJ5FUO8131B:023M(H&[   X)]!^0J\
M?%&ARWEGJ,]I<M=Q1["!C"8SR!GGDUQ I16G]I5^=S=FW;IIIJK+YLGZO"UO
MZU.F;Q' ;'6$"2FYOI258J,"/H >>H&:H^'=4CTC5EN949HBI1MO4 ]Q62*4
M5@\95<XU+ZQV^]O\V7[*/*X]SJ[C7](@TO4+33K:X66Y/,CX.[/7/.1P3@4E
MUK.C:GI5NM[#<_:[>+8HCQ@G YZ].*Y44HK1YA5=TTK-6M;3>_YDK#P7>_J=
M%+KEG)9:/9K%*(;1U><;1\Q&,[>?][KCK5P>*;8:GJ5Z(IM\T(BMLJ/EP.=W
M/K@\9KDA2BI685T[IKIT[+E7X/[]1NA!_P!>=SKK3Q#ISZ/;6UV]]#);KM_T
M9RH<?@?YU5TC7+&PO=0>:.Y>"Y&U ,,V.?O$GK@US@I11_:-:\9:7CY>5M=>
MWH'U>%FNYTZ>)X_^$F_M!XY/LHC\I$&-RK],XZ^]1ZOJFGS(GV.6_EE$@?\
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MGOR>E<_16:S*NH<FCWUMKJ[O7U*>'A>_]::&CK6HKJ>HM<1JRQ[0JANN!_\
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 'Y;_"C^RM1_Y\+K_ORW^%>GT4O]6Z7_ #\?W(/[1E_*OQ/,?[*U'_GPNO\
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M_P _']R#^T9_RK\3S_\ LZ^_Y\[C_OTW^%*-.OO^?.X_[]-_A7?T4?ZKT?\
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MB5<7+-ZC_"I:3'.: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"*5=TD9]#4M(1FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ IKC,;#V-.HH CA&V)14E &!10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !4<0QO]V)J2C&* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (E7_ $EF]O\ "I:3'.:6@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "HI5W/&?0U+2$9H 6BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ea028392501_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028392501_img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %_!/D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC(H **,BC(H *
M*,BC(H **,BC(H **,BC(H **,BC(H **,BC(H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@".6:.",R2NJ(.K,<"JW]KZ9_P!!&T_[_K_C5B:"
M*XB,4\22H>JNH8'\#7S?_P (WH]Q^TM/H\VGP/IKNSFUVX3/V??T'^USB@#Z
M-@O;6Y)$%S#*1U\N0-_*K%>+_$_X;:1I/A>X\1>&K=M*U'3P)"UH[('3(SD9
MX(ZY%=%\'O&=YXP\(N^HMYE]92^1+*1CS!C*L??UH ]&HIH8$D C(ZCTH!##
M(((/<4 .HII=00"P!/0$]:=0 44G09- (89!!^E &7K/B'2/#UJ;G5M1M[.,
M#CS7 +>P'4GV%7K:XBN[6*Y@;=%*@=&QC*D9!KR#]H/2-/'A&+5OLD0O_M<<
M?V@* Y7:>">XXZ5ZCX;_ .16TG_KSB_] % #;#Q)H^IZK=Z99:A!->V9Q/"C
M99.W\^*UZY[2_"&A:-K]_K-A9+%J%]S.^XG.3DX!.!D^E;Y8*,L0!ZF@!U%-
M) (!(&>E.H R(_$FCR:^^AIJ$+:G&F]K<-\P'^>U:]<]'X/T*'Q;)XF2R4:O
M+'L,N\\\ $A<XS@ 9KH: "BDW#.,C/I2T %%,9T7[S*/J:?0!B:GXKT+2+J"
MTOM3MHKFXD6.*'?EV8G ^4<]:VZ\#^*^D:?IWQ1\&W%E:102W5T&G:-<&0B5
M.3ZGD\U[Y0!'+-'!&9)75$'5F.!5;^U],_Z"-I_W_7_&K$\$-S$8IXDEC/57
M4,#^!KYOB\-Z-<_M*W.CSZ= ^FL[O]FVX3/D;N@_VN: /HV"]M;DD07,,I'7
MRY W\JL5XO\ %#X;:3I'AF?Q%X9MSI6HZ>!(3:.4#1YYR,\$=<CTKI/@_P",
M[OQCX1:346WWUE+Y$LF,>8, AC[^M '6VOB31[[6KG1[;4()=0MAF:W5OF4?
MY(K7KGK#PAH6F^);S7[2R6/4[P8EEW$_7 Z#.!G%= 2 ,DX% "T4TD @$@9Z
M4Z@ HI"0!DG I%8, 5((/0B@#,UKQ%H_AZV^T:MJ5O9QC_GJX!/T'4_A5ZVN
M(KNUBN86W12H'1L8RI&0:\>_:$TG3AX3@U06D0O_ +6B?: H#E=IX)ZD<#\J
M]4\._P#(LZ7_ ->D7_H H ;I_B31]3U2[TVRU"&:\M#B>%&R4K6KG=)\(:#H
MFNW^KZ?9+%J%\=T\F\GJ<G )P 3Z5T!8*,L0!ZF@!U%-) (!(&>E.H **:S!
M02Q  ZDTH((R#D4 +1144LT<$3RRN$1%+,S'  '4T 1WM]::=:O=7MQ%;P)]
MZ25@H'XFHVU2Q3;YEY!&64,%DD"G!Z<&N"\%7;_$#6+OQ3=ACI%G.;?2+5ON
MY7[T[#NYS@'MSWYI?C5I-A<?#;5;R6T@-U#Y;QS^6-ZG>H^]UZ$B@#O4U.PE
M=4BO;9V8X"K*I)/YU<KRCX&:'IL?P]L]1^Q6[7<TTCM.R!G^5L#!ZC&*]7H
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MI_*C/U'X4 )^)[=J/H3WZBE_$T<^GZT )G^6?>G4G<TGIQCI]: '44@_6EH
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M_&P0*$%U$%V] -TW3VH =\9?^2D^ O\ KX'_ *-CKV^O$/C+Q\2? 7_7P/\
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MC%F[[(E977 ^4<CGOFKWPK_Y+'XY_P"NC>__ "T/>CX[?\C#X,_Z_/\ V=*
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MN*\&?"B]\#WTD^F>*I6AFP)[>2R4K)CH?O<'W]Z]/HH \Z\<?#:_\=K%#?\
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M$5&+2(=B?J<T\0(/7\Z6A6H\,#TS^5.IH0"G4AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "=1@T'KUI:* $Z'./RI.F.W8<T
MZDP1W_2@!/H.@]:7VYHQ[#CI28_ =L&@!?3L?>D__4>*=BF@?@/04 +^!%)[
MX/K2X^OYTN* &8[<>G(ZTOX<]<9I<>YHQZ\T )VZGTI?Q/Y48I: $S[G\J3\
M2?PIU% "<YIO'MZ9//TIV!Z"EH ;Z@?H*7\#^=+10 GX'\Z,>Q_.C'U_.EH
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MA#_H8;'_ +^5\MBGBG]6CW)>*EV/J'_A8?A#_H8+'_OY2_\ "PO"/_0?L?\
MOY7S",=:D4"J^JQ[D/&2['TW_P +!\)_]!^R_P"^Z/\ A8'A/_H/67_?=?-
MJ0<4_JL>Y#QL^R/I0>/O"AZ:_9?]_*7_ (3WPJ?^8[9?]]U\VK4@[?E3^J1[
MDO'S[(^CO^$]\*G_ )CME_WW1_PGWA7&?[=LO^^Z^<?>CZ4_JD.[%]?GV1]'
M?\)[X5_Z#ME_WW1_PGOA7_H.V7_?=?./:BCZI#NP^OS[(^GM*U_2=<\W^S+^
M&Z\G'F>4V=N<XS^1_*I]2U.RT?3Y+[4;F.VM8\;Y9#A5R0!G\2!7F/P5^]K7
M_;#_ -GKH/C!_P DOU;D#F'K_P!=4KBG34:G(CT:55SI\[+_ /PLOP9_T,EA
M_P!]T?\ "R_!?_0R6'_?ROD[& < <>U&.N!Z5K[!=R?;/L?6/_"R_!G_ $,E
MA_WW1_PLOP9_T,EA_P!]U\G8X. .E''4 <4>P7</;/L?67_"RO!G_0QV'_?R
MC_A97@T]/$5A_P!]U\H*/ICZ5(I]_K_G_/2G[!=R77?8^K/^%C^#?^ABL?\
MOY2_\+'\'G_F8;'_ +^5\L*3[U(II_5X]R'B9=CZD'Q%\('_ )F&Q_[^4O\
MPL3PC_T'[+_OY7R\*D4"J^K1[D/%R['T[_PL'PG_ -#!8_\ ?=+_ ,+!\)_]
M!^R_[[KYF QSCT_S_GUJ4 57U6/<AXV?9'TJ/'_A0_\ ,>L_^^Z7_A/O"O\
MT';/_ONOFU?I4G%/ZI'N0\?/LCZ._P"$]\*_]!VS_P"^Z/\ A/?"O_0=L_\
MONOG''M^E&,'I^E/ZI'N+Z_4[(^C?^$]\*]]=L_^^ZN:;XGT36+LVVGZG;W,
MX3>4C;)V\<_J*^9L>U=[\(1_Q6<O'_+E)_Z$E9U,-&,7),TI8R<YJ+2U/;;F
MXAL[::ZN)%CAA1I)'8\*H&23] *YO_A9G@L_\S)8?]_*T_%G_(GZY_V#Y_\
MT6U?'2?=7CG [?Y]JYJ=-2W.^I-Q/K+_ (67X,_Z&2P_[[H_X67X,_Z&2P_[
M[KY-XQV]C2\9XQUQVK7V"[F?MGV/K'_A9?@O_H9+#_OY1_PLOP7_ -#)8?\
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M/_0P67_?=?+PJ0#C_&J6&CW,WBY=CZ=_X6'X2/\ S,%E_P!]TO\ PL'PD?\
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M]5?\+(\''_F8K'_ONE'Q&\'GIK]G_P!]'_"OED$XZU(M5]7CW(>)DNA]1?\
M"Q?"/_0?LO\ OL_X4O\ PL3PC_T'[+_OY7S HY_QJ5?_ *]5]6CW,WBY=CZ;
M_P"%A^$O^@_9?]]TO_"P/"?_ $'K/_ONOF@>G/\ G/\ A4B@9Z4_JL>Y#QL^
MR/I0>/\ PH>FNV?_ 'W1_P )[X5_Z#EG_P!]U\X*/:G?A5?5(]R/K\^R/HW_
M (3WPK_T';/_ +[H_P"$]\*_]!VS_P"^Z^<N/04<>@H^J1[A]?J=D?1O_"?>
M%?\ H.6?_?=:NF:OI^M6[7.G7<5U"KE"\9R P[?J*^7?P%>V?!S_ )%2[/\
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M37D8PA%S<7YG!#I2]_\ /^?_ -5(.E+]:W.4/2BC^='3I0!T?@'_ )'S1O\
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M=NS*5/WK'FH( SVJ13D=?QS7J=W'H.A?%G5([N-;2VFM\131Q K:2NH_>8Y
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M'3_^O:/_ -!%<.,V1Z67_%(^>/C=_P E&?K_ ,><7_LU><^Q_P ^M>B_&_\
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M'P1\8YR1IW_@2?\ XFCF@]V'+-;(XO3M4N--U2+4K5(5GB?S(PT09%./[O\
MGM72/\1_$,C7Q8V!-\ MR?LBYE &T9_"M(?!3Q>!]W3O_ D__$_YQ3Q\%O%X
M[:=CVN#_ /$U7-3>[,^6HMD<W9^*]7LM%&D07"+9B7SD4Q@LCYSE6ZCFK5UX
MQUG4-4DU"XE@:XEM_LTA\A<21Y!(([]*WQ\&/%H[:?\ ^!!_^)IX^#7BP?\
M0/\ _ @__$U2G3[HS<*O9G,R>)]6FU.TU 3K!/9H([98$")$@_A51VZY^M.U
M7Q!?:W,\UX+=9)"&E-O"(_-(Z%L=2*Z<?!WQ6."-/(]K@_\ Q-.'P?\ %??^
MS\_]?!Y_\=JE.EW1G*G6>EF<[H_B74]$M[FVLWA-O<_ZV*>$2*V!Z&J]WJ%S
M?E!,46.,$1Q1J$CCR<G:HX'/-=:/A#XI[_V?_P!_S_\ $U(/A'XH'_/A_P!_
MS_\ $U2J4KWNC)TJS5K,X:BNZ_X5+XH_Z</^_P"?_B:/^%2^*/2P_P"_Y_\
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M3KG)'KG)J"3QIJTEO900K8V<-E<?:84L[58@LN#\W'7KWKH_^%(>,N.--_\
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MOAN(J52JH3CRI];W^\SJ8&<8WB[G744U6#*&4@@]"*=7TZU//"BBBF 4444
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MK"1HB=.WX&IEZU"G7KS_ )_S^=2J/; KGD62"I!4:]>U2"LF,D'(_P _Y_\
MU5(/\\4Q>OX_X4]>@K-B-O1]6-H1!.282< G^'_ZU=2K!@&4@@]"*\_%;&DZ
MN;8B"8YB/0_W?_K5]7DN=>SMA\0_=Z/MY/R/+Q>$O[\-^IU=%-5@RAE((/0B
MG5]V>0%%%% 'E/PTS_PLCX@^GVY>W^W)7JU>4_#/'_"R/B#Z_;A_Z')7JU5/
M<B&P4445)84444 %%%% !1110 4444 %%%% !1110 4444 )7E-F/^,D+_\
M[!8_DE>K5Y1:#_C)&_\ ^P8/_04JX=?0B70]8HHHJ"PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /)_C5_KO"/_ &%%_FM>KCH*\H^-/^O\(?\
M857^:UZN.@JI?"B5\3%HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 3O7"?%KGP2HQG_ $^UX_[:K7=]ZX7XM?\ (E+W_P!/M>/^VJTX_$A/8[L=
M!10.@HI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_P#C/_R3
M'4O]^'_T8M=3X5_Y%'1O^O&'_P! 6N6^-'_),=2_WXO_ $8M=3X5_P"11T?_
M *\8?_1:U3^!$+XF:]%%%26%%%% !1110 4444 %%%% !1110 4444 %%%%
M!6#XT_Y$C7?^O"?_ - -;U8/C3_D2-=YQ_H$_/\ P TUN)[&)\(?^27Z-_NR
M?^C7KN>]</\ "'_DE^C?[LG_ *->NX[T2W8H[(****104444 %%%% !1110
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MZ22,\Q1^J!F) _(BN@H **** "BBB@ HHHH **** ,'QG_R)&O<X_P")?/\
M^BS7 ^',_P##/=G]#_Z4&N^\9\>"->_[!\__ *+-<!X<Q_PSW9_0_P#I0:RQ
M7^[3]'^0Z?\ %C_74Y5*G3CG\?RYJ!*L)].G^?\ /^17Y_(^@1.HQCC]/\_Y
M J9*A3J,?7_/^>PJ9*YY%HG7BK"=?IZ<^G_UJKI5A.H/^>W^'_ZJYY&B)T[#
MM[>G^<U*OO42< <=/6I5&"!C]/I6$BR1>M2+UJ->M2"L6,D7_P#54@Z?_6IB
M]?QYIZ]*S8B05J:5I37K"60%80>O]X_X4W2=*:^?S)!MA4X_WOI76HBQH%48
M4< "OJ<FR7VS5>NO=Z+O_P  \S%XJWN0W'(@1 JC  P!3J**^[2MHCQPHHHJ
M@/*?AI_R4CX@\?\ +\O/_ Y*]6KRGX9C_BY'Q!/_ $_#M_MR5ZM53W(AL%%%
M%26%%%% !1110 4444 %%%% !1110 4444 %%%% "5Y1:?\ )R%__P!@P?\
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M-/\ DI'Q!X_Y?EY_X')7JU5/<B&P4445)84444 %%%% !1110 4444 %%%%
M!1110 4444 )7E-I_P G(7W_ &"Q_)*]6KRBSQ_PTA?\?\PL?RCJX=?0B70]
M8HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)_C5_KO"/_
M &%5_FM>KCI7E'QJ_P!=X1_["J_S6O5QTJI?"B%\3%HHHJ2PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 3O7"_%K_D2E[_Z?:\?]M5KNN]<+\6O^1*7O
M_I]KQ_VU6G'XD)['=CH**!T%%(84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'G_ ,:/^28ZE_OQ?^C%KJ/"O_(HZ-C_ )\8?_1:UR_QH_Y)CJ7^
M_%_Z,6NH\*_\BCHV/^?&'_T6M4_@1"^)FQ1114EA1110 4444 %%%% !1110
M 4444 %%%% !1110 5@^->/!&N\X_P! G_\ 0#6]6#XT_P"1(UWG'^@3_P#H
M!IK<3V,3X0_\DNT;C'$O'_;5Z[GO7#_"'_DE^C?[LG_HUZ[CO1+=BCL@HHHI
M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** /)_C5_KO"/_857^:UZN.E>4?&K_7>$?\
ML*K_ #6O5QTJI?"B%\3%HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 3O7"_%K_D2E[_ .GVO'_;5:[KO7"_%K_D2E[_ .GVO'_;5:<?B0GL=V.@
MHH'044AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?_&?_ ))C
MJ7^_%_Z,6NI\*_\ (HZ/_P!>,/\ Z+6N6^-'_),=2_WXO_1BUU/A7_D4=&_Z
M\8?_ $!:I_ B%\3->BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH 3O7"_%K_ )$I>_\
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M %%%% !44D,<P42QJX5@P# '!'0_6I:* "BBB@ HHHH **** "BBB@ HHHH
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M\UKU<=*\I^- S-X2_P"PHO\ -:]6'2JE\*(7Q,6BBBI+"BBB@ HHHH ****
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M444 %%%% '"?%_\ Y)OJ(]7A_P#1BUTOAG_D5=(_Z\H?_0!7-_%WGX<ZB/\
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M_DE>F&O-;4?\7\O#C_F&C^25I3^UZ&-7[/JCTNBBBLS8**** "BBB@ HHHH
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MQ=H1Z:C&?^ M_A7C$0& 2/?-78^G3_/^<U\I+.JR^ROQ/:6"@^K/71XIT0G
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MM>AA6^SZH]&HHHK(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\V^+ S)X9_["2_TKTCTKSGXJJ6D\-<9_XF2_S%>C#M6L_@C\S"G_ !9_+\A:
M***R-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH 2N.^)?_(J)_U^V_\
MZ,%=C7(?$@;O"J@=?MMMC_OZM7#XD95/@9UX^Z/I2T@Z"EJ#4**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#B?BN,_#S4/\ >B_]&+71^'N/#6EC
M_ITB_P#0!7/?%0%OA]J '7=%_P"C%KH?#X(\-Z8",$6L0(_X *U?\)>K,%_&
M?HOS-.BBBLC<**** "BBB@ HHHH **** "BBB@ HHHH **** &UC^*_^10UG
M_KRF_P#0#6Q61XI_Y%'6/^O*;_T U4?B1$_A?H9/PR&/A[I8]G_]&-775R7P
MT4K\/],!&#A__0VKK:*GQOU)H_!'T%HHHJ34**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ()[:"ZC$=Q"DJ AMKJ",CH<&J=MH&DV
M5E/96VG6T=M<$F:(1C;)GKN]:J^)[^6QTZ&.W<QSWEU%:1R#JAD8*6'N!DUQ
MOBR2;1M4L[2VU"ZL[00HEM-%*_E6TQD^9[H _,K \%N"<^N: .T/A/P^VDG2
MSHUD;!G$AM_)&PMZD=S2+X0\/*+H+HUD!=QB.X'DC]ZHQ@-ZXP*7Q%KDV@VM
MK<K9K<QRW4=O)F;84#L%##@[N2..*YZ7QW?1ZP=*7PY+)<&_>R21+E?*R(_,
M#$D9&0>>#CGKT(!T^G>'](TBYFN=.TVVM9YE"R211A2X'0$]\5%=^$_#]_J:
MZG=Z/9S7RD$7#Q N".F#60/&$EYI-A]FTTOJ6H336Z6GVG8JM$6$A,H7@ *2
M"!SQ7-^!-26)=+MKK2[T7<%E>SI</<%P0)R&C SEV''S$?SH [_4O#6BZQ<"
MXU+2K2[F$9BWS1!CL/5>>U59_!7AFY<//H5@["(0 M"/]6.B_3VK+TWQTU_I
M/VT65LSS3QV]K%!?"0O(^?ED^0&(C'((.*S8+VY3XAC4=5M)M/>+29S-#]J\
MZ+8CJ0Z'@ $$]@>* .OL/#.AZ5=FZL-*M;>X,?E&2.,!BG]W/I[5&/"7A\1W
M<8T>R"7@Q< 0C$HSG!]L\XK$'CUXH)I;O29(MUE_:%F$E,GGPY'WL+E",@D8
M.!ZTV?QZ;;1;*\-E!/<WLKI;QV=RUS$RJ,EB\<9(X_V..] '22:!I$NGQ:?)
MIULUG"NR.$QC:B^@'8<5=M[>&SMX[>WB2*&-0J1H,!1Z 5Y]KWBRYUOPG=6E
MGH]VEW-IDMQ=133M:O;(,KG.W))(.!@9'7%:FIZU<:#\*H=3M@&N8[& 1EQD
M!F"J"1[;L_A0!VE%>>Z[!>^$-$AUVVU>_N;F.:$74=U<M)%<*[!6"H>$/.1M
M QC'2JFCW=\FOIIFMZAJVG:Q+-(V)7,EI>KAMHA/1, @[1M/'.: /3:*\]C\
M..?%T^FC7M=VQZ='.C'49B/-,C@L1NP1\H^7I6EXPU*RD\.:G80:X(M4M;9I
M@EM>>7.&5<Y(4[L>HH ["BN>NK\^'?!KW_DW5]]CM?-*M+NEDP,G+L?S)[>M
M8<OCW4H1=;_#3K]GL$U([KQ<"W.?O87B3Y3\O(.#\U '>T5%!,L]O%.GW9$#
MC/H1FI: ,KQ$-WAK5!G&;27_ - -<3$GE_!:-=N, <?]MJ[O7!NT+4!ZVT@_
M\=-<7<)Y?P@"8Y '_HZLL5_NL_ZZ$TU^_B_ZW//X^G0=/\_Y]ZN1]_U_S_GK
M52+MVX_*K<?N,>U?GDSZ1%N/@5<CXYP..^.*IQ\8/(JY'P.>W&/3IG_/O7%,
MV1:08J9/6H4Z_P#UO\_Y-3+TKDD:$Z9&".HZ$>M=5H^L^<JVURW[SHKG^+_Z
M]<JG7I\U2KP<CMTKJP./J8*KSPVZKN<]>C&M&S/1,T8K%T34I+D&"8%G0??Q
MU'O6U7Z9A,3#$TE5ALSYZI3E3DXR%HHHKJ("BBB@ HHHH **** .$\&1E/&/
MBQCGYKD?^A/7<BN1\+1[/%'B1_[TX_\ 0GKKA5U'>7W?D8T5:'S?YCJ***@V
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*X2WB_XO'=RX_Y<0,_@M=V
M*X^"+_BZ%S(?^?0 ?DM73Z^AC55^7U1V-%%%0;!1110 4444 %%%% !1110
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MXB&[PUJ8];64?^.FM3M6?KJ[M U!?6VD_P#033CNB)_"S(^'R>7X(TY?0/\
M^AM73=ZP/!B>7X5LE(Q@-Q_P-JWZ<OB8J>D%Z#J***DT"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)U_2VU;3##$ZI/'(D\#MG"
MR(P9<X[9'-95_P"%4UZ1KNXFO+&2[@6WO[6)T9)T4G"DD$@<M@J5)!Y]K?BO
M7IO#NDK>0V,MXSSQQ!(RHV[V"@G<P]>WZ=:YO1O%$FF:_K=OJC:K<Q-J<,22
MRJI2U\V--J'!  W-CY=WJ?6@#K];T6#7-*:QDEE@ =)(Y82-T;HP92,@@X('
M!!%8$'@$1:LFH_V]J3RB\^VD.D)#2^7Y9/W. 5[#@=L4DWQ/\.PZM-8&25VC
M,B!X@LF]T!+*$5B^>".5 XZU<M/&"WVD6^HVNA:Q-%<[3;J(4#2*5W%N7PH&
M.K$9/3- %>'P##;V5K%%J^H+=V=S+<V]Z/+\Q#)G>I&S:RG)X(-)I'@1=(U"
M*[CUS49_(CFBCC=80%$K%VY" YW'(.?;I4,7Q.T>=9F@L=6DCMXDFN7^R[1
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M?3/1;D'I]*Z0=!61KD?F&S'I,*UQ5-^ZB(KWFQ:***DL**** "BBB@ HHHH
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M]36A1+=BA\*%HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH I6L>RZN6_O-FKM,50I)'>GTV)*P4444AA1110 4444 %%%% !1110
M4444 %%%% !1110 526/_B9M)_L8_E_A5RDVC?N[TQ-#J***0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** *5]%YAAXSA_\_P JN"FL@;&>U.IB
MMJ+1112&%%%% !1110 4444 %%%% !1110 4444 %%%% "57O$WP@8_C4_K5
MFD9=PP:!/46BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6
M^C,EJR@9R1_.IH1B&,>BC^5.*AA@TH&!BF*VHM%%%(84444 %%%% !1110 4
M444 %%%% !1110 4444 %13C=;R =U-2TA&00>] %>R3R[6-/3/\ZLTU5"C
MIU D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Mar. 27, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001795091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">OS Therapies Incorporated<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_RegnFileNb', window );">Registration File Number</a></td>
<td class="text">333-289443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">424B7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_RegnFileNb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_RegnFileNb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Mar. 27, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">10,529,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">1.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 14,846,478.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 2,051.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), of OS Therapies Incorporated (the &#8220;Registrant&#8221;) being registered hereunder include such indeterminate number of shares of Common Stock as may be issuable as a result of stock splits, stock dividends, or other distribution, recapitalization or similar events.<br/><br/>The offering price estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The maximum offering price per share and maximum aggregate offering price are based upon the average of the high and low sales prices of the Registrant&#8217;s Common Stock on September 26, 2025, as reported on NYSE American.<br/><br/>The amount registered represents (i) 4,289,441 shares of Common Stock issuable upon the exercise of outstanding warrants and (ii) 6,239,976 shares of Common Stock issuable upon the exercise of outstanding unsecured convertible promissory notes, each of which is to be offered for resale from time to time by certain of the selling stockholders named in the prospectus that forms a part of the registration statement to which this exhibit is attached.<br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Mar. 27, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 14,846,478.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">2,051.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 2,051.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea028392501ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea028392501ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea028392501ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="ea028392501ex-fee.htm">ea028392501ex-fee.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea028392501ex-fee.htm": {
   "dts": {
    "inline": {
     "local": [
      "ea028392501ex-fee.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2025": 1,
    "http://xbrl.sec.gov/ffd/2025": 6
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 22,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028392501ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028392501ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028392501ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028392501ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028392501ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028392501ex-fee.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-26-037438-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-037438-xbrl.zip
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M\YS:?P!02P$"% ,4    "  -@7]<9W$\AO,+  "D.   %0
M@ $     96$P,C@S.3(U,#%E>"UF964N:'1M4$L%!@     !  $ 0P   "8,
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ea028392501ex-fee_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-27</startDate>
            <endDate>2026-03-27</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2026-03-27</startDate>
            <endDate>2026-03-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">424B7</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0001795091</dei:EntityCentralIndexKey>
    <ffd:RegnFileNb contextRef="c_report" id="fee_004">333-289443</ffd:RegnFileNb>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_005" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_006">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="c_report" id="fee_007">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_008">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_009">OS Therapies Incorporated</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_010">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_011">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_012">Common Stock, par value $0.001 per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_1" id="fee_013">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c_offering_1"
      decimals="0"
      id="fee_014"
      unitRef="shares">10529417</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="USD">1.41</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_016"
      unitRef="USD">14846478.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_017"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="ixv-226"
      unitRef="USD">2051.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="ixv-227"
      unitRef="USD">14846478.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="ixv-228"
      unitRef="USD">2051.00</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt
      contextRef="c_report"
      decimals="INF"
      id="ixv-229"
      unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="ixv-230"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="ixv-231"
      unitRef="USD">2051.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="ixv-177">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the shares of common stock, par value $0.001 per share (&#x201c;Common Stock&#x201d;), of OS Therapies Incorporated (the &#x201c;Registrant&#x201d;) being registered hereunder include such indeterminate number of shares of Common Stock as may be issuable as a result of stock splits, stock dividends, or other distribution, recapitalization or similar events.&lt;br/&gt;&lt;br/&gt;The offering price estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The maximum offering price per share and maximum aggregate offering price are based upon the average of the high and low sales prices of the Registrant&#x2019;s Common Stock on September 26, 2025, as reported on NYSE American.&lt;br/&gt;&lt;br/&gt;The amount registered represents (i) 4,289,441 shares of Common Stock issuable upon the exercise of outstanding warrants and (ii) 6,239,976 shares of Common Stock issuable upon the exercise of outstanding unsecured convertible promissory notes, each of which is to be offered for resale from time to time by certain of the selling stockholders named in the prospectus that forms a part of the registration statement to which this exhibit is attached.&lt;br/&gt;</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
